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ABSTRACT
People with Down syndrome (DS) have elevated neuroinflammation early in life
and develop neuropathology by the age of twenty. Most individuals with DS go on to
develop abnormal dementia and Alzheimer’s disease (AD). This dissertation is focused on
biological pathways involved in DS-AD and includes studies in humans with DS and DS
mouse models. Locus coeruleus (LC) noradrenergic (NE) neurons decline before other
transmitter systems on the path to DS-AD, which leads to increased neuropathology and
accelerated memory loss. To investigate the specific roles of LC-NE in DS-AD, designer
receptors exclusively activated by designer drugs (DREADDs) were utilized in the Ts65Dn
mouse model of DS to selectively stimulate or inhibit LC-NE activity. LC-NE activity
modulated neuroinflammation, memory performance, and AD pathology in this mouse
model. Altogether these findings implicate the importance of LC-NE function in the
context of DS-AD. LC-NE dysfunction may also affect resolution response to
neuroinflammation. Insufficient resolution activity was already known to correlate with
AD neuropathology in humans and mouse models, but specialized pro-resolving factors
have not been evaluated as a therapeutics in DS-AD. In the next portion of my thesis, I
developed a novel therapeutic approach to enhance resolution activity in Ts65Dn mice with
a pro-resolving mediator, resolvin E1 (RvE1). RvE1 treatment significantly reduced glial
activation in the brain and pro-inflammatory cytokines in the periphery of Ts65Dn mice.
RvE1 therapy reversed Ts65Dn deficits in memory and cognitive flexibility, which
correlated with significant proteomic measures of the inflammatory resolution process.
Finally, I investigated blood biomarkers that are relevant to AD including neuron-derived
exosome levels of amyloid-beta peptides and phosphorylated-Tau (P-Tau) and serum
BDNF levels. These AD biomarkers were already significantly elevated early in childhood
with unique trajectories associated with dementia in humans with DS. Serum BDNF levels
correlated with exosome P-Tau levels, suggesting an interaction between these two
pathways in the development of DS-AD in humans. These data provide novel hope for
meaningful therapeutics, to be implemented in early childhood in those with DS and inform
both research and clinical perspectives at the crossroads of DS and AD.
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1. Introduction

1.1 Aneuploidy: Etiological Consequences for Alzheimer’s disease
Identifying the factors that contribute to or reduce healthy aging can lead to
improved precision medicine that could prevent the onset of aging-related diseases such as
Alzheimer’s disease (AD). Genetic links to AD have been found in select gene alleles,
point mutations and also in broader chromosomal abnormalities. In humans, the most
common survivable chromosomal abnormality is aneuploidy which can occur as
monosomy of trisomy so chromosomal segments or whole chromosomes. Although 5% of
all recognized pregnancies have aneuploidy (Hassold and Hunt 2001), this chromosomal
abnormality is usually not compatible with mammalian embryogenesis, and thus the
majority of aneuploid pregnancies end during the early stages of embryonic development
and are responsible for about 35% of spontaneous abortions (Hassold and Sherman 2000).
The most common human aneuploidies are trisomies, which are characterized by the
presence of one additional chromosome, which brings the total chromosome number from
46 to 47. Of all potential human chromosome trisomies that could occur, only a few are
viable. Trisomy 13, also referred to as Patau syndrome, causes severe intellectual
disabilities, early medical conditions, and with only 5 to 10 percent living beyond six
months of age. Trisomy 18, or Edward Syndrome, is the second most common trisomy
condition and is also characterized by severe intellectual disabilities along with
microcephaly, so only 1 percent of those with condition survive beyond their first year.
Given the high mortality rate after birth, Trisomy 13 and 18 are not associable to AD, but
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the linkages of aneuploidy to intellectual disability are noteworthy. Finally, the most
common human trisomy worldwide is Trisomy 21 or Down syndrome (DS). John Langdon
Down first described the intellectual disability coupled with distinct facial features in 1866
but the exact causative mechanism was unknown. Nearly a century elapsed before Peter
Harper and Jerome Lejeune discovered Trisomy 21 in 1959, shortly after chromosomestaining techniques established the normal human chromosome complement at 46, not 48.

1.2 Down syndrome and Alzheimer’s disease (DS-AD)
Since 1929, life expectancy in the DS population has dramtically increased
(Zigman 2013, Ballard, Mobley et al. 2016) through improvements in health care, social
inclusion and family support structure. The most significant improvements in longevity
came after 1970 when average age at death was less than 9 years of age. In only two
decades, the average age at death dramatically rose to 40 years and today that age has risen
to above 56 (Figure 1-1, A). It is important to note that longevity saw the greatest increases
in the White/Caucasian population while the African American /Black population and
others still lagged behind (Kucik, Shin et al. 2013). This racial disparity for those with DS
speaks to societal issues in health care accessibility, income wealth divide, and other
addressable factors. Today, the incidence of DS is approximately one in 800 live births
with more than 300,000 people affected in the US and 5-8 million people affected
worldwide (Zigman 2013). Individuals with DS are at high risk of developing early-onset
AD and this risk increases at very early ages with a prevalence trend abruptly emerging at
around 35 years of age (Figure 1-1, B). There is a current debate on when Trisomy 21 sets
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Figure 1-1. Demographics in the DS population. (A) Life expectancy in the DS
population over three decades by race. Image was modified from (Kucik et al, 2013)
(B) Summary of a meta-analysis of prevalence/incidence studies of DS-AD in
various clinics. Image was modified from (Wiseman et al, 2015).
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the stage for eventual DS-AD. DS fetal development anomalies, such as fewer synapses in
the DS forebrain (Petit, LeBoutillier et al. 1984) and smaller dendritic arborization in the
cerebral cortex (Becker, Armstrong et al. 1986) predispose babies with DS to have
impaired brain development. Perturbations in DS brain development also involve impaired
neuronal differentiation, which leads to abnormally reduced growth in the neocortex, which
has been found to be most prominent in the temporal and frontal lobes of the brain (Lubec
and Engidawork 2002). Infants with DS are also at increased risk for conditions in the 1)
cardiac system, 2) digestive system, 3) respiratory system, 4) musculoskeletal system, and
5) urinary system (Davidson 2008). Whether these comorbidities affect AD-risk at the
physiological level is not well established, but it is reasonable to assume that clinical
studies should account for known comorbidities if possible. These early developmental
disturbances manifest a unique situation where the early stages of AD can be studied from
the aging paradigm but also from a developmental perspective in this unique population.

Genetics has been proposed to account for at least 30% of longevity in animal
models and, in humans, general stability of gene expression is a primary driver for healthy
aging (Arking 2001, Arking, Novoseltsev et al. 2004). From a genetic aneuploidy
perspective, it is important to mention that brain and cognitive development is not only
disrupted by the overexpression of specific trisomy genes on chromosome 21, but also by
the deregulation of non-coding genetic elements and abnormal expression of nontriplicated genes, along with epigenetic alterations at the DNA level. The development of
new therapies and preventive agents that could halt DS-AD and discovery of reliable
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biomarkers to AD is a paramount priority to the highly susceptible DS population. For
these reasons, the central focus of this dissertation is centered on biological crossroads
between DS and AD. My investigations using human biosamples and mouse models were
conducted with the aim of improving life quality specifically for those who have DS.

1.3 Mouse Models Enable Down Syndrome Research
There are several mouse models of DS which recapitulate both developmental and
age-related pathology in DS and in DS-AD. The use of these mouse models to study DS
enables studies that are not currently possible in Humans including 1) safety and efficacy
investigations of prevention or intervention strategies, 2) the study of neurological disease
processes in a controlled environment, 3) validation of imaging and surgical
methodologies, and 4) studies of gene-gene interactions relevant to DS. A minimum of 166
protein-coding genes are syntenic between human chromosome 21 (Hsa21) and mouse
chromosomes (Mmu) within three regions located on (Mmu) 10, 16 and 17 (Sturgeon and
Gardiner 2011, Busciglio, Capone et al. 2013). Several DS mouse models have been
developed to investigate the role of different gene segments of Hsa21 developmental and
age-related impairments observed in DS. A summary of these mouse models is provided
in (Figure 1-2) and has been extensively reviewed in our recent publication in Current
Alzheimer Research (Hamlett, Boger et al. 2016). One of the first models of DS to be
developed had complete trisomy of the Mmu 16 (Ts16), which proved to be lethal (Haydar,
Blue et al. 1996). In this model, hippocampal neurons are lost at an accelerated rate via
caspase-mediated apoptosis, which can be abrogated by caspase inhibitors (Bambrick and
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Figure 1-2. Summary of available DS mouse models to date. Hsa = human
chromosome, Mmu = murine chromosome, gray lines delineate included gene
segments per mouse, and light gray dotted box represents the so-called Down
syndrome Critical Region (DSCR). Figure adapted from (Hamlett, et al, 2016).
Krueger 1999). Due to lethality, this model continues to be used to explore developmental
effects of Trisomy 21 primarily in vitro. Another mouse model for DS, Ts1Cje, contains
62 orthologous Hsa21 genes but excludes the gene segment containing the amyloid
precursor protein (APP) and superoxide dismutase 1 (SOD1). These mice display certain
neurodegenerative features including oxidative stress (Ishihara, Amano et al. 2009), Tau
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hyperphosphorylation, mitochondrial dysfunction (Shukkur, Shimohata et al. 2006), along
with learning and memory deficits (Belichenko, Belichenko et al. 2009). Another DS
mouse model, Ms1Ts65, is trisomic for a region that contains over 33 orthologs of Hsa21
genes. These mice display poor performance in water maze tasks but do not exhibit
hyperactivity.

The Ts2Cje mouse model of DS has a chromosomal rearrangement caused by a
translocation to Mmu12 via a Robertsonian chromosome (Villar, Belichenko et al. 2005,
Levine, Saltzman et al. 2009). Studies of Ts2Cje revealed abnormalities in neuronal
networks, endosomal changes, and accelerated neurodegeneration in basal forebrain
cholinergic neurons (BFCN) (Villar, Belichenko et al. 2005). Recently, the DpYey mouse
models for DS were developed to have orthologous genes that are syntenic to the entire
Hsa21 region (Yu, Li et al. 2010). These colonies exist as three separate aneuploid mouse
models: Mmu10:Dp(10)1Yey, Mmu17:Dp(16)1Yey, and Mmu16:Dp(17)1Yey. The triple
aneuploid mice, Dp(10/17/16)Yey was achieved by conventional breeding of the three
distinct models (Yu, Li et al. 2010). Interestingly, investigators have found distinct
phenotypes for each model. Dp(17)Yey mice display abnormal synaptic long-term
potentiation (LTP)in the hippocampus while the genotype of Dp(16)Yey mice display more
pronounced impairments in memory, abnormal hippocampal LTP (Yu, Li et al. 2010). This
evidence suggests that the Mmu16 genes syntenic to Hsa21 represent a crucial element
related to the cognitive impairments associated with DS-AD. Dp(10)Yey mice display
alterations in brain morphology which suggests that all three regions are necessary to
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completely recapitulate most elements of a DS phenotype. Finally, recent studies revealed
that the Mmu17 region is also a significant determinant of DS related cognitive deficits
(Zhang, Meng et al. 2014). These novel mouse models allow stricter studies of the Mmu17,
Mmu10 and Mmu16 homologous regions in the biology of DS and, when bred together,
may aid studies that can finally tease out specific genetic contributions to cognitive
impairments observed in individuals with DS. Currently, Dr. Dian Bianchi, the director of
NICHD, is assessing several of these DS mouse models for behavior, signaling biases,
neurodegeneration, and developmental abnormalities to ascertain better how each model
may best be applied to DS research (Personal communication, T21rs meeting Chicago,
2017). In this dissertation, I focus exclusively on the Ts65Dn mouse model because it is a
well-characterized mainstay of the research field and currently has over 372 peer-reviewed
articles listed by the National Center for Biotechnology Information PubMed database.

1.4

The Ts65Dn Mouse Model of Down syndrome
The Ts65Dn mouse model for DS was developed by Muriel Davisson and remains

the most widely studied mouse model for DS (Davisson, Schmidt et al. 1990). The
aneuploidy complement of Ts65Dn mice represents 122 orthologs to Hsa21 protein
encoding genes through a segmental trisomy for Mmu16, and includes the so-called Down
syndrome critical region (DSCR) (Dierssen, Fillat et al. 2001, Bambrick, Yarowsky et al.
2003, Gardiner, Fortna et al. 2003, Belichenko, Belichenko et al. 2009). It should be noted
that the trisomy in this mouse also contains a segment of Mmu17, which has approximately
60 protein-encoding genes that are not syntenic to Hsa21 genes. Most of these genes have
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orthologues on Hsa6 (Duchon, Raveau et al. 2011, Busciglio, Capone et al. 2013). Even
though Ts65Dn mice lack complete synteny to Hsa21, they exhibit many developmental
and age-related deficits seen in the DS population, including progressive memory decline
(Reeves, Irving et al. 1995, Hunter, Bimonte-Nelson et al. 2004), adult-onset degeneration
of BFCN and LC-NE neurons (Holtzman, Santucci et al. 1996, Granholm, Sanders et al.
2000, Cooper, Salehi et al. 2001), hippocampal synapse abnormalities (Siarey, Stoll et al.
1997, Insausti, Megias et al. 1998), and increased APP production (Hunter, Isacson et al.
2003, Seo and Isacson 2005). Within the DSCR segment lies the APP gene
(Kleschevnikov, Belichenko et al. 2004) which is responsible for the production of amyloid
beta (Aβ) peptide monomers and oligomers (Aβ40 and Aβ42), though these oligomers do
not form plaques in the brain as observed in the Human population.

Work from multiple groups has demonstrated that Ts65Dn mice have significant
increases in levels of APP production (Cataldo, Petanceska et al. 2003, Hunter, Bimonte et
al. 2003, Hunter, Bimonte-Nelson et al. 2004, Choi, Berger et al. 2009, Lomoio, Scherini
et al. 2009). Even though Ts65Dn mice do not develop plaques, alterations in APP
processing have been observed in the hippocampus and prefrontal cortex (Hunter 2003b,
Jason Lockrow 2009, Salehi, Faizi et al. 2009). The overexpression of APP has been
associated with decreased neurotrophic support, as well as cholinergic and noradrenergic
neurodegeneration via several mechanisms (Salehi A 2006, Salehi, Ashford et al. 2016).
Proteolytic processing of APP into Aβ peptides is likely a major driver of neuropathology
in the Ts65Dn mouse since deletion of one copy of the APP gene from the triplicated DSCR
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segments rescues many degenerative phenotypes in the brain (Cataldo, Petanceska et al.
2003). The Granholm lab has investigated age-related degeneration and memory loss in
Ts65Dn mice for the past 20 years, and demonstrated significant progressive declines in
working and spatial memory (Granholm et al., 2000; Bimonte et al., 2003; Hunter et al.,
2004; Lockrow et al., 2011), hyperactivity (Lockrow et al., 2011; 2012; Fortress, Hamlett
et al., 2015), and LC-NE as well as BFCN and hippocampal degeneration with age
(Granholm et al., 2001; Hunter et al., 2004; Lockrow et al., 2011, 2012). See Figure 1-3
and Figure 1-4 for a summary of these previous studies. I focused on this well
characterized Ts65Dn mouse model to take advantage of the extensive peer-reviewed
knowledge on neurodegenerative and memory decline hallmarks that aid the studies
conducted.

1.4.1 Cognitive Impairment in Ts65Dn Mice
Several studies have demonstrated that Ts65Dn mice exhibit age-related memory
loss, starting at least by six months of age (Reeves, Irving et al. 1995, Hyde and Crnic
2001, Driscoll, Carroll et al. 2004). Behavioral testing revealed that deficits exist
specifically in spatial and recognition memory (Demas, Nelson et al. 1996, Demas, Nelson
et al. 1998, Bimonte-Nelson, Hunter et al. 2003). Several different memory tasks have been
utilized including 1) the 8-arm water radial arm maze (Lockrow, Prakasam et al. 2009), 2)
novel object recognition tasks (Fernandez and Garner 2008, Belichenko, Belichenko et al.
2009), and 3) the Morris water maze (Escorihuela, Vallina et al. 1998, Stasko and Costa
2004, Costa, Stasko et al. 2010). In a meta-analysis of the 3-day water radial arm maze
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Figure 1-3. Behavior studies of normosomic and Ts65Dn mice at various ages. (A)
Analysis of WRAM performance in Ts65Dn mice (gray symbols) and age-matched NS mice
(black symbols) from several different experiments across age. Note that the Ts65Dn mice
exhibit no statistical difference in average errors the first four trials, indicating that they are
capable of performing the task, but have significantly more errors during the last four trials,
showing a significant reduction in learning. (B) Analysis of total spontaneous activity (in cm)
in Ts65Dn mice (grey squares) and age-matched normosomic mice (NS, black diamonds)
across several different experiments. Note that significant hyperactivity is observed at all ages
examined (6-13 months of age). Plotted dots represent the average of the cohort. (C) Analysis
of locus coeruleus (LC) phenotypic loss from 4 to 13 months of age. There is a progressive
loss of LC neurons with age, most notable at 13 months of age. TS= Ts65Dn; NS =
normosomic. Error bars represent an average ± SEM. Figure was adapted from (Hamlett, et
al, 2016).
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(WRAM) performance at 4, 8, and 10 months of age (Figure 1-3, A), I found significant
karyotype effects in the last testing day (F=4.708; p = 0.003) in Ts65Dn mice compared to
Normosomic (NS) littermates. In post hoc analyses using Bonferroni correction, I also
found that Ts65Dn mice WRAM performance progressively declined (more errors) from
4 to 10 months of age (p = 0.003), suggesting a similarity to the progressive declines seen
with DS-AD. Ts65Dn performance on behavioral tasks gets worse from 4 to 12 months of
age, (Hunter, Bimonte et al. 2003, Stasko and Costa 2004). Ts65Dn mice also exhibit
significant hyperactivity at a young age (Whitney and Wenger 2013), and a meta-analysis
of Ts65Dn activity demonstrated that hyperactivity also increases with age until 10 months
(Figure 1-3, B). As seen in (Figure 1-3, C), Ts65Dn mice had markedly reduced LC
neuronal counts by the age of 10 months. At 4 months of age, Ts65Dn mice show a broader
distribution of LC neuronal counts but seem to have a similar overall average. Few studies
have been conducted on the aging process of other DS mouse models (Sabbagh MN 2015),
which makes the Ts65Dn mouse model a mainstay in the research field.

1.4.2 Early Neurodegeneration in Ts65Dn Mice
Basal forebrain cholinergic neurons (BFCN) provide cholinergic innervation to the
frontal cortex and the hippocampus, and influence attention and cognition in animal models
and humans (McGeer 1984, Dunnett, Everitt et al. 1991, Perry, Walker et al. 1999).
Progressive BFCN neuropathology occurs in Ts65Dn mice at 6-8 months of age
(Holtzman, Santucci et al. 1996, Granholm, Sanders et al. 2000, Cooper, Salehi et al. 2001,
Seo and Isacson 2005, Contestabile, Fila et al. 2006, Salehi, Delcroix et al. 2006), with
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Figure 1-4. Neuropathology in Ts65Dn mice. Neuron loss in the basal forebrain
(TrkA staining), hippocampus (Calbindin), and the locus coeruleus (tyrosine
hydroxylase, TH) in middle-aged Ts65Dn mice compared to age-matched normosomic
mice (NS). In all these three neuronal populations, there is a progressive loss of
phenotype with age, starting at six months of age. For BFCNs, this phenotypic loss is
significant at eight months of age, and for the LC and hippocampal neurons at 10-12
months of age. Scale bar in (A) represents 150 microns, in (D) 60 microns, and in (F)
50 microns. Figure was adapted from (Hamlett, et al, 2016).
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significant neuronal loss by 10 months of age (Figure 1-4, A-B) as observed by
immunostaining of choline acetyltransferase (ChAT) and the high-affinity nerve growth
factor (NGF) receptor, tyrosine receptor kinase A (TrkA). These findings are consistent
with Ts65Dn deficiencies in hippocampal-dependent spatial memory tasks, such as the
WRAM, during this age span (Granholm, Sanders et al. 2000) (Hunter, et al. 2004).

Calbindin-D28K (Cal) is a calcium binding protein, which buffers neuronal
calcium, and may provide greater resistance to neuronal injury and loss since Cal-positive
pyramidal cells in the hippocampus do not accumulate heavy intraneuronal neurofibrillary
tangle (NFT) pathology (Sutherland, Wong et al. 1993). However, Cal-positive neurons
still degenerate in the human brain with aging and greater loss is associated with AD (Lally,
Faull et al. 1997). In Ts65Dn mice, I also observed a significant loss of Cal-positive
neurons in the hippocampal CA1 region (Figure 1-4, C-D) (Hunter, Bimonte-Nelson et al.
2004). In Chapter 5 studies, I also observed significant reductions of Cal-expressing
neurons in the hippocampus in Ts65Dn mice at 9 months of age. Cal-positive neuron loss
specifically observed in Ts65Dn BFCNs may be driven by abnormal reductions in
neurotrophin expression in the hippocampus (Sutherland, Wong et al. 1993, Pappas and
Parnavelas 1997). In line with this, the Granholm lab has conducted several studies on
mature forms of NGF and BDNF and observed significant age-related reductions in levels
of both factors in the hippocampus and cortex of Ts65Dn mice (Bimonte-Nelson, Hunter
et al. 2003, Fukuda, Berry et al. 2010).
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The LC-NE may be one of the first neuronal transmitter systems to display
neurodegeneration along with reductions in cortical innervation before the onset of DS-AD
(Tomlinson, Irving et al. 1981, Mann, Yates et al. 1984, Whitehouse, Struble et al. 1985,
Chan-Palay 1991, Haglund, Sjobeck et al. 2006). This decline in the LC-NE leads to
norepinephrine (NE) deficiencies which exert negative effects on neurons, glia, and blood
vessels throughout the CNS (Feinstein, Heneka et al. 2002, Heneka, Nadrigny et al. 2010).
A meta-analysis of several different groups of Ts65Dn mice has also confirmed LC
degeneration with age in this DS mouse model (Lockrow, Boger et al. 2011). LC-NE
neurons in Ts65Dn mice have normal morphology and cellular density at 4 months of age
but then progressively degenerate with major neuronal loss evident by 12 months of age
(Figure 1-4, E-F) (Lockrow, Boger et al. 2011). NE effects on brain function are mediated
directly, via neurotransmission, and indirectly, via aggravation of Aβ accumulation,
inflammation, and oxidative stress pathways (Marien, Colpaert et al. 2004, Counts and
Mufson 2010). LC-NE lesions using the selective NE neurotoxin, N-(2-chloroethyl)-Nethyl-2-bromobenzylamine (DSP-4), aggravated amyloid accumulation, oxidative stress,
and memory loss in transgenic AD models (Kalinin, Gavrilyuk et al. 2007, JardanhaziKurutz, Kummer et al. 2010). Recent work in the Granholm lab showed that DSP-4 lesions
in Ts65Dn mice gave rise to accelerated memory loss, elevated inflammation, and more
robust neurodegeneration (Lockrow, Boger et al. 2011). In previous studies, the Granholm
lab and others discovered that a long-term administration of the NE prodrug, L-threodihydroxyphenylserine (L-DOPS) recovered memory loss in Ts65Dn mice, which suggests
that rescue of noradrenergic tone before degeneration is evident may provide lasting
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neuroprotective effects (Salehi, Faizi et al. 2009, Lockrow, Boger et al. 2011, Fortress,
Hamlett et al. 2015). In Chapter 3, I further tested the role of the LCNE on cognition by
utilizing designer receptors exclusively activated by designer drugs (DREADDs). This new
approach allowed selective stimulation of declining LC-NE neurons to determine if
modulation of noradrenergic tone could rescue behavioral deficits in this mouse model
(Fortress, Hamlett et al. 2015). Altogether, these studies clearly define an obligatory role
for LC-NE function in cognition and memory performance in mice.

1.5 AD Hallmarks Observed in the Human DS Brain
As individuals with DS age, they exhibit a far greater incidence of short-term
memory impairments compared to their normal baseline performance (Coyle, OsterGranite et al. 1986). This age-related change results in significant reductions in
performance on behavioral indices that measure orientation, object-naming (aphasia), and
general knowledge (Coyle, Oster-Granite et al. 1986). It is important to note that this
measurable decrease in cognitive ability is not seen in individuals with other kinds of
intellectual disabilities, as these people develop AD with an incidence rate that is similar
to the general population (Dickerson, Sperling et al. 2007). Starting abruptly around the
age of thirty, individuals with DS experience abnormal declines in executive function,
language skills, decision making, and cognitive flexibility several years before dementia
can be clinically diagnosed (Wiseman 2009). Cognitive and neuropathological features of
AD continue to worsen through the sixth decade in individuals with DS (Lott and Dierssen
2010, Head, Silverman et al. 2012) which is why this population experience tripled the
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incidence rate of AD shown in Figure 1-1, B when compared to the general population
(Wiseman, Al-Janabi et al. 2015). Albeit very early, the progression of AD pathology
suggests that there may be a preclinical phase where therapeutic interventions may be
effective. In the general population, the delay is at about ten years between the onset of
some AD pathological biomarkers and dementia diagnosis in the general population
(Wisniewski and Rabe 1986, Schupf and Sergievsky 2002). The interval between dementia
AD diagnosis and death is shorter in the DS population, and thus the preclinical phase may
be entirely different for DS-AD.

1.5.1 Profound Protein Accumulation
DS-AD seems to involve a multitude of changes in molecular mechanisms, but two
molecular hallmarks have been the subject of intense investigations and major hypotheses
over the last three decades: 1) extracellular amyloid  protein (A) accumulation leading
to amyloid plaques and 2) significant increases in P-Tau protein leading to NFT deposition.
Due to its localization on Hsa21, individuals with DS have an overexpression of the APP
gene. APP can be cleaved into a variety of smaller peptide fragments, with some of them
being harmful. One of these toxic peptides is A42 peptide, which has a tendency to
aggregate into fibrils and plaques and is a process that can be exacerbated by changes in
enzymatic processing that favor the production of toxic amyloid peptides. Amyloid
deposition is profound in individuals with DS and accumulates in dense plaques that are
easily visualized by Bielchowsky’s silver stain method after the age of 30 years (Figure 15) (Mann and Esiri 1989, Hirayama, Kobayashi et al. 2004). Early diffuse plaques have
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Figure 1-5. Bielschowsky’s silver stain of Human neuropathology. Age-matched
individuals comparing a control individual without cognitive impairments to a DS
individual with clinically diagnosed dementia resulting from DS-AD. Under high
magnification (bottom row), both amyloid plaques NFTs are abundant in brain sections
from patients with DS-AD while absent from the healthy control. NFTs are labeled
with white arrows. Black bars represent scale.
Page 30

been described in individuals with DS already in their teens (Lemere, Blusztajn et al. 1996,
Head 2001), which speak to the etiological consequences of Trisomy 21 on AD pathology,
especially since accumulation of amyloid in plaques is believed to trigger additional
pathology in the brain including inflammation and oxidative stress (Butterfield, Griffin et
al. 2002).

In addition to the pronounced Aβ deposition in subjects with DS (Lott, Head et al.
2006, Cardenas, Ardiles et al. 2012), intracellular NFTs also occur abundantly (Hof,
Bouras et al. 1995, Stoltzner, Grenfell et al. 2000, Mormino, Kluth et al. 2009). NFT
pathology begins in the entorhinal cortex by the mid‐thirties, and then spreads into the
hippocampus by mid‐forties, and then into the neocortex by the mid‐fifties, but biological
variability exists between DS individuals like that seen in the general population (Mann,
Yates et al. 1984, Mann, Yates et al. 1986, Mann and Esiri 1989, Hof, Bouras et al. 1995).
However, results from several research studies have reached a consensus that NFTs may
not appear before the age of 20 in DS (Wisniewski, Dalton et al. 1985, Wisniewski,
Wisniewski et al. 1985), although a recent manuscript demonstrated abnormal
phosphorylation of Tau already in the brain of fetuses with DS. This suggests that Tau
pathology, albeit not accumulating in actual NFTs, is an early event in DS and may
contribute to later development of other AD pathology (Milenkovic, Jarc et al. 2017). The
absence of early NFT pathology originally led researchers to hypothesize that APP gene
dosage and A accumulation are the primary drivers of DS-AD. In Chapter 5, I present
novel biomarker data in support the amyloid hypothesis and tauopathy.
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1.5.2 Hippocampal Atrophy
The hippocampus is essential for working memory function (McGaugh 2000,
Morris, Moser et al. 2003, Morris, Inglis et al. 2006) and the acquisition, consolidation,
and retrieval of declarative memories that contain spatial and contextual information
(Murchison, Zhang et al. 2004). Hippocampal volume is associated with the degree of
cognitive impairment observed in individuals with DS-AD (Beacher, Daly et al. 2009) and
with AD (O'Brien, Desmond et al. 1997), suggesting that atrophy resulting from
neurodegeneration at least partly underlies this decline. Alterations and synaptic integrity
(Garcia-Cerro, Martinez et al. 2014) and reductions in hippocampal neurogenesis (Lazarov
and Marr 2010) are also hallmark changes in the hippocampus associated with DS-AD.
Cal-positive neurons are known to degenerate in the human brain with age, with greater
loss associated with AD (Lally, Faull et al. 1997). Interestingly, Cal-positive pyramidal
cells do not accumulate AD pathology with a heavy burden, which suggests that a greater
ability to buffer calcium correlates with greater resistance to injury and loss (Sutherland,
Wong et al. 1993). The hippocampus is not the first brain structure to undergo degenerative
changes but rather may be a secondary consequence of preceding deterioration of afferent
neuronal populations. The hippocampus is innervated by several important neuronal
systems including 1) basal forebrain cholinergic neurons (BFCN) (Mesulam, Mufson et al.
1983, Hunter 2004, Jason Lockrow 2009), 2) serotonergic neurons of the raphe nucleus
(Levin, Rose et al. 1990) and 3) LC-NE neurons (Mair, Zhang et al. 2005, Salehi, Faizi et
al. 2009). Primary degeneration of these essential transmitter systems predisposes the
hippocampus to neurodegeneration and physiological changes associated with AD.
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1.5.3 Degeneration of Transmitter Systems in DS-AD
The medial septal area, particularly the diagonal band of Broca, provides the
primary source of the neurotransmitter acetylcholine (Ach) in the hippocampus (Dutar,
Bassant et al. 1995). Individuals with DS exhibit progressive degeneration of BFCN, which
correlates with memory loss (Yates, Simpson et al. 1983, Mann, Yates et al. 1985, Isacson,
Seo et al. 2002, Ikonomovic, Mufson et al. 2003, Schliebs and Arendt 2010). Furthermore,
decreases in hippocampal ACh due to phenotypic loss of cholinergic neurons are associated
with cognitive deficits that are typical of AD (Cole and Nicoll 1983, McGeer 1984,
Dunnett, Everitt et al. 1991, Perry, Walker et al. 1999). BFCNs also provide cholinergic
innervation to frontal cortical regions, which exert significant influence on information
processing, attention, and cognition. Although BFCNs are not the focus of this dissertation,
degeneration of this critical population of neurons may influence other brain-related
changes observed in my studies.

LC-NE activity seems to be essential for proper memory function. Noradrenergic
terminals extensively innervate the central nervous system including the hippocampus
(Loy R 1980), prefrontal cortex (Stanton PK 1985, Bramham CR 1997, Morris, Moser et
al. 2003, Vazey EM 2012), and basal forebrain (Espana and Berridge 2006), but also the
hypothalamus, midbrain, medulla and spinal cord (Marien, Colpaert et al. 2004), with
minimal innervation of the basal ganglia. For those who suffer AD or DS-AD, LC-NE
neuron dysfunction and decline occurs very early (Mann, Yates et al. 1984, Marcyniuk,
Mann et al. 1988, Phillips, Fahimi et al. 2016). LC neuropathology in patients with DS-AD
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has been reported to be similar to that observed in AD patients (Wisniewski, Dalton et al.
1985) albeit more severe, with 60% greater neuronal loss relative to age-matched controls
(Mann, Yates et al. 1984, German, Manaye et al. 1992). The loss of LC-NE neurons results
in decreases in NE innervation by as much as 30-50% in both cortical and hippocampal
brain regions (Yates, Ritchie et al. 1981, Reynolds and Godridge 1985, Godridge, Reynolds
et al. 1987). For patients with DS-AD, it is important to note that LC-NE neuron loss occurs
earlier than that observed in the BFCN (Zarow, Lyness et al. 2003) (Mann, Yates et al.
1982, Chalermpalanupap T 2013). This early vulnerability suggests that these neurons are
among the most sensitive to the etiological factors of AD, but there may be a more complex
systems level involvement of different neuronal populations that predispose the LC-NE to
early declines. A declining or dysfunctional LC would result in reduced noradrenergic tone
throughout the brain. Reductions in NE would specifically affect BFCNs via ɑ1 adrenergic
receptor activity (Gibbs and Summers 2002), prefrontal regions via ɑ2 adrenergic receptors
(Faraone, Biederman et al. 2005, Chamberlain, Del Campo et al. 2007), and the
hippocampus via β1 adrenergic receptors (Devauges and Sara 1991, Gliebus and Lippa
2007), although other receptor subtypes are expressed throughout these regions.
Consequences of LC-NE degeneration on specific memory functions in the Ts65Dn mouse
model of DS will be discussed in Chapter 3.

1.5.4 Chronic Neuroinflammation
Inflammation in the brain is often characterized by the activation of resident
microglia, which perform immune surveillance and can upregulate the innate immune
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response (Gehrmann, Matsumoto et al. 1995) via secretions of cytokines and other
inflammatory factors (Kong, Ruan et al. 2010). In acute situations, activated microglia
produce inflammatory mediators that have neuropathic as well as neuroprotective actions,
which suggests that neuroinflammation participates in defense mechanisms against injury
and the ensuing cell degeneration and death. In contrast, chronic microglial activation leads
to significant elevations of multiple neurotoxic factors which drive progressive neuronal
damage (Cagnin, Brooks et al. 2001, Lull and Block 2010). Chronic inflammation is a wellestablished comorbidity with AD (Wyss-Coray and Rogers 2012) and DS-AD (Wilcock
2012), but for those with DS, this hallmark is exaggerated by trisomy 21 aneuploidy very
early in life. Previous studies have shown that pro-inflammatory cytokines are elevated in
fetuses with DS in utero (Hartley, Blumenthal et al. 2015). Dramatic proliferation of
activated microglia occurs in the brain of children with DS resulting in proinflammatory
cytokine overexpression (Wilcock and Griffin 2013, Wilcock, Hurban et al. 2015).

Children with DS also have significant increases in systemic inflammation,
including more proliferation of cytokine-producing microglia in the brain and elevated
peripheral immune responses. Similarly, increases in neuroinflammation very early in life
are assumed to predispose individuals with DS to DS-AD (Wisniewski KE 1985, Webb,
Collins et al. 1986, D'Eustachio, Jadidi et al. 1987, Swardfager, Lanctot et al. 2010,
Wilcock and Griffin 2013). Since the 1980s, studies of postmortem brain specimens from
AD patients revealed significant elevations in neuroinflammatory markers (Eikelenboom
and Stam 1982, Combs, Bates et al. 2001). Then activated microglia, suggesting chronic
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inflammation, were found to be closely associated with AD pathology. Inflammatory
responses, including immunoglobulin and complement factors, were found to be closely
associated with abnormal plaque deposits (Eikelenboom and Stam 1982). Inflammatory
cytokines like interleukin (IL)-1β, IL-6, IL-12, and tumor necrosis factor-ɑ (TNF-ɑ) were
significantly elevated in the serum from patients with AD (Griffin, Stanley et al. 1989,
Griffin 2006, Swardfager, Lanctot et al. 2010, Bagyinszky, Giau et al. 2017). Altogether,
chronic inflammation represents an overall disturbance of innate immunity in the brain,
which is manifest by alterations in resident microglia cells, the degree of which is
exacerbated by the genetics of trisomy 21 which worsens with age (Wierzba-Bobrowicz,
Lewandowska et al. 1999, Head, Lott et al. 2016). In Chapter 4, I utilized a novel antiinflammatory therapy in Ts65Dn mice to investigate whether inflammatory resolution
factors might modulate neuroinflammation.

1.5.5 The Role of LC-NE in Neuroinflammation
One important mechanism behind chronic neuroinflammation observed in those
with DS involves the noradrenergic influence on inflammatory modulation (Cagnin,
Brooks et al. 2001). In addition to its actions as a neurotransmitter, norepinephrine has
other roles that help prevent and limit the progression of neuropathology in a variety of
diseases and conditions. For example, NE reduced lipopolysaccharide (LPS)-induction of
proinflammatory cytokines, like TNFα, in microglia (Szabo, Hasko et al. 1997), interferon
γ-induced expression of class II D-related Human Leukocyte antigens (Lull and Block
2010, Feinstein, Kalinin et al. 2016), and cytokine-dependent induction of type 2 nitric
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oxide synthase (NOS2) expression in astrocytes and microglia (Feinstein, Galea et al. 1993,
Pahan, Namboodiri et al. 1997, Dello Russo, Boullerne et al. 2004). Noradrenergic control
seems to be conserved in mammals as previous research has demonstrated a strong LC-NE
influence inflammation-related pathology in transgenic models for Alzheimer's disease.
Loss of LC-NE innervation with aging or by the selective LC neurotoxin, DSP-4, led to an
increase in pro-inflammatory cytokine expression and increased activation of microglial
cells in the limbic system of the brain (Feinstein et al., 2002; Heneka et al., 2002). Previous
work in our lab has shown that DSP-4 mediated ablation of LC-NE neurons in Ts65Dn
mice led to activation of microglia in the hippocampus, coupled with increased messenger
RNA (mRNA) expression of IL-1β (Lockrow et al., 2011). The increased
neuroinflammation observed in Ts65Dn mice with LC lesion suggests that the LC-NE
denervation modulates the innate immunity in the brain, but the precision of this control
remains unknown. However, as mentioned earlier, neuroinflammation is abnormally
increased even during fetal development in DS. LC-NE degeneration occurs later. This
suggests that other mechanisms or perhaps an uncharacterized LC-NE dysfunction may
exist. Studies using designer receptors in Chapter 3 demonstrated significant and rapid
effects on the immune system of the brain when the activity of LC-NE neurons was
inhibited, providing further evidence for the strong connection between LC-NE signaling
and immune control that is temporally precise. If the brain noradrenergic axis fails over
extended periods of time and neuroinflammation becomes chronic, the LC itself may then
be subject to the detrimental effects of enhanced inflammatory stress, possibly leading to
a neuroinflammatory syndrome in the brain.
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1.6 Therapeutic Pathways to Resolve Chronic Neuroinflammation
The connection between neuroinflammation and DS-AD is a central theme of this
dissertation and can be explored beyond the LC-NE influence. Neuroinflammation is a
multifaceted and persistent hallmark of AD neuropathology, and likely contributes to
neuronal stress, which may manifest disturbances of the proteome, metabolome, and the
lipidome. Research into inflammation as a major contributor to AD has been spurred by
several important discoveries. As mentioned earlier, significant elevations in
neuroinflammation markers and microglial activation is associated with AD pathology.
Another pivotal discovery was that individuals who regularly consume anti-inflammatory
therapeutics seemed to be protected from AD. An indirect proof for the role of
inflammation in AD has been provided by studies utilizing targeted anti-inflammatory
drugs, such as the tetracycline derivative minocycline (Cuello, Ferretti et al. 2010,
Lockrow, Boger et al. 2010). The Granholm lab previously demonstrated that minocycline
treatment in Ts65Dn mice successfully prevents both memory loss and neurodegeneration
if implemented at 4 months of age (Hunter et al., 2004). Minocycline was also shown to
reduce neuroinflammation and inhibits amyloid pathology in a transgenic model of AD
(Ferretti, Allard et al. 2012). Memantine, a glutamatergic N-methyl-D-aspartate (NMDA)
receptor antagonist, is the only FDA-approved drug for the treatment of AD that is not an
acetyl cholinesterase inhibitor. However, a meta-analysis of six clinical trials determined
that Memantine’s protective effect is minimal (Winblad, Jones et al. 2007, Gauthier, Loft
et al. 2008).
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Several epidemiological studies suggested that non-steroidal anti-inflammatory
drugs (NSAIDs) are neuroprotective against AD pathology (Broe, Grayson et al. 2000,
Zandi, Breitner et al. 2002). However, early clinical trials studying NSAID treatment
showed no cure or prevention effects for patients with mild cognitive impairment (MCI)
or AD (Breitner, Baker et al. 2011, Tabas 2013). Alarmingly, some clinical trials that have
implemented NSAID therapies (Imbimbo, Solfrizzi et al. 2010, Sonnen, Larson et al. 2010,
Wu, Rosa-Neto et al. 2011, Sudduth, Schmitt et al. 2013, Amor, Peferoen et al. 2014) have
observed dangerous long-term outcomes including risks of heart failure, gastrointestinal
bleeding and kidney failure (Breitner, Baker et al. 2011, Jaturapatporn, Isaac et al. 2012,
Tabas 2013). Interestingly, individuals with DS demonstrated a significant and chronic
upregulation of the innate immune system, including elevated cytokines in serum
(Convertini, Menga et al. 2016, Iulita, Ower et al. 2016) and increased glial activation in
the CNS (Wilcock, Hurban et al. 2015). NSAIDs and other therapeutic inhibitors like
aspirin, ibuprofen or rofecoxib had broad and multifaceted impacts on inflammatory
processes (Ricciotti and FitzGerald 2011, Alhouayek and Muccioli 2014), likely by
modulating the cyclooxygenase 2 (COX-2) pathway of lipid metabolism. However,
subsequent clinical trials using NSAID treatment showed minimal effects in patients with
MCI or AD (Breitner, Baker et al. 2011, Tabas 2013, McGeer, Rogers et al. 2016).
Altogether, these findings suggest that anti-inflammatory targets other than COX inhibitors
have to be developed for successful treatment or prevention of neuroinflammation in AD
or DS-AD. Disease-modifying drugs for neuroinflammation associated with AD are still
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under extensive research, and no current clinical trials show significant promise to halt the
disease (Yiannopoulou and Papageorgiou 2013, Sikazwe, Yendapally et al. 2017).

Interestingly, lipid metabolism is coupled to noradrenergic influences from the LCNE and is mediated by β-adrenoreceptors (AR), since only β-AR agonists (and not α-AR
agonists) produced similar results (Alhouayek and Muccioli 2014). Modulation of lipid
metabolism has been described in AD (Hewett, Uliasz et al. 2000, Bazan, Colangelo et al.
2002) and may correlate with the severity of dementia in AD patients (Ho, Purohit et al.
2001). The intersection of NE and lipid metabolism reveals yet another noradrenergic
process that may either promote or inhibit neuroinflammation, depending on the balance
of signaling mechanisms, bioavailable metabolites and downstream secondary metabolite
production by other enzymes. These data strongly suggest that anti-inflammatory therapies
may be successful in slowing or preventing AD pathology in DS if one could find a novel
approach that does not interfere with LC-NE modulation and does not have significant
peripheral side effects. In order to prevent, or significantly slow down, neuron loss and AD
progression for individuals with DS, strategies to inhibit accumulations of Aβ peptide
products (like Aβ40 and Aβ42), excessive P-Tau, oxidative stress, neurotrophic
imbalances, and neuroinflammation may extend life by halting AD progression.

One of the most pressing questions in the field is how do to decrease inflammation
in the brain to stop AD progression without chronic adverse side effects? Due to mixed or
poor outcomes of COX-2 inhibitors alternative anti-inflammatory approaches need to be
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explored. Disease-modifying drugs for neuroinflammation are still under extensive
research, and clinical trials have yet to show significant promise for AD therapy
(Yiannopoulou and Papageorgiou 2013, Sikazwe, Yendapally et al. 2017). The lack of
efficacious therapies has bolstered new investigations into inflammatory modulation. In
this dissertation, I explore a novel therapy based on recent knowledge gleaned from polyunsaturated fatty acid (FA) biology, lipid metabolism, and potent modulation of
inflammation that has shown great promise to reduce AD pathology.

1.6.1 Specialized Pro-Resolving Mediators
Epidemiological and animals studies have suggested that omega-3 (Ω3) FAs might
have protective properties against AD, but the recent OmegAD study and other Ω3 clinical
trials found mixed results that suggest few or no benefits of the therapy in multiple
evaluation indices (Freund-Levi, Eriksdotter-Jönhagen et al. 2006, Freund-Levi, Hjorth et
al. 2009, Cederholm and Palmblad 2010) even though it was proven that Ω3 crossed the
blood-brain barrier and elevated levels in the brain (Freund Levi, Vedin et al. 2014). This
lack of response might have ended studies of Ω3 protective effects if not for
groundbreaking research, conducted by Dr. Charles Serhan at Harvard University, which
previously uncovered novel leads connecting Ω3 biology to inflammatory modulation. Ω3
FAs are converted into a family of specialized pro-resolving mediators (SPMs) (Serhan,
Chiang et al. 2008) that are capable of counter-balancing inflammation, a unique process
that is called resolution (Serhan 2007, Buckley, Gilroy et al. 2014). A follow-up
investigation on the OmegAD study, sought to determine if SPM levels released from
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circulating peripheral blood mononuclear cells (PBMCs) from the participants, were
altered after administration of Ω3. The Ω3 administration did not elevate SPM levels but
did prevent reductions in SPM levels released from PBMCs of AD patients (Wang, Hjorth
et al. 2015). It is important to mention that these SPM levels were also correlated with
cognitive function. Studies in animal models are needed to evaluate how Ω3 biology
translates to bioactive SPMs in the brain. Methods to enhance Ω3 conversion to SPMs
remain to be developed.

The resolution mediator process begins with long chain Ω-3 FAs received from a
diet rich in fish, fish oils, and some plant oils. These long-chain Ω-3 FAs, composed
primarily of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are converted
into a large variety of SPMs by a coordination of several enzymatic processes (Figure 16). COX-2 is an important first-step enzyme for the formation of many E-series resolvins
(RvE). The synthesis of RvE (1-3) from EPA involves cytochrome P450 monooxygenases
or acetylated COX-2, thus E-series resolvins that can be aspirin-triggered. Further
enzymatic activities include the formation of 18-hydroxy-eicosapentaenoic acid (18HEPE) that is converted by 5-lipoxygenase (5-LOX) to resolvins (Spite and Serhan 2010).
EPA can also be converted to RvE3 by 15- lipoxygenase (15-LOX) in humans (Isobe, Arita
et al. 2012). The metabolism of DHA to D-series resolvins (RvD1-6) involves acetylated
COX-2 or 15-LOX via formation of 17- hydroperoxy-docosahexaenoic acid (17-HpDHA)
and 17-hydroxy-docosahexaenoic acid (17-HDHA) (Serhan and Petasis 2011). In the
absence of 5-LOX, neuroprotectin D1 (NPD1) is formed from 17-HpDHA. In humans,
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Figure 1-6. Ω-3, SPMs and receptors of the resolution pathway. Enzymatic
conversion of Ω-3 to SPMs is highly coordinated and mediates precise resolution
signaling via G-protein coupled receptors. This schematic was created by Eric Hamlett.
DHA can be metabolized by 12-LOX to form 14-HDHA and the maresins. It is important
to mention that SPM-producing enzymes, COX-2 and 5-LOX, are abundantly expressed in
neurons and glial cells (Zhang L 2006). Chemerin-like receptor-1 (ChemR23) and
leukotriene B4 receptor (BLT1) are expressed in neurons and microglia of the mouse brain
(Schwab, Chiang et al. 2007, Serhan 2007) and ChemR23 is also expressed in the human
brain, both in neurons, astrocytes and microglia (Wang, Zhu et al. 2015). Altogether, the
ongoing transformation of Ω-3 FAs to SPMs (resolvins, lipoxins, maresins, and
neuroprotectins) involves several enzymatic steps and metabolite bioavailability that may
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each be influenced by disease processes. Perturbations in any of these enzymatic steps
could have local or systemic consequences on initiation of the resolution process and
promote inflammation.

1.6.2 Novel Proresolution Therapies
In the periphery, SPMs have been shown to down-regulate pro-inflammatory
cytokines, up-regulate anti-inflammatory cytokines, and promote non-phlogistic
phagocytosis by macrophages (Ji, Xu et al. 2011). In the heart, lipoxin A4 (LXA4) and
NPD1 provide enhanced protection upon ischemic stroke in rodent models (Bazan 2009,
Wu, Wang et al. 2011). RvE1 has been clinically investigated in chronic inflammatory
conditions in peripheral systems and shows positive results in Phase II clinical trial for dry
eye inflammation (NCT00799552), for peripheral artery inflammation reduction
(NCT02719665) and for allergic airway inflammation (NCT01992835). LXA4 has also
been reported to reduce production of reactive oxygen species (ROS) and to inhibit IL-1βinduced IL-8 in vitro. RvD1-2 and RvE1 can attenuate inflammation-associated pain in
mice (Xu ZZ 2010). Interestingly, NPD1 and LXA4 have been reported to protect neuronal
cells from Aβ-induced cytotoxicity (Bazan 2009, Calandria, Asatryan et al. 2015, Zhu,
Wang et al. 2015). RvE1 inhibits neutrophil migration into sites of inflammation, which
reduced cytokine production that can amplify inflammation (Serhan C. 2008, Raouf R
2010, Xu ZZ 2010). Finally, a recent study by Drs. Schultzberg and Granholm and their
collaborators identified and quantified SPMs and receptors in the brain of AD patients and
found several dysfunctions including reduced SPM levels, significant compensatory
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elevations of receptors and alterations of enzymes linked to SPM synthesis (Wang X 2015).
Furthermore, it has been shown in vitro that SPM therapies mediate Aβ clearance and
improve neuronal survival (Zhu, Wang et al. 2015). Lastly, in vitro studies by Schultzberg's
group and others show that SPMs reduce neuronal cell death as well as modulate microglial
phenotype (Hjorth, Zhu et al. 2013, Zhu, Wang et al. 2015, Rey, Nadjar et al. 2016).

1.6.3 Signaling Pathways Involved in Resolution of Inflammation
Several studies have revealed a role for SPMs in the nervous system, where they
initiate a resolution response via a unique class of G-protein coupled receptors (GPCRs)
(see Figure 1-6). The GPCRs affect cAMP-dependent protein kinase activation and alter
signaling pathways that are known to be linked to both AD and DS-AD (Perluigi M 2014,
Burkewitz, Weir et al. 2016, Paschoal, Amano et al. 2017). Specifically, both Mammalian
target of rapamycin (mTOR) and ERK signaling pathways are effector pathways to some
resolution receptors and have been shown to be abnormal in individuals diagnosed with
DS-AD (Iyer, van Scheppingen et al. 2014, Perluigi M 2014) and in mouse models of DSAD (Ahmed, Dhanasekaran et al. 2013, Tramutola, Lanzillotta et al. 2016). A recent study
revealed that specific SPMs are agonists to PPAR-γ and act to modulate cytokine
production (Muralikumar, Vetrivel et al. 2017). Collectively, these SPM receptors are
expressed in the neurons and glial cells in the brain (Schwab, Chiang et al. 2007, Serhan
2007, Wang, Zhu et al. 2015)(Wang et al, 2015). Altogether, the abundance of SPM
enzymes and receptors in the brain suggests that proresolution processes may influence
inflammatory homeostasis specifically in the CNS.
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Although it is established that ChemR23 and BLT1 respond to RvE1, alternative
ligands may play a role in resolution processes. ChemR23 can also transduce
proinflammatory signals upon binding other ligands such as chemerin and Aβ42 (Peng, Yu
et al. 2015). Interestingly, Aβ42 binding led to internalization of the Aβ42-ChemR23
complex, suggesting a potential role for Aβ42 clearance or potentially as a signaling
endosome. Hence, a complex variety of ligands for ChemR23 and for BLT1 may provoke
biased signaling mechanisms that are dependent upon local conditions that balance proresolution and proinflammatory processes over a chronic time scale. Recently, RvE1 was
observed to have a profound binding capacity to the ubiquitously expressed peroxisome
proliferator-activated receptor gamma, PPAR-γ (Arita, Yoshida et al. 2005, Schwab,
Chiang et al. 2007, Oh, Pillai et al. 2011, Herova, Schmid et al. 2015). PPAR-γ belongs to
a superfamily of related nuclear receptors (Tyagi, Gupta et al. 2011) that modulate lipid
homeostasis (Heneka, Reyes-Irisarri et al. 2011). The specific resolution signaling
pathways include phosphatidylinositol 3-kinase (PI3K), protein kinase B (Akt) and
extracellular-signal-regulated kinase (ERK) (Hoeffer 2010). Signaling via Akt and ERK
pathways is abnormal in individuals with DS, in comparison to age-matched controls, and
is also abnormal in the Ts65Dn mouse model of DS-AD (Iyer, van Scheppingen et al. 2014,
Perluigi, Di Domenico et al. 2015), suggesting that perturbations in this pathway may be
involved in neurodegeneration.
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A barrier for studies of resolution processes has been in the development of
appropriate markers and sensitive methods that allow quantification of the resolving
cascade in the human brain. SPM serum and tissue concentrations are relatively low, and
SPM studies necessitate mass spectrometry-based approaches with high sensitivity (Serhan
2000, Serhan 2002). Studies have also revealed that some if not most SPMs are short-lived
in the extracellular matrix and serum of mammals (Dangi, Obeng et al. 2010) suggesting
that ongoing SPM production may be coordinated spatially and temporally to augment
inflammatory processes as needed. If enzyme coordination is protracted, then
inflammatory homeostasis may be affected. Although Bazan and collaborators have
shown that NPD1 promotes neural cell survival (Stark and Bazan 2011), no studies have
been performed to date to test whether SPM-based pro-resolving therapies could be
beneficial in the Ts65Dn mouse model of DS-AD as was done in Chapter 4. Although
SPMs and their binding receptors are abundantly expressed in the brain (Wang X 2015),
their role in modulating chronic inflammation remains been clarified in DS-AD. In
Chapter 4, I observed proteomic modulations in ChemR23, BLT1 and PPAR-γ receptor
levels in response to a novel RvE1 proresolution therapy along with significant increases
in ERK phospho-activation.

1.7 Biomarkers of DS-AD
After clinical diagnosis of DS-AD, a patient has approximately five to ten years
before eventual death (Wisniewski and Rabe 1986, Schupf and Sergievsky 2002) which is
typically less than observed for the general population. For this reason, clinical biomarkers

Page 47

of AD that offer predictive value for this disease are critically needed. The
neuropathological biomarkers, Aβ40 and Aβ42, have been detected in brain tissue and
cerebrospinal fluid (CSF) decades before the onset of dementia in the general population
(Blennow and Zetterberg 2015), as well as in DS (Englund, Anneren et al. 2007) but present
challenges in the clinic. Performing lumbar punctures to acquire CSF in those with DS is
challenging and depends on the functionality of the patient; thus there is a need for the
development of reliable blood-based biomarkers that are clinically relevant for those with
intellectual disabilities and pose minimal to no risk to the patient. I envision that a clinical
test should ideally be able to quantify protein and metabolites specifically from CNS
neurons glia or microglia to be relevant to AD. A clinically relevant test should utilize
either serum, plasma, saliva, or urine samples to provide advantages for DS research since
a consortium of biobanks with blood biosamples representing longitudinal sampling across
ages already exist worldwide. A reliable clinical test may also prove useful in evaluating
potential drug targets for early intervention of AD, by enabling reliable measures of
therapeutic efficacy and provide both diagnosis and prognosis. Finally, an ultimate goal for
biomarker testing would be to guide and integrate extensively into precision medicine,
which might enable disease prevention and treatment that is personalized to an individual’s
specific pattern of genetic variability, environment and lifestyle factors (Reitz 2016).

1.7.1 Exosome Biomarker Potential
In the last two decades, a new biomarker target has emerged that involves the
intercellular transfer of extracellular vesicles (EVs) (Gho and Lee 2017). Most cell types
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in the body, including neurons, release small (~100 nm) endosomally-derived vesicles,
known as cellular exosomes (Figure 1-7) (Coleman and Hill 2015, Fiandaca, Kapogiannis
et al. 2015). Exosomes contain rich sources of proteins, mRNA, and microRNA (miRNA)
cargo that reflect their cellular origin and play a prominent role in cellular signaling,
removal of unwanted proteins, and transfer of pathogens to other cells (Coleman and Hill
2015). Interestingly, bioactive lipids have also been found in exosomes, (Laulagnier, Motta
et al. 2004) which reveal that exosomes may also act as vectors of inflammatory
modulation (Kourembanas 2015). Whether other COX-2-derived lipids, like SPMs, get
sorted into exosomes remains unknown. Secreted exosomes are found in most biological

Figure 1-7. Neuronal exosome isolation. Neuronal exosome get trafficked through
the blood brain barrier and can be readily isolated clinically by blood draw by immunoselection of the L1CAM neuronal marker. L1CAM expression levels are 10-30 times
the mean observed anywhere else in the mammalian body.
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fluids (blood, CSF, and urine) and circulate in interstitial space, both in the brain and the
periphery (Salido-Guadarrama, Romero-Cordoba et al. 2014). The mechanisms of
exosome transport into biological fluids is likely driven by endothelial intracellular
transport, which seems to be governed in part by exosomal surface markers. A recent study
discovered that removal of exosome surface proteins with proteinase K decreases
endothelial transport rates of exosomes by 45% while inhibition of endocytosis, with
cytochalasin D, caused a 50% decrease in transport (Kusuma, Manca et al. 2016).
Collectively, exosomes are actively transported from interstitial space, regardless of origin,
through endothelial cells into the blood which makes the cargo of exosomes an extremely
attractive target for clinical biomarker testing. Neuronal exosomes have unique neuronspecific surface markers, which enable targeted isolation from circulating biological fluids
(Fiandaca, Kapogiannis et al. 2015, Goetzl, Boxer et al. 2015, Goetzl, Boxer et al. 2015).
Specifically, a neural cell adhesion molecule, L1-cell adhesion molecule (L1-CAM, or
CD171), is highly expressed on the neuron surface in all brain regions and is therefore
transferred to the surface of exosomes (Figure 1-7). Therefore, L1-CAM is a relatively
stringent surface protein that allows immuno-enrichment of neuronal exosomes for
biomarker studies.

Recent studies have found that neuronal exosomes may act as vectors of several
important pathological hallmarks of AD. Early endosomes deliver APP to neuronal
exosomes which possess the ability to process APP into Aβ peptides by self-contained
proteases (Haass, Lemere et al. 1995, Rajendran, Honsho et al. 2006, Sharples, Vella et al.
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2008, Perez-Gonzalez, Gauthier et al. 2012, Yuyama, Sun et al. 2015). Therefore neuronal
exosomes seem to have the potential to vectorize toxic Aβ peptide products and also P-Tau
to neighboring cells, other brain regions, and across the blood brain barrier into the
circulatory system. Since AD biomarkers are exosome cargo, this suggested that neuronal
exosomes extracted from either plasma or CSF can be used to assess neuropathological
processes within CNS neurons (Vingtdeux, Sergeant et al. 2012, Jaunmuktane, Mead et al.
2015, Yuyama, Sun et al. 2015). Recent findings indicate that Aβ, Tau, and other AD
biomarker cargos found in neuronal exosomes accurately predict the onset of dementia as
early as ten years before symptom onset in patients with sporadic AD or frontotemporal
dementia (FTD) (Fiandaca, Kapogiannis et al. 2015, Kapogiannis, Boxer et al. 2015). Since
these exosomal biomarkers had not been analyzed in individuals with DS, I hypothesized
that neuronal exosomes obtained from individuals with DS would have elevated levels of
Aβ peptides and P-Tau that could document a preclinical AD-phase in the DS population.
Neuronal exosomes analyses were the focus of Chapter 5.

1.7.2 BDNF as a Clinical Biomarker of DS-AD
Brain-derived neurotrophic factor (BDNF) is necessary for development and
maintenance of several different neuronal populations in the brain and can be retrogradely
or anterogradely transported within the neuronal axon (Adachi, Kohara et al. 2005).
Released BDNF can be measured in cerebral spinal fluid (CSF), but the most attractive
approach would be to measure BDNF in serum due to ease of acquisition and sample
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availability. Serum BDNF levels seem to be strikingly associated with AD and several
other neurological conditions and thus make it an attractive potential biomarker for AD
risk. Several studies have been conducted to test this plausibility. For example, reduced
serum BDNF levels were associated with decreased cognitive performance in patients with
AD as compared to healthy older subjects (Laske, Stransky et al. 2007, Gunstad, Benitez
et al. 2008, Lee, Shin et al. 2009, Forlenza, Torres et al. 2011), but did not correlate with
age or various cognitive test scores (Yasutake, Kuroda et al. 2006). However, a recent study
revealed a positive correlation between serum BDNF levels with specific working memory
and decision-making scores in healthy older adults (Hakansson et al., 2017), suggesting
that BDNF levels may be correlated with specific memory modalities rather than global
cognition performance. It is important to note that significant reductions in serum BDNF
have been reported in patients with MCI (Yu, Zhang et al. 2008), a cognitive stage
preceding AD (Winblad, Palmer et al. 2004, Forlenza, Diniz et al. 2010, Albert, DeKosky
et al. 2011). In contrast, other studies have reported increased serum BDNF levels in
patients with MCI and early AD (Laske, Stransky et al. 2007, Angelucci, Spalletta et al.
2010). These oppositional findings may suggest that BDNF levels reflect an early
compensatory response that gives way to decreases in latter AD stages or with age.

In the DS population, circulating BDNF dynamics seem to be markedly different
to that observed in the general population. Although AD incidence is severe in the DS
population, several studies have counter-intuitively found significant elevations in serum
BDNF levels in individuals with DS when compared to age-matched controls (Dogliotti,
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Galliera et al. 2010, Tlili, Hoischen et al. 2012). The DS-associated increase in serum
BDNF at early ages is profound in multiple cross sections of age and up to 500% increases
(ages 2-14) to 623% increases (ages >60) were observed when compared to age-matched
controls (Dogliotti, Galliera et al. 2010). This marked increase in serum BDNF for those
with DS seems to be correlated to regulatory roles of the Dual-specificity tyrosine
phosphorylation-regulated kinase (DYRK1A), a trisomy 21 gene that is triplicated and
overexpressed (Tlili, Hoischen et al. 2012). Contrary to these findings in young subjects
with DS, a recent study by our group has demonstrated significantly reduced levels of
BDNF in frontal cortex and hippocampus of middle-aged and aged Ts65Dn mice,
suggesting either that brain levels of BDNF are different from those found peripherally, or
that BDNF levels are shifted to down-regulation as memory loss and AD pathology sets in
later in life (Lockrow, Boger et al. 2010). Studies have not been undertaken in the human
DS population across lifespan, nor have studies been done to correlate BDNF levels with
AD biomarkers in this population. This was the focus of Chapter 5 in this dissertation.

1.8 Purpose of the Study
In this dissertation, I investigated biological mechanisms at the crossroads of DS and
AD, using both a mouse model for DS and blood samples isolated from individuals with
DS. Despite the fact that more than 300,000 people in the US are affected by this condition,
few treatments are available for DS-AD, which is a paramount concern for the DS
community. I specifically focused on the contribution of LC-NE degeneration to memory
and neuroinflammation and implemented a novel proresolution therapy to modulate
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neuroinflammation. My studies are tied by a common thread between DS-AD related
pathology including memory loss, inflammatory processes occurring in DS and exacerbated
by LC-NE degeneration, as well as the contribution of BDNF signaling to AD biomarkers
and inflammation. As shown in Figure 1-8, there is a balance between LC-NE activity,
BDNF, and inflammation in the brain, where both BDNF and NE innervation can prevent
the activation of inflammation to occur. The studies in this dissertation focused on this
balance from different perspectives. Within this interdependence, this dissertation addresses
elements that could each aid the future of precision medicine in the DS community.

Figure 1-8. Interplay of LC-NE activity, BDNF and inflammation. Three facets of
DS-AD that have significant impacts upon each other. Each is modulated by highly
coordinated processes and upon failure creates failure in the whole. DS-AD reflects an
emergent spectrum of neuronal disorders that occur subsequently.
In Chapter 3 of this dissertation, I utilized DREADDs, a novel chemical genetic
approach, to specifically control LC neuronal activity to assess the influence that the LCNE system has on various aspects of memory and inflammation in the Ts65Dn mice. I
employed two study paradigms: 1) LC inhibition at four months when LC morphology
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appears intact and 2) LC stimulation at 14 months when the LC has suffered
neurodegeneration. The first series of experiments were designed to assess whether
stimulation of the LC-NE after degeneration is evident, would rescue memory deficits
neuroinflammation. The second series of experiments were designed to assess whether
inhibition of the LC-NE before degeneration is evident, would enhance memory deficits and
exacerbate the neuroinflammatory phenotype that is observed in Ts65Dn mice. Having
determined that inflammation may be rapidly modulated by LC-NE activity, Chapter 4
assessed the efficacy of activating the resolution system via a proresolution mediator SPM
therapeutic approach. These experiments were designed to test the efficacy of administering
a purified resolution mediator, RvE1, to rescue memory deficits, chronic neuroinflammation
and a peripheral component of inflammation in Ts65Dn mice. In Chapter 5, I examined
three circulating neuronal exosome biomarkers, Aβ42, P-T181-Tau and P-S396-Tau along
with serum BDNF levels over broad cross sections of age with the hypothesis that exosome
markers and circulating BDNF levels would define a preclinical period for DS-AD.
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2. General Methods

2.1 Sample Details
For animal studies, Ts65Dn mice (B6EiC3Sn a/A-Ts(1716)65Dn/J, stock# 005252)
and Normosmic mice (B6EiC3SnF1/J, stock# 001875) males were obtained from the
Jackson Laboratory (Bar Harbor, ME). Ts65Dn mice are partially trisomic for a segment
of murine chromosomes 16 and 17, (Davisson et al., 1990). Human blood samples were
obtained from 84 individuals at several sites including 1) The MUSC Down syndrome
Clinic, 2) Linnaeus University (Sweden), 3) University of California at Irvine (UCI)
Institute for Clinical and Translational Science (Irvine, CA), 4) Barrow Neurological
Institute and Banner Sun Health Research Institute (Arizona), 5) Hospital of Sant Pau in
Barcelona (Spain), and 6) Harvard University. Participants either had a normal
chromosomal count (control) or were trisomic for chromosome 21 (DS). Blood samples
were processed at each clinical site according to standard protocols, and aliquots were
shipped on dry ice to MUSC for banking. Human postmortem brain samples were obtained
from 1) the MUSC Brain Bank, (Charleston, SC) and 2) The UCI MIND Down Syndrome
Center. All subjects gave written consent approved by an Institutional Review Board
(IRB), were approved for organ donation under state regulatory control practices for organ
donation, and/or at the equivalent regulatory agency at all of the collaborative institutions.
Specific sample sizes and demographics used for each study are detailed in each Chapter.
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2.2 Vivarium Practices for Mouse Studies
All experimental procedures were approved by the Institutional Animal Care and
Use Committee (IACUC) of the Medical University of South Carolina in accordance with
the guidelines described in the US National Institutes of Health Guide for the Care and Use
of Laboratory Animals. The U.S. Department of Agriculture (USDA) has approved
MUSC's license and registration (56-R-0001) for compliance with the Animal Welfare Act
(accreditation #: A3428-01). The institution’s animal program has maintained accreditation
with AAALAC International since 1987 (Institution #695) with constant compliance with
regulatory inspections by the U.S. Department of Agriculture (USDA).

Ts65Dn mice have been used by our laboratory routinely (Bimonte- Nelson et al.,
2003, Hunter et al., 2003a, Hunter et al., 2004a, Lockrow et al., 2009, Lockrow et al., 2010,
Lockrow et al., 2011 and Hamlett et al., 2016). Animal care was also supplemented by
trained vivarium staff members in the Division of Laboratory Animal Resources (DLAR)
at the Medical University of South Carolina who are on call as needed for any health
problems that may arise. Mice were uniquely identified by two methods: cage cards and
ear punch. The cage cards detailed species, strain, sex, body weight, date of birth,
investigator, department, protocol number and special remarks. When the mice arrived
from Jackson Labs, each animal received a unique ear-punch identification pattern. All
mice were tracked and frequently monitored with key parameters and observations copied
in a laboratory notebook and in a secure digital database. All mice were co-housed (4 per
cage), received food and water ad libitum, and were maintained on a 12 hour light/dark
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cycle (light 6:00 a.m. through 6:00 p.m.). If mice exhibited aggressive behavior, they were
switched to single housing until experimental endpoint. All cages had bedding changes
once every week, and nesting material was maintained for enrichment.

2.3 General Surgical Practices
All instruments, mats, sharps, gauze, cotton and other materials used in surgical
procedures were either pre-sterilized or prepared by autoclave sterilization. The analgesics,
Buprenorphine [0.05 - 0.1mg/kg body weight], 100-200 microliters per mouse) and a
subcutaneous injection of a long-acting local anesthetic, Bupivacaine [1 mg/kg body
weight] were administered at the incision site 30 minutes prior to surgery. For anesthesia,
all mice received an intraperitoneal injection of Ketamine: Xylazine (120 mg/kg: 6 mg/kg
body weight) to induce a deep anesthesia plane where direct toe pinch did not result in a
reflex response. Mice were examined first every hour for 3 hours postoperatively and
thereafter mice were monitored daily, with records being kept to ensure the health and
overall well-being of the animals. Animals were allowed a minimum of 21 days to recover
following surgical procedures before behavioral analyses were conducted. After surgeries,
all animals were singly housed in sterile cages with fresh bedding to decrease infection
potential during healing. To ensure repeatability of the experiments, all mouse experiments
were conducted in two separate waves, which promotes scientific rigor in the design.

2.4 Drug Administration Pathways
For the DREADD experiments (Chapter 3), I delivered stereotactic injections of
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the DREADD construct carried by the adeno-associated-virus (AAV) bilaterally into the
LC via a Hamilton syringe Dr. Heather Boger performed the majority of the stereotaxic
injections and provided me with training with the instrument and practical considerations
with viral particles. Animals were kept isolated for a period of 3 days postoperatively to
allow for viral shedding and protection of vivarium personnel and then placed in cages
with fresh bedding. After 21 days, all behavioral experiments were conducted after
intraperitoneal injections of Clozapine-N-Oxide (CNO; Sigma, St. Louis MO.), or vehicle
(Saline) in a randomized cross-over design. After initial testing, the injections were
switched so that each animal received the alternate treatment. This design allowed for each
animal to also serve as its own control for all behavioral paradigms, except the Water
Radial Arm Maze which could only be performed once. For the Resolvin E1 (RvE1)
experiments (Chapter 4) I utilized subcutaneous implantation of mini-osmotic pumps
(Alzet, Cupertino, CA) because it is rapid, can be done with a very small incision, does not
require daily injections and collectively minimizes stress, discomfort, and pain to the
animal. More extensive details of drug administrative procedures are outlined in each
Chapter.

2.5 Behavioral Testing in Ts65Dn mice (Chapters 3-4)
Proper and consistent handling reduces any unnecessary stress the animal might
experience while under laboratory care and during behavior analyses. This is important
because anxiety would have a negative impact on the accurate measurement of behavior
and memory outcomes. Therefore, all mice were acclimated to the behavior room for at
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least 30-minutes prior to behavior experiments to minimize anxiety. I performed behavioral
tasks in this sequential order: 1) Locomotor testing, 2) Novel object recognition task
(NORT), 3) WRAM “win stay,” 4) WRAM reversal, and 5) rotarod. This behavioral
battery was utilized in all animal experiments with the exception of rotarod which was only
tested in the Resolvin E1 experiments (Chapter 4). Rotarod measures were discontinued
since no significant motor deficiencies were observed between NS and Ts65Dn mice.

2.5.1 Spontaneous Locomotion Testing
In order to monitor changes in overall motor activity in mice, spontaneous activity
was measured using the Digiscan Animal Activity Monitor system. Mice were placed in
the darkened plexiglass testing chamber (40cm x 40cm wide and 30 cm tall) and allowed
to move freely while photobeam breaks in X, Y, and Z axes were recorded (Figure 2-1).
Measurements for total activity, horizontal activity (movement left or right), and vertical
activity (rearing or jumping) were collected over a period of one hour with sampling at 12minute intervals. The data obtained were represented as movement over time, average
movement, and total movement as well as center time, which indicates the mouse
confidence level in moving in an open space. All animals were tested in waves, and all
tasks were performed on each mouse individually behind black plastic sheeting to avoid
distraction interference with task activity. This is a common behavioral measurement for
general activity in rodents and has been utilized for many years by our research group
(Boger, Middaugh et al. 2006, Boger, Mannangatti et al. 2011, Lockrow, Boger et al. 2011).
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Figure 2-1. Open field and NORT testing sequence. Locomoter and NORT tasks
were performed sequentially over 3 days to assess hyperactivity and familiarity
memory. All experiments were conducted at similar times each day cycle after 30
minutes of habituation.
2.5.2 Novel Object Recognition Task (NORT)
The NORT is a 3-day memory task based on familiar object recognition. The
Granholm lab has extensively utilized the NORT in Ts65Dn mice, showing a significant
deficit in discrimination of novel versus familiar objects, both after a short and long delay
interval (Lockrow, Boger et al. 2010, Hamlett 2015). Briefly, mice were individually placed
in the testing arena for a period of 30 minutes with no objects present for habituation
purposes (Figure 2-1). This habituation period is necessary to reduce anxiety in the mice so
that they will interact with the objects in the latter stages of the task. On the next day of
testing, mice were placed in the chamber with two identical objects in the midline that were
equidistant from each other and the walls (approx. 12 cm from the side walls and 12 cm
apart). Interactions with both objects were recorded for 15 minutes with a digital video
camera mounted overhead. After a 90-minute delay, mice were placed in the chamber with
two objects: a familiar object from the preceding set and a novel object. Interactions with
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both objects were recorded for 15 minutes. The spatial location of the objects remained the
same throughout testing. Videos were scored for the amount of time spent with each object
by a blind observer. For each study, The data were calculated as two dependent measures:
the percent time with the novel object and the discrimination index as performed previously
(Jason Lockrow 2009, Hamlett 2015). The discrimination index (DI) represents the net time
with the novel object relative to total time spent with both objects. All trails were digitally
recorded on a webcam coupled to iSPY software, which is freely available online
https://www.ispyconnect.com/.

2.5.3 Optimization of the NORT
During my thesis work, I evaluated the impact NORT arena dimensions could have
on overall object interactions in mice. This placement of objects in this square arena
presented two open space zones which made slightly different object distance from the
wall, depending on where the mice traveled. I sought to create homogeneity in this
parameter and replaced the arena with a rectangular box with optimal dimensions (36cm x
25 cm wide x 25 cm high), made of durable white plastic, and was light-weight (Target
Inc., Minneapolis, MN) (Figure 2-2, A). The optimized arena had no extra open spaces
and the mice explored within a 10 cm radius of an object at all times (roughly double the
body length of the mouse). The original NORT arena had the same dimensions used in
locomotor testing (40cm x 40cm wide and 30 cm tall) and typically had interaction times
around 30 seconds which was not significantly different between NS or TS mice (Figure
2-2, B). I compared overall object interactions in the new arena to previous measures made
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Figure 2-2. Optimization of the NORT task. (A) Old vs Optimized Arena dimensions.
(B) Total Object time for Novel or Familiar objects was not significantly different. (C)
Two way ANOVA revealed that the optimized arena significantly increased object
exploration for both NS and TS mice. (D) Image of the objects used in this task for
clarity. Error bars represent the average ± SEM.
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in the original arena. A two-way ANOVA of these data revealed a significant effect of
optimizing the arena (p < 0.0001), [F1,67 = 33.82]. Tukey's post hoc analysis revealed the
optimization effects were significant for both NS (p = 0.0001) and TS mice (p = 0.0004)
with no differences in overall object interaction time between the two groups (Figure 2-2,
C). The optimization resulted in an 83% improvement in object interaction time thus
making the NORT task interface more powerful. With the optimized arena, mice achieved
an interface with the object over 10% of total time measured, which allowed for more
reliable discrimination index measures.

While attending the Neuroscience 2014 conference, I surveyed the types of objects
that researchers utilize in NORT arenas worldwide and discovered alarming differences in
size, shape, and materials of construction, which altogether could affect the outcome and
repeatability of the task. Objects should be non-odorant and easy to clean between trials,
so plastic or metal construction is preferable. Objects should be of comparable size to each
other so that mice will not have an overtly different surface area for object interface. Also,
objects should not be larger than the mouse to avoid overwhelming the mouse which might
decrease interaction time. I utilized plastic or metal objects that were similar in size (3 cm
wide by 4 cm tall) (Figure 2-2, D). All objects were stabilized to heavy metal washers with
epoxy resin to resist movement by the mice. To ensure equivalence between the objects, I
compared interaction times for NS and TS mice. One way ANOVA revealed that
interaction times for the familiar objects were not significantly different during the
familiarization phase of the NORT. One way ANOVA also revealed that interaction times
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for the unique novel objects were not significantly different during the novelty phases of
the NORT. This test increased my confidence in the methods used since no exploration
bias could be observed with any object used in the NORT task.

2.5.4 Water Radial Arm Maze (WRAM): a Spatial Reference Memory Task
There are two major paradigms utilized to evaluate spatial memory in rodents: (1)
“win-stay” tasks, such as the Morris water maze, in which a single escape platform remains
in the same position throughout testing, and the mouse must remember the platform location
in order to escape, and (2) delayed spatial “win-shift”, tasks, which require the subject to
alternate, or shift, search strategies in order to find multiple targets. As win-stay tasks
involve only one target, they specifically measure reference or recognition memory. Winshift tasks, such as radial arm mazes, contain multiple targets and assess spatial working
memory function if the objects are removed as testing progresses within the same day. I
utilized only the “win stay” version of the WRAM task in Chapter 3 and 4, which was
slightly modified from previous studies (Shukitt-Hale, McEwen et al. 2004, Alamed,
Wilcock et al. 2006), and has been used in mouse models for AD to evaluate spatial memory
function (Wilcock, Alamed et al. 2006) and in our laboratory previously (Bimonte, Hyde et
al. 2000, Lockrow, Boger et al. 2010). The “win stay” WRAM task is similar in design to
the land version of the DS, where the escape platform remains fixed while the starting
position varies. Since the land RAM requires the use of food as a motivator, requiring the
subjects to be food deprived, this presents confound to studies of Ts65Dn mice because they
tend have reduced appetite and reduced body weights. The WRAM water motivation
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effectively mitigates the risk of these factors to influence the outcome of spatial memory.

Water motivated RAM tasks are superior to land based behavior tasks since mice
will attempt escape with near 100% completion (Cravens 1974; Alamed, et al., 2006). The
WRAM is motivated by the innate tendency of mice to swim immediately to an escape
platform, which is a consistent motivator across age and karyotype. The task is nonappetitive and thus allows interpretation regardless of differences in body weight or the
reward value. The WRAM measures memory function in a manner similar to the Morris
water maze but with restricted swim vectors. While the Morris water maze utilizes a round
tub and measures swim speed and distance, spatial memory performance in the WRAM is
measured by arm entry errors. The maze itself is constructed of galvanized steel and painted
black and filled with water to a level 1 cm above the escape platforms. The maze consists
of an eight-arms containing the hidden platform at the end of one arm and is located in a
room with salient extra-maze cues that remained constant throughout the first days of testing
(Figure 2-3, A). It is important that the testing individual is also a salient extra-maze cue so
care must be made in odorants, clothing presentation, and room position to keep task
performance optimal. I utilized large images directly above the arms including 1) solid
black, 2) black and white stripes, and 3) white with a red dot. Since mice do not see red
colors, I assume they see the cue as solid white/light gray. Mice must be monitored during
the WRAM task, so the testing individual is also an extra maze cue. For all WRAM work
in this dissertation, the testing individual refrained from odorants, wore the same highcontrast shirt with the letters “Ba-Zn-Ga,” and held a relatively fixed position during each
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Figure 2-3. WRAM task design. (A) WRAM “win stay” arena design with visual cues
utilized. The platform remained fixed in the same location. On day 3, the platform was
switched to a new location to evoke a set shift in the task to test cognitive flexibility (B)
The testing sequence over 3 days followed a strict algorithm. (C) Swimming ability
between NS and Ts65Dn mice was equivalent
Page 69in all studies.

trial. The WRAM is favorable to the open Morris water maze testing in this mouse
population testing for several reasons including 1) it is more rapidly performed, 2) results
(errors) are quantifiable, and 3) thigmotactic behavior is reduced (swimming in a tighter and
tighter spiral without using extra-maze cues), which can confound interpretation of the
outcome and has been documented in Ts65Dn mice (Escorihuela RM 1995, Costa, Walsh
et al. 1999). As Ts65Dn mice are susceptible to swim-induced hypothermia at lower water
temperatures (Stasko and Costa 2004), water and ambient temperatures were maintained at
24oC, and mice were towel dried and placed under warming lamps between trials.

For all experiments in this dissertation, I utilized a 3-day “win-stay” WRAM spatial
memory task that was optimized to facilitate rapid testing with less fatigue than other water
maze paradigms. To prevent exhaustion, only 12 trials were run each day as two blocks of
six trials, with mice run in cohorts of six per block, permitting a short rest (3-5 min) between
each trial and a longer rest (45 min) while the other cohort of mice were being run. WRAM
trial frequency and duration facilitates rapid testing with decreased likelihood of fatigue
during the task. All WRAM experiments performed in this dissertation, I utilized a strict
sequence of entry arms that randomized the starting position for each trial (Figure 2-3, B)
to force the mice to utilize extra-maze cues to locate the fixed hidden platform through all
trials of testing. On day 1, 9 trials of training were performed where the platform was
alternated between visible (up above the water) and hidden (down under the water) and
remained hidden in the last 3 trials. On days 2-3, spatial memory testing was performed with
the platform hidden for all 12 trials. On day 3, after spatial memory testing and a resting
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period of 45 min, a final test was performed to measure cognitive flexibility. For this test,
the fixed hidden platform was moved to a new location while all extra-maze cues remained
unchanged. Entries to the original platform location (perseverance) and incorrect arm entries
were counted over 8 trials. Trials were run as two blocks of eight trials, with mice run in
cohorts of six per block, permitting a short rest (3-5 min) between each trial.

Because swimming deficiency could bias WRAM spatial reference memory testing,
I examined swim speed and transition times between all arms of the maze. I found that the
overall means of each group were not significantly different and that all mice, regardless of
experimental condition, were able to complete 95% of all swim transit arm-to-arm in
approximately 8 seconds (Figure 2-3, C). These results indicated that all experimental
groups had equivalent swimming capacity and performed the WRAM spatial memory task
without swimming or visual deficits that are found in some Ts65Dn mouse colonies. The
data were recorded as incorrect arm entries with one error added for every 8 seconds of
failure to make an arm selection. For each mouse, four trials of errors were summed into a
block to smooth intertrial variance. Data were reported in blocks with 3 blocks per day for
the WRAM “win stay” trials, and 2 blocks for the subsequent WRAM reversal trials. All
trails were digitally recorded on a webcam coupled to iSpy software mentioned earlier.

2.5.5 Accelerating Rotarod
In order to test motor coordination and motor learning, the accelerating rotarod
(Ugo Basile, Verese, Italy) was utilized to direct mice to walk and balance on a rotating
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rod at increasingly higher rates of rotations per minute (r.p.m). On day zero, mice were
exposed to the slowest rate of 4rpm for 10 minutes to allow them to acclimate to the
expectations of the task so that there was no learning deficit on day one of testing. On days
1-3, mice were subjected to the rotating speeds of 4, 8, 16, 24, 32, and 40 r.p.m. for a
maximum of 5 min per speed. The amount of time the mouse spends on the rotating rod
was recorded by the instrument and then recorded into a spreadsheet. The data were
recorded as the latency to fall, with a mouse with perfect motor performance staying on the
rotarod for 300sec for that speed. It becomes increasingly harder for the mouse to stay on
the rotating platform with increased speed. All animals were tested in waves to allow a rest
between each speed and each testing wave had a random sampling of mice from different
experimental conditions to prevent any chance for testing bias.

2.6 Mouse Euthanasia and Tissue Preparation
To prepare biosamples, mice were euthanized by isoflurane exposure and
subsequent decapitation. All methods were consistent with the recommendations of the
Panel on Euthanasia of the American Veterinary Medical Association (AVMA). Blood was
harvested by cardiac puncture and allowed to coagulate for 30 mins at room temperature.
Coagulated blood was spun at 700 x g, and the resultant serum was decanted into sterile
tubes for further study. During blood coagulation, brains were carefully removed from the
cranium and rapidly dissected. Tissues were divided for Western blot and immunostaining
according to our standard procedures (Boger, Mannangatti et al. 2011, Lockrow, Boger et
al. 2011, Hamlett 2015). The frontal cortex, left parietal cortex, and left hippocampus were
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dissected and placed into pre-weighed tubes, weighed to determine tissue weight, snap
frozen on dry ice, and stored at -80ºC until further use. Remaining brain tissue was fixed
in 4% paraformaldehyde for 48 hours, then placed into 30% sucrose in PBS for at least 72
hours before sectioning at 40µm on a Microm cryostat (Thermo Scientific, Waltham, MA).

2.7 Immunohistochemistry
Pre-fixed brain specimens including regions with the hippocampus, BFCN, and
LC-NE and cortex were sectioned at 40µm and processed for immunohistochemical
analyses as described previously (Lockrow et al., 2011, Fortress and Hamlett, 2015). To
reduce unspecific background signal, sections were blocked in protein-rich 10% normal
serum that was matched to the host species that produced the secondary antibody, typically
normal goat serum (NGS) in TBS-Triton X-100 for 1 hour at room temperature. Primary
antibodies were first tested at various concentrations within the manufacturer’s
recommendations on select testing sections. For Diaminobenzidine immunostaining,
sections were incubated with biotin-conjugated secondary antibodies directed against the
appropriate species, then ABC solution (Vector, Burlingame, CA) followed by
development with 3,3′-Diaminobenzidine tetrahydrochloride (DAB, Sigma, St. Louis,
MO) (see Lockrow et al., 2011). The tissue was mounted onto slides, dehydrated, and
cover-slipped with Permount (Fisher Scientific, Fair Lawn, NJ). For immunofluorescence,
sections were incubated for one hour with secondary antibodies directed against the
appropriate species. Secondary antibodies were conjugated with either TRITC or FITC and
used at a dilution of 1:200, (Jackson Immunoresearch, West Grove, PA). The tissue was
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mounted onto slides, dehydrated, and coverslipped with ProLong Gold Anti-fade Mountant
(Fisher Scientific, Fair Lawn, NJ). All images were captured using a Nikon Eclipse 80i
microscope (Nikon Instruments, Melville, NY) equipped with a Q-cam digital camera or
with an Olympus confocal laser scanning microscope equipped with FlowView FV3000
software (Olympus, Tokyo, Japan). Primary and secondary antibodies utilized in all
experiments are listed in each Chapter method section.

2.8 Enzyme-linked Immunosorbent Assay (ELISA)
For cytokine detection in serum (Chapter 4), I utilized a novel bead-basedcytometry multiplexed ELISA technology to quantify cytokines. The multiplexing
technology is based on color-coded polystyrene beads built using different concentrations
of red and infrared fluorophore dyes (over 100 uniquely-colored bead sets exist). The
unique beads are combined with selective antibodies to individuals cytokines (34 in total)
and then utilized concurrently within the same assay well. For example, a capture antibody
for IL-6 is coupled to a population of dark red beads, and a capture antibody for GM-CSF
is coupled to a population of pink beads. These two antibody-coupled beads can now be
mixed together forming a 2-plex. Each analyte is distinguished from the other because they
are bound to differently colored/fluorescent beads. The beads were washed and then
analyzed by a dual-laser system and a flow cytometry system (Bio-Plex 200, Biorad,
Hercules, CA). One laser activates the fluorescent dye within the beads which identifies
the specific analyte. The second laser excites the fluorescent conjugate (streptavidinphycoerythrin) that has been bound to the beads during the assay. The amount of the
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conjugate detected by the analyzer is in direct proportion to the amount of the target
analyte. The results were quantified according to a standard curve. Multiplexed ELISA
analyses were performed with Eve Technologies (Calgary, Canada).

2.9 Western Blots
Samples

for

western

blot

analyses

were

homogenized

in

standard

radioimmunoprecipitation buffer that was supplemented with protease and phosphatase
inhibitors (Sigma-Aldrich, St. Louis, MO) via handheld pulse grinder followed by 4 x 20
seconds of sonication with a handheld sonic dismembrator that fragmented DNA and
thoroughly mixed the sample. Protein rich sample homogenates were quantified using the
BCA protein assay (Peirce, Rockford, IL). Sample homogenate was combined with
reducing buffer (4 × solution: 4.5% sodium dodecyl sulfate (SDS), 15% β-mercaptoethanol, 0.018% bromophenol blue, and 36% glycerol in 170 mM Tris-HCl pH 6.8) to a
concentration of 25 μg of protein per 30μl and heated at 90°C for 10 min. Samples were
then separated by SDS-PAGE (BioRad, Hercules, CA) 10% gradient gels and transferred
to PVDF membranes by BioRad trans-blotter system. The membranes were blocked with
Licor blocking buffer (Lincoln, NE) for 1 hour at room temperature, then probed with
primary antibodies diluted in 0.1% Tween + Licor blocking buffer. The membranes were
washed twice for 10 min each in 0.1% Tween phosphate buffer solution (PBST) was then
probed with goat anti-mouse or goat anti-rabbit IR-Dye 670 or 800cw labeled secondary
antisera in 0.1% Tween, 0.01% SDS + Licor blocking buffer for 1 hour at room
temperature. Washes were repeated after secondary labeling, washing twice for 10 min in
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PBST, then placed in water. Membranes were imaged using a LICOR Odyssey scanner.
Boxes were manually placed around each band of interest, which returned near-infrared
fluorescent values of raw intensity with intra-lane background subtracted using Image
Studio analytical software (LICOR, Lincoln, NE).

2.10 General Statistical Considerations
I tested all data sets for outliers using Grubbs’ with alpha set at 0.05 and removed
any outliers found in any data set per cohort. I performed Shapiro-Wilk normality test and
found that all or most data sets (Chapters 3-5) passed normality and were well suited for
univariate/parametric tests including analysis of variance (ANOVA) and linear regression.
Due to specific requirements for each data set, statistical tests for behavioral tasks are
defined in each Chapter section. For Western blot and immunostaining data, I performed
ordinary two-way analysis of variance (ANOVA) to test for differences between the four
groups (karyotype x treatment), and Tukey’s post hoc analyses were used in order to
examine statistical patterns that were not specified a priori. It is important to have sufficient
animal numbers in each treatment group to sufficiently power the analyses. Power analyses
were performed on pilot data from previous work in our group, and the following group
sizes would be needed to yield 80% power with α set at 0.05: n=8 for behavioral outcome
measures, morphological and western blot assessments, and for multiplex ELISA tests. All
post hoc results were reported with an acceptable alpha value of p < 0.05 and graphical
data are presented as a mean ± standard error of the means (SEM). All statistics were
performed with GraphPad Prism 7.03 (San Francisco, CA).
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Chapter 3. The Locus Coeruleus, Memory, and Neuroinflammation

3. Introduction
In the Ts65Dn mouse model of DS, depletion of NE levels exacerbates cognitive
impairment and AD neuropathology. Studies utilizing DSP-4, an irreversible inhibitor of
the NE transporter that selectively lesions the LC, revealed a significant increase in
cognitive impairment and AD neuropathology in young Ts65Dn mice (Lockrow, Boger et
al. 2011) and other mouse models (Kalinin, Gavrilyuk et al. 2007). On the other end of the
spectrum, restoring deficient NE levels with chronic L-DOPS or Xamoterol
supplementation significantly enhanced hippocampal-dependent memory (Salehi A 2009)
and restored cued memory and memory recall of platform location in the Morris Water
Maze (Murchison, Zhang et al. 2004). Our group has contributed to these findings during
observations where a chronic L-DOPS treatment was found to protect LC, BFCN, and
hippocampal neurons from degeneration in the Ts65DN mouse (Fortress et al., 2015).
Remarkably, the rescuing effect of L-DOPS supplementation can be observed in middleaged 10 month old Ts65Dn mouse cohorts that have significant LC degeneration (Fortress,
Hamlett et al. 2015). We assume that NE must be in decline at this age and that L-DOPS
rescued this insufficiency. These recent studies suggest that the LC-NE system provides
substantial neuroprotective effects in Ts65Dn mice, but it has not been shown previously
whether selective stimulation of LC-NE neuronal firing rates may improve cognitive
performance in Ts65Dn mice. Furthermore, selective inhibition of LC-NE neuronal firing
rates would provide a valuable understanding of the connection between LC activity,
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hippocampal-dependent behavior, neuroinflammation and neurotrophic support. New
molecular tools that could directly control LC firing would be valuable to studies especially
if they limit the inflammatory confounds of chemical lesions and non-target effects of
pharmacological manipulations

DREADDs are a novel chemical-genetic tool that allows for direct GPCR control
over a specific neuronal population. DREADDs can be targeted to LC-NE neurons under
control of the synthetic PRSx8 promoter for dopamine-beta-hydroxylase (DβH, which is
an enzyme selective for LC-NE neurons (Alexander, Sarah C. Rogan et al. 2009). By
combining the PRSx8 promoter sequence contained within the genetic DREADD construct
carried within AAV viral particles with precise stereotaxic injection to the LC pontine
nucleus, bilateral expression of either hM4D (Gi-coupled, inhibitory) or hM3D (Gqcoupled, stimulatory) mutated ACh muscarinic receptors were bilaterally targeted to LCNE neurons (Vazey EM 2012, Fortress, Hamlett et al. 2015). For the nomenclature in the
term hM3D, M3 denotes the muscarinic receptor subtype, the prefix “h” refers to the
Human species, “D” stands for DREADD and “q” for the G protein coupling preference of
Gq/11 or “i” for the G protein coupling preference of Gi/o. Visualization of viral transfection
efficiency was enabled by a hemagglutinin tag (HA 1.1), which was engineered as a
transgene product fused to the DREADD receptors (Alexander, Sarah C. Rogan et al.
2009).
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Discreet control of human muscarinic DREADDs is achieved because these
receptors do not bind and are not activated by the native cognate ligand, ACh, but instead
bind an exogenous compound, CNO, due to select point mutations in the receptor gene
coding sequence (Armbruster, Li et al. 2007a,b). Specifically, M3 had two point mutations
(Y149C, A239G) to become hM3D and M4 had two point mutations (Y113C, A203G) to
become hM4D. CNO is biologically inert in rodents at physiologically active
concentrations, is readily soluble, and can be delivered systemically to animal models by
intra-peritoneal injection. Despite the short half-life of CNO in mice (Guettier, Gautam et
al. 2009), the biological effects of acute treatment of experimental animals that express
DREADDs are usually much longer (over 10 hours). Although DREADDs lack high
temporal resolution, because of the longer-term effects of CNO and also due to temporal
dynamics of GPCRs, they enable studies of longer-term processes such as LC activity
during wakeful periods of memory assessment. Further, LC activity manipulation over
longer periods provides a unique experimental window to explore the role of the LC during
the neurodegenerative paradigms of AD or DS-AD.

A schematic of DREADD GPCR signaling processes for both hM3D and hM4D
are depicted in Figure 3-1. The physiological effects of DREADD G protein-coupled
receptor activation have been shown to be very similar to the wild-type muscarinic
counterpart (Nawaratne, Leach et al. 2008). When CNO binds the stimulatory, Gq-coupled
hM3D receptor, it evokes the GPCR signaling cascade, similar to M1, M3, and M5
muscarinic receptor types, that stimulates PLC-dependent IP3 release of calcium from the
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Figure 3-1. DREADD mechanism. After 1) stereotaxic delivery of AAV viral
particles, 2) construct integration occurs with high efficiency. LC-NE expression is
driven by 3) the Prsx8 promoter of the 4) DREADD construct which features the
HA1.1 tag as a transgene. 4) CNO activates the DREADD receptor which then signals
through a G-protein to 5) change neuronal probability of firing.
endoplasmic reticulum. The increase in intracellular calcium leads to persistent activation
of neuronal activity (Vazey and Aston-Jones 2014). When CNO binds the inhibitory hM4D
receptor, it leads to neuronal silencing along the Gi/o pathway. To date, there has been
limited focus on using DREADDs to study memory consolidation (Zhu, Pleil et al. 2014,
Fortress, Hamlett et al. 2015, Varela, Weiss et al. 2016, Whissell, Tohyama et al. 2016). In
this study, I employed DREADD Gq- and Gi-dependent signaling because of the known
role that LC activity plays in learning and memory processes (Berridge and Waterhouse
2003, Mather, Clewett et al. 2016, Chmielewski, Muckschel et al. 2017, Unsworth and
Robison 2017).
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3.1 Chapter 3 Specific Aims
The objectives of this study were: 1) to examine if cognitive deficits observed in
middle-aged (11-13 month old) Ts65Dn mice could be reversed by stimulation LC-NE
neurotransmission and 2) to examine the role of LC-NE neurotransmission in younger (four
months old) Ts65Dn mice by inhibiting LC-NE neurotransmission. In the first study, AAV
delivery of hM3D DREADDs specifically into LC-NE neurons in 14 month old Ts65Dn
mice and age-matched normosomic controls was employed to explore whether stimulation
of LC-NE neuronal activity would enhance working memory and decrease
neuroinflammation or AD pathology in the brain. For all hM3D experiments, I employed
sequential locomotor and memory tasks to evaluate working memory. I hypothesized that
hM3D-mediated stimulation of LC-NE neurons would have a greater impact on behavioral
function in Ts65Dn mice than in age-matched normosomic mice since normosomic mice
already demonstrate maximum task performance. AAV delivery of hM4D DREADDs
specifically into LC-NE neurons in Ts65Dn mice and age-matched normosomic controls
was employed to explore whether inhibition of LC-NE neuronal activity would inhibit
working or spatial reference memory and affect AD pathology in the brain. For all hM4D
experiments, I employed a sequential locomotor and memory tasks to evaluate working
memory, spatial reference memory and cognitive flexibility during reversal learning. In the
second study, I hypothesized that hM4D-mediated inhibition of LC-NE neurons into young
Ts65Dn mice would lead to earlier memory loss and associated degeneration of neurons
and inflammation, which would suggest that the loss of LC-NE neurons drives other ADrelated pathology in this mouse model.
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3.2 Chapter Specific Methods
3.2.1 Animal Cohorts
Ts65Dn mice and normosomic (NS) littermate controls (all male) were obtained
from Jackson Laboratories (Bar Harbor, ME). For DREADD hM3D studies, all mice were
aged 11-13 months before treatment. For DREADD hM4D and Green fluorescent protein
(GFP) control studies, all mice were aged four months before treatment. Cohort size is
provided in Figure 3-2.
Figure 3-2. Chapter 3 Cohort size.

3.2.2 AAV-DREADD Vectors Employed
In Chapter 3, three different constructs were utilized including 1) DREADD
hM3D-Gq to stimulatory, DREADD hM4D-Gi inhibitory, or 3) GFP inactive. The
construct contained the PRSx8 promoter (Hwang et al., 2001) which drove the expression
of the hM3D and hM4D designer receptors which coexpressed a C-terminal HA tag for
subsequent identification by microscopy (Armbruster, Li et al. 2007a,b, Alexander, Rogan
et al. 2009) (developed by Bryan Roth, University of North Carolina). Male Ts65Dn mice
and littermate normosomic male mice (NS) were anesthetized with Ketamine: Xylazine
(120 mg/kg: 6 mg/kg i.p.) and given a long-acting local anesthetic in the skin overlying the
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injection site (Bupivacaine, 1 mg/kg s.c.) prior to surgery. Anesthetized mice were placed
in a rodent stereotaxic apparatus with a mouse adaptor, and intracranial injections of AAV
were delivered bilaterally into the LC via a Hamilton syringe at the following stereotaxic
coordinates: -5.34 AP, -2.5DV, ±1.0ML from Bregma (Paxinos 2004). The AAV vectors
included either: 1) AAV-PRSx8-hM3D HA, 2) AAV-PRSx8-hM4D or 3) AAV-CMVGFP (Vazey EM 2014). Each vector was cloned and packaged with AAV viral particles
(serotype 2/9) at the University of Pennsylvania Vector Core at a concentration of (2 x 1012
tu/µl). Both DREADD receptors contained a c-terminal HA tag for identification (provided
by Bryan Roth, University of North Carolina, Chapel Hill, NC). For sham control
experiments, Syn-GFP viral vector (addGene, Cambridge, MA) was cloned and packaged
into AAV viral particles (serotype 2/9) at the University of Pennsylvania Vector Core.
AAV viral particles were delivered at a rate of approximately 0.1 µl per minute over ten
minutes for a total volume of 1.0µl per injection site. After microinjection, the syringe was
left in place for 10 minutes to limit diffusion into the injection track. Animals were then
sutured, removed from the apparatus, and monitored for a full recovery before returning to
disposable cages housed in a BSL2 room. Behavioral testing began 20 days after the AAV
injections. Stimulation of the hM3D receptor with the pharmacologically inert agent, CNO,
facilitates tonic neuronal stimulation of NE release in target neurons (Armbruster, Li et al.
2007a,b). The same hM3D construct used in the current study has recently been utilized by
our lab and others to demonstrate increased firing rates of LC neurons (Vazey EM 2014,
Fortress, Hamlett et al. 2015). Stimulation of the hM4D receptor with CNO facilitates tonic
neuronal inhibition of NE release in target neurons (Armbruster, Li et al. 2007a,b). The

Page 83

same hM4D construct used in the current study has recently been utilized by others to
demonstrate decreased firing rates of LC neurons (Smith, Bucci et al. 2016).

3.2.3 Stereotactic Surgery and Intracranial Injections
We utilized a stereotaxic instrument that uses a Vernier scale to make use of a threedimensional map of the skull in order to locate specific anatomical brain regions which can
be obtained from atlases for various species. Once the subject is placed in the stereotaxic
frame, an incision was made to expose the skull surface. Once the anatomical location had
been determined on the skull, marks were placed on the skull, and burr holes were drilled
to expose the superficial brain tissue. This method provides a level of precision and
accuracy that allows neurosurgeons and neuroscientists to target manipulations at discrete
subsets of neuronal populations. Stereotactic injections of AAV were delivered bilaterally
into the LC via a Hamilton syringe at the following stereotaxic coordinates: -5.34 AP, 2.5DV, ±1.0ML from Bregma. AAV was delivered at a rate of approximately 0.1 µl per
minute over ten minutes for a total volume of 1.0µl per injection site. After microinjection,
the syringe was left in place for 10 minutes to limit diffusion into the injection track. The
incision was closed using sterile monofilament nylon suture for skin incisions, and topical
antibiotic ointment was applied. Animals were kept under a heat lamp until normal
consciousness and mobility were regained. All sutures were removed after complete
healing of the incision, usually after 7 days. Animals were allowed 21 days to recover
following surgical procedures. Dr. Heather Boger performed the majority of the stereotaxic
injections and provided me with training in using the instrument.
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3.2.4 Clozapine-N-Oxide Activation of DREADDs
It has previously been shown that the administration of CNO in rodents leads to
detectable levels of retroconversion into the bioactive compounds clozapine and N-Des
which may create experimental bias in behavioral outcomes. In rodents, a [1 mg/kg body
weight] dose of CNO reduced the acoustic startle reflex, and higher dosages demonstrate
a dose response curve (MacLaren, Browne et al. 2016). The [0.3mg/kg body weight]
dosage was chosen for the experiments in this dissertation because it is efficacious in
creating a biological response in LC neurons by EEG measurements (Vazey and AstonJones 2014). Furthermore, retroconversion of CNO has been shown to be attenuated by
ascorbic acid in vitro and mice have high endogenous levels of ascorbic acid that are stable
through 14 months of age in the brain (Iwama, Amano et al. 2012). Finally, we utilized the
control GFP vector comprising viral infection and delivery of an inert GFP-construct. Upon
CNO administration in these cohorts, no effects were observed on any behavioral indices
suggesting that the CNO dosage did not bias the outcomes measured.

All mice were tested 21 days after intracranial surgery to allow healing and receptor
translation/trafficking. Intraperitoneal injections of Clozapine-N-Oxide (CNO; Sigma, St.
Louis MO.), can be administered five minutes before the start of behavioral testing, which
provides ample time for CNO activation of DREADD receptors (Vazey and Aston-Jones
2014, Fortress, Hamlett et al. 2015). For each behavioral testing day, mice received either
CNO [0.3 ug/g body weight] or vehicle (Veh) injection in a randomized cross-over design.
The vehicle used in both conditions consisted of sterile 0.9% saline (Figure 3-3).
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Figure 3-3. Chapter 3 Experimental design.

Following injections, mice were placed in locomotor activity chambers for 1 hour
immediately before habituation in the NORT arena. The next two days, all mice were given
the same injections again and evaluated in the NORT memory task. The mice were then
rested for one day to ensure CNO clearance. Then the treatments were switched for each
mouse (i.e., CNO to Veh cross-over) followed by habituation and NORT memory testing.
WRAM testing was performed on all groups with CNO injections only since task
performance is positively affected by practice and cannot be carried out under a reversal
paradigm. After testing, mice were sacrificed and the brains rapidly extracted within one
week from behavioral testing.
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3.2.5 Tissue Preparation
Within one week of behavioral testing, all mice were euthanized using an overdose
of isoflurane, and the brains were rapidly dissected. Tissues were divided for HPLC or
immunohistochemistry according to our standard procedures (Boger, Mannangatti et al.
2011, Lockrow, Boger et al. 2011). The right frontal cortex and right hippocampus were
dissected for catecholamine tissue levels and placed into pre-weighed tubes, weighed for
tissue weight, snap frozen on dry ice, and stored at -80ºC until use. The remaining brain
tissue was placed into 4% paraformaldehyde for 48 hours for immersion fixation, then
placed into 30% sucrose in PBS for at least 72 hours before sectioning at 40µm on a
Microm

cryostat

(Thermo

Fisher

Scientific

Inc.,

Waltham,

MA)

for

immunohistochemistry.

3.2.6 Immunohistochemistry
The hippocampus and the pontine region containing the LC were sectioned at 40µm
and processed for immunohistochemical analyses. For DAB staining (Figure 3-2) sections
were incubated with biotinylated anti-rabbit secondary antibodies, then ABC solution
(Vector, Burlingame, CA) followed by development with 3,3′-Diaminobenzidine
tetrahydrochloride (DAB, Sigma, St. Louis, MO) (Fortress, Hamlett et al. 2015). The tissue
was mounted onto slides, dehydrated, and cover-slipped with Permount (Fisher Scientific,
Fair Lawn, NJ). All images were captured using a Nikon Eclipse E-600 microscope
equipped with a Q-cam digital camera.
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Series of every sixth section were blocked in 10 % normal goat serum (NGS) in
TBS-Triton X-100 and incubated with anti-β1 receptor (1:500, Santa Cruz, Dallas, TX), or
anti-tyrosine hydroxylase (TH, 1:1000, Pel-Freeze, Rogers, AR) and anti-HA antibodies
(1:1000, Cell Signaling Technologies, Danvers, MA) overnight at room temperature. The
sections processed for fluorescence microscopy (HA and TH immunohistochemistry) were
then incubated for one hour with secondary antibodies directed against the appropriate
species, conjugated with TRITC or FITC, respectively (1:200, Jackson Immunoresearch,
West Grove, PA). Details about primary antibodies used in Chapter 3 are included next.

3.2.7 LC Characterization
Confocal laser scanning microscopy (Olympus Fluoview BX61) was utilized to
generate 3D images of at least 7 randomly distributed sections from the locus coeruleus in
both normosomic and Ts65Dn mice. NIS-Elements software was used to determine the
percentage of HA-labeled TH-positive LC neurons based on blind hand-counting.
Specifically, all TH-positive neurons in the LC were counted in multiple sections from
each brain. Thereafter, all TH-immunoreactive neurons co-labeled with HA and were
counted on the same sections. Percent co-expression to total TH was quantified.
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3.2.8 Statistical Considerations
For DREADD hM3D studies, one-way ANOVA was performed for comparison
between the groups, eliminating the need for multiple pairwise hypothesis tests. Tukey’s
post hoc analysis was used for all post hoc tests in order to examine statistical patterns that
were not specified a priori, and post hoc results were reported with an acceptable alpha
value of p < 0.05. For DREADD hM4D studies, I wanted to rule out effects of surgery,
stereotactic injection of virus into the LC and viral transfection effects. I first performed
ordinary one-way ANOVA to test for significant differences between control groups (AAV
GFP) with saline or CNO treatment and the inactive inhibitory DREADD group (AAV
hM4D) with only saline treatment. In order to examine statistical patterns that were not
specified a priori, I used Tukey’s post hoc analysis for all for all one-way ANOVAs. Since
no significant within-group differences were observed in either NS or Ts65Dn mice, for
any behavioral task I focused subsequent analyses to compare CNO treatment effects
relative to the viral construct (AAV-GFP control or DREADD hM4D) and karyotype (NS
or Ts65Dn). I performed ordinary two-way ANOVA to test for differences within AAV
groups (karyotype x treatment), and Tukey’s post hoc analysis was used in order to
examine statistical patterns that were not specified a priori. For the 3-day WRAM task, I
performed a linear regression to test for significant differences in slope and elevation (yintercept) over the repeated measures of errors made. All statistics were performed with
Graphpad Prism 6 (v 6.04), and all data were presented as a mean ± SEM.
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3.3 Results
3.3.1 LC Degeneration in Ts65Dn mice
Immunohistochemical assessment of the LC-NE region using TH antibodies
revealed a marked loss of both TH-positive cell bodies and neurites in the LC region in
adult Ts65Dn mice compared to NS mice (Figure 3-4). The loss of TH-immunoreactive
neurons in the LC was not observed at earlier ages (Ts65Dn and NS mice, four months old,
(Figure 3-4, A vs. B). TH-stained sections in 12 month old Ts65Dn mice revealed atrophic
neurons as well as swollen and dystrophic neurites in the LC (Figure 3-4, D), and reduced
TH staining within neuronal cell bodies. It has been established that the LC begins to
degenerate as early as six months of age in Ts65Dn mice (Salehi A 2009, Lockrow J 2011),
with a significant loss of neurons observed in our group at 12 months of age using unbiased
stereological cell counting. The age of mice chosen for the two studies in Chapter 3 was
based on the LC-NE cell loss reported previously. Given that LC-NE morphology is
equivalent between Ts65Dn and Normosomic mice at four months of age, the DREADD
hM4D-mediated approach targeting this age allowed functional assessment without major
confounds associated with LC-NE neurodegeneration observed in older Ts65Dn mice.

In order to determine transduction efficiency of the vector in LC-NE neurons, I
performed immunostaining of the HA tag included in the viral construct, utilizing double
labeling with TH and HA antibodies (Figure 3-5). Five weeks post-injection, robust
expression of the HA tag was observed in the LC region using immunofluorescence, in
both NS (Figure 3-5, C) and Ts65Dn mice (Figure 3-5, D). Co-labeling of HA and TH
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Figure 3-4. LC-NE immunostaining in Ts65Dn and NS mice at various ages. At
four months of age, there was no difference in terms of TH staining density between
NS (A) and Ts65Dn (B) mice. However, at 12 months of age, there was a marked
reduction in TH-immunoreactive fiber density and cell packing density in Ts65Dn
mice (D), compared to NS mice (C). (E) Average staining density is significantly
reduced in Ts65Dn mice. Images taken at 10X, scale bar in (D) = 200µm.
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Figure 3-5. TH and HA immunostaining in the LC. (A) Experimental design for the
DREADD study. The AAV-HA tag vector was injected via stereotaxic injections into
Ts65Dn or NS mice. Twenty days after surgery, mice were tested for behavior. After a
two-day wash-out period, mice were given the opposite treatment in a cross-over design,
(B-D) TH immunostaining (green), HA staining (red), and overlay (yellow, D) in a
Normosomic mouse LC. (E-G) TH (green), HA (red), overlay (yellow) in the LC of a
Ts65Dn mouse. (H): Transduction efficiency table, showing range, mean and st. dev.
measured in a total of 19 double labeled sections. (H) FITC-labeled HA immunostaining
in the LC region at a higher magnification, with evidence of axonal transport of the
DREADD receptors (arrow heads). The scale bar in D and G represents 100 microns,
and the scale bar in H represents 40 microns.
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revealed that average of 98% of TH-positive cells in the LC also co-stained with the HA1.1
tagged DREADD receptor (sampling was performed in 19 sections in 5 subjects, both NS
and Ts65Dn mice; range of co-labeling: 86-100 percent, see Figure 3-5, G). Anterograde
hM3D receptor trafficking in axons adjacent to the LC nucleus was observed, suggesting
a functional integration of the DREADDs into LC neurons (Figure 3-5, H white arrows).
The HA-TH double labeling demonstrated that AAV transduction of the DREADD
receptors in LC-NE neurons was successful, efficient, and specific to the LC neurons, both
in NS and in Ts65Dn mice. Immunostaining gave us great confidence that our combined
targeting approach with a stereotactic injection of AAV delivery particles into the LC, with
expression driven by the PRS x 8 promoter effectively invoke DREADD-mediated control
of the locus coeruleus.

3.3.2 AAV DREADD hM3D-mediated behavior
DREADD hM3D Spontaneous Locomotion Behavior
Stimulation of the hM3D receptor with the pharmacologically inert agent, CNO,
facilitates neuronal tonic increases in target neurons. The same hM3D construct used in the
current study has recently been utilized by others in our group to demonstrate increased
firing rates of LC neurons. Statistical analysis of the two NS groups (with or without CNO
injections) revealed that NS mice showed no significant differences in locomotion (p =
0.673), center time (p = 0.847), or object discrimination in the NORT task after hM3D
activation with CNO (p = 0.522) as evident from the graphs in Figure 3-6, A-C. Based on
these findings, the two NS groups have been collapsed for the purpose of examining a
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priori the effects of trisomy and CNO + trisomy compared to NS mice.

Because hyperactivity has been observed in the Ts65Dn mouse model and may
influence other behavioral components, I first examined the effects of LC hM3D
stimulation on baseline motor activity in Ts65Dn mice (Figure 3-6, A). Both NS and
Ts65Dn mice without CNO exhibited spontaneous behavior similar to what I have
previously reported for age-matched mice of both karyotypes (Lockrow, Boger et al. 2011),
strongly indicating that the AAV injection itself did not give rise to alterations in
spontaneous activity. An ANOVA analysis revealed overall statistical differences between
the groups [F2,15 = 5.101; p = 0.0249], and Tukey’s post hoc analysis further revealed that
vehicle-treated Ts65Dn mice displayed significantly increased spontaneous activity
relative to NS control mice (p = 0.0231), revealing hyperactivity in TS mice. CNO
injections in Ts65Dn mice significantly attenuated hyperactivity, with CNO-treated
Ts65Dn mice exhibiting significantly less total activity than vehicle-treated Ts65Dn mice
(Tukey’s; p = 0.0111). CNO-treated Ts65Dn mice were not significantly different in
overall

locomotor

activity
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than

NS

control

Figure 3-6. Stimulatory DREADD hM3D behavioral outcomes. (A) Vehicle-treated
Ts65Dn mice exhibited a significant increase in total distance traveled (cm) which was
attenuated with CNO treatment. (B) Vehicle-treated Ts65Dn mice spent less time in the
center of an open-field compared to NS mice, which was reversed with CNO. (C)
Vehicle-treated Ts65Dn mice spent significantly less time with the novel object than
NS mice, and this deficiency was normalized after treatment with CNO, with a
significant difference between Ts65Dn mice with our without CNO. (D) NS mice were
significantly more likely to recognize the novel object than vehicle-treated Ts65Dn
mice, which was normalized after CNO treatment. There was no significant difference
between the NS VEH and CNO groups for any of these measures. Error bars represent
mean ±SEM.
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mice (p =0.4508), suggesting that stimulating hM3D receptors restored spontaneous
activity to levels observed in NS mice. Next, the time spent in the center of the activity
arena was evaluated, and an overall ANOVA revealed significant group differences also
for this measure [F2,15 = 5.315; p = 0.0243], (Figure 3-6, B). Interestingly, although
vehicle-treated Ts65Dn mice were significantly more active than NS mice, they spent
significantly less time in the center of the open field arena relative to NS mice, as revealed
using post hoc analysis (Figure 3-6, B, p = 0.0088). However, Ts65Dn mice treated with
CNO spent significantly more time in the center of the open field arena compared to nontreated Ts65Dn mice (p = 0.0291), with center times that were comparable to those
observed in NS mice, suggesting that hM3D-mediated stimulation of LC activity reduced
anxiety-like behavior and hyperactivity in Ts65Dn mice. The spontaneous locomotion data
are the first to demonstrate that hM3D/CNO stimulation of LC-NE can acutely reduce
hyperactivity in the Ts65Dn mouse model, without exerting any effects on either total
activity or on center time in NS mice transfected with the DREADDs.

DREADD hM3D NORT Performance
I first evaluated whether or not hM3D-mediated stimulation of the LC could
alleviate memory deficits in Ts65Dn mice at an age when LC degeneration and cognitive
impairment are both apparent (Figure 3-6, C vs. D). Twenty days post AAV injection, I
tested NS and Ts65Dn in the novel object recognition task. All mice received an i.p.
injection of either CNO or vehicle each day of the task, 5 min prior to testing. To determine
if mice had a preference for the novel object, I first calculated the percent time spent with
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the novel object. A Student’s t-test between the two NS groups revealed that there was no
significant difference between CNO or vehicle treated NS mice in terms of Discrimination
Index in NORT (p = 0.6470, Figure 3-6, D), therefore the two NS groups were collapsed
for further comparison with the Ts65Dn groups. An overall ANOVA between NS mice vs.
the two Ts65Dn groups revealed group differences for time spent on the novel object
between Ts65Dn mice with or without CNO treatment and NS mice [F2,21= 4.623; p =
0.0231]. Tukey’s post hoc analysis revealed that mean time spent with the novel object was
significantly less in vehicle-treated Ts65Dn mice when compared to all NS mice,
regardless of treatment (Figure 3-6, C, p = 0.048).

3.3.3 AAV DREADD hM4D-mediated behavior
DREADD hM4D Cohorts were Equivalent to all GFP Control Groups
To ensure that injection of the control viral construct with green fluorescent protein
(GFP) did not elicit behavioral effects, I performed one-way ANOVAs to test for
significant differences between non-inhibited LC-NE groups (GFP saline-treated, GFP
CNO-treated and hM4D saline-treated) for each dependent variable (Spontaneous
locomotion, percent center time, NORT discrimination index) separately. I found no
significant differences between these groups (data not shown) for any outcome measure of
behavior, which suggested that the inactive state of hM4D is equivalent to any GFP control
group regardless of treatment. Since all measures were equivalent, I next focused on within
group (GFP or hM4D) analyses.
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DREADD hM4D Spontaneous Locomotion Behavior
Because hyperactivity in the Ts65Dn mice may influence other behavioral
components, I examined the effects of hM4D stimulation on baseline motor activity in an
open field chamber for all groups (Figure 3-7, A-B). I performed two-way ANOVA to test
for differences within AAV groups (karyotype x treatment). For AAV-GFP (Figure 3-7,
A-left), the main effect was attributable to karyotype alone which accounted for 60% of all
variation (F1,16 = 24.9, p = 0.0001). Tukey’s post hoc analyses revealed that Ts65Dn mice
displayed significantly increased hyperactivity relative to NS mice (p = 0.01). CNO
treatment did not affect this significant difference (p = 0.015) which supports that CNO is
biologically inert. For AAV hM4D (Figure 3-7, A-right) karyotype alone accounted for
43% of all variation (F1,32 = 25.2, p < 0.0001). Tukey’s post hoc analyses revealed that
Ts65Dn mice displayed significantly increased hyperactivity relative to NS mice (p =
0.01). CNO treatment did not affect this significant difference (p = 0.001) indicating that
inhibition of the LC has no effect on hyperactivity or spontaneous locomotion in mice, at
least not in the current paradigm and age examined. Further, no significant effect was
observed on mean velocity in the open field between NS and Ts65Dn mice, regardless of
experimental condition (data not shown), indicating that LC manipulations do not
adversely affect motor ability. Since changes in stress or anxiety can affect LC-NE
modulation of arousal required to sustain attention for behavioral tasks, I next examined
the effects of hM4D-mediated LC inhibition on center activity (Figure 3-7, B) for all
groups. I performed two-way ANOVA to test for differences within AAV groups
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Figure 3-7. Inhibitory DREADD hM4D open field behavioral outcomes. (A)
Vehicle-treated Ts65Dn mice exhibited a significant increase in total distance traveled
(cm) and this affect was not lost by CNO treatment. (B) There was no significant
difference between the NS VEH and CNO groups regardless of viral vector. Error bars
represent mean ± SEM.
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(karyotype x treatment). For both AAV-GFP and AAV hM4D, Tukey’s post hoc analyses
revealed no significant effects on center time in any of the groups. These results indicated
that karyotype or AAV groups and suggested that measures of discrimination index in
novel object recognition tasks were unbiased.

DREADD hM4D NORT Performance
I next evaluated if hM4D-mediated inhibition of LC-NE neurons could exacerbate
NORT recognition memory deficits in NS or Ts65Dn mice. I performed two-way ANOVA
to test for differences within AAV groups (karyotype x treatment). The analysis was
performed independently for 90 minutes (short-term memory) and 24 hr (long-term
memory) when novel objects were introduced. For AAV-GFP at 90 minutes (Figure 3-8,
A-left), the main effect was attributable to karyotype which accounted for 67% of all
variation (F1,14 = 29.49, p < 0.0001). Tukey’s post hoc analysis revealed that the mean
discrimination index was significantly less in vehicle-treated Ts65Dn GFP mice compared
to NS GFP mice (p = 0.01). Since CNO is biologically inert, CNO treatment did not affect
this significant difference (p = 0.008). Importantly, the AAV injection per se did not appear
to exert any behavioral effects, since non-AAV injected NS and Ts65Dn control mice in
previously published experiments exhibited close to identical NORT performance as AAVinjected NS and Ts65Dn mice in these experiments.

For AAV-hM4D at 90 minutes (Figure 3-8, A-right), the significant effects were
observed by karyotype and treatment. Karyotype accounted for 28% of all observed
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Figure 3-8. Inhibitory DREADD hM4D NORT behavioral outcomes. (A) Vehicletreated Ts65Dn mice spent significantly less time with the novel object than NS mice,
and this deficiency affected by treatment with CNO. CNO treatment of NS mice
significantly decreases time spent with the novel object. (B) NS mice were significantly
more likely to recognize the novel object than vehicle-treated Ts65Dn mice, and this
effect was exacerbated after CNO treatment. CNO treatment of NS mice significantly
decreases time spent with the novel object. Error bars represent mean ± SEM.
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variation (F1,34 = 18.25, p = 0.0001), treatment for 14% of all variation (F1,34 = 9.46, p =
0.004). Tukey’s post hoc analysis revealed that mean DI was significantly less in vehicletreated Ts65Dn hM4D mice compared to saline-treated NS hM4D mice (p = 0.003).
Notably, CNO activation of hM4D receptors significantly decreased DI in NS mice (p =
0.005) and TS mice (p < 0.0001) compared to inactive saline-treated NS mice with hM4D.
For AAV-GFP at 24 hours (Figure 3-8, B-left), the main effect was attributable to
karyotype which accounted for 62% of all variation (F1,14 = 22.45, p = 0.0003). Tukey’s
post hoc analysis revealed that mean discrimination index was significantly less in salinetreated Ts65Dn GFP mice compared to NS GFP mice (p = 0.02). Since CNO is biologically
inert, CNO treatment did not affect this significant difference (p = 0.03). For AAV-hM4D
at 24 hours (Figure 3-8, B-right), the significant effects were observed by karyotype and
treatment. Karyotype accounted for 16% of all variation (F1,33 = 11.01, p = 0.002),
treatment for 36% of all variation (F1,33 = 24.36, p < 0.0001) with no significant interaction.
Tukey’s post hoc analysis revealed that mean DI was significantly less in saline-treated
Ts65Dn hM4D mice compared to vehicle-treated NS hM4D mice (p = 0.04). Similar to the
90 minute interval, CNO activation of hM4D receptors significantly decreased DI in NS
mice (p = 0.003) and TS mice (p < 0.0001) compared to inactive saline-treated NS mice
with hM4D. Notably, CNO activation of hM4D receptors significantly decreased DI in
Ts65Dn mice (p < 0.0001) compared to saline-treated Ts65Dn mice.

Importantly, the AAV injection per se did not appear to exert any behavioral effects,
since AAV-GFP injected NS and Ts65Dn control mice exhibited close to identical
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performance in both locomotor activity (Figure 3-7) and in the NORT Discrimination
Index (Figure 3-8) as the AAV injected NS and Ts65Dn mice with vehicle in this
DREADD experiment. Collectively, these findings suggest that CNO-mediated hM4D
inhibition of LC-NE neurons reduces performance in a working memory task, both at
shorter and longer inter-trial intervals, in 4 month old Ts65Dn and NS male mice. Agematched Ts65Dn and NS control mice without AAV injection exhibited close to identical
behavioral performance compared to Ts65Dn, and NS mice injected with AAV-GFP,
strongly suggesting that surgery, AAV injections, and viral transfection did not give rise to
behavioral alterations. Thus, these data demonstrated that LC-NE inhibition via hM4DCNO administration affected working memory performance in both karyotypes (TS and
NS mice) at 4 months of age.

DREADD hM4D WRAM Performance
Before subjecting the mice to spatial reference memory testing, I examined swim
speed and transition times between the arms in the maze. I found that the overall means of
each group were not significantly different and that all mice, regardless of experimental
condition, were able to complete 95% of all swim transit arm-to-arm in under 8 seconds
(refer to Chapter 2, Figure 2-4, C). These results indicate that all experimental groups
have equivalent swimming capacity and can perform the WRAM spatial memory task
without visual deficits that are found in some Ts65Dn mouse colonies (Scott-McKean,
Chang et al. 2010).
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As seen in Figure 3-9, A Ts65Dn mice exhibited more errors than NS groups on
all three days, regardless of treatment with hM4D-CNO or with the vehicle. In addition,
the Ts65Dn group with hM4D-CNO treatment showed a marginal increase in errors on day
3 of the trial when compared to GFP-CNO treatment, although this difference was not
statistically significant from within the day. I performed a linear regression to test whether
the slopes and overall elevations were different between the four cohorts. Although the
slopes for each mouse cohort were not significantly different from each other, only the
Ts65Dn hM4D-CNO treated group had a slope which was not significantly different from
zero (p = 0.07). The elevations (y-intercepts) were significantly different (F3,19 = 14.40, p
< 0.0001) and were primarily driven by karyotype with Ts65Dn mice having an overall
trend of 63% increase in errors over NS mice.

The WRAM task can be evaluated from the initial start trial block (maximum errors
made) to the final finish trial block (minimum errors made) in order to focus statistical
analyses on the overall performance of the task. I performed two-way ANOVA to test for
differences within AAV groups (karyotype x trail learning) in order to assess learning
aspects relative to the groups when the LC-NE is inhibited. Both karyotype (F3,44 = 21.3, p
< 0.0001) and trail learning (F1,44 = 68.6, p < 0.0001) had significant effects and together
accounted for 73% of all variation. Tukey’s post hoc analyses revealed that both NS GFP,
NS hM4D groups displayed significantly fewer errors at the final trial (p < 0.0001)
compared to the start trail (Figure 3-9, B). The Ts65Dn GFP group also displayed
significantly fewer errors at the final trial compared to the start trail although considerably
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Figure 3-9. Inhibitory DREADD hM4D WRAM behavioral outcomes. (A)
Longitudinal comparison. Ts65Dn mice make significantly more errors than NS mice,
and this was not affected by LC inhibition (hM4D) until the very last trails in Day 3.
(B) Start-to-Finish comparison. NS mice were significantly more likely to enhance
WRAM performance than Ts65Dn mice. LC inhibition (hM4D) in Ts65Dn mice did
not significantly enhance performance. Error bars represent mean ± SEM.
Page 105

less robust (p = 0.001) than any NS group. Interestingly, the Ts65Dn hM4D group did not
show a strong trend of fewer errors in this task comparison, but this was not significant
suggesting that LC-NE inhibition did have some impact on spatial learning. To ensure there
was no bias in summing errors of four trails into one block, I evaluated longitudinal
differences in this WRAM task with the highest fidelity on a per trial basis without binning.
I performed a paired, longitudinal two-way ANOVA to compare mean differences between
experimental groups which resulted in a similar overall result (data not shown).
Collectively, LC-NE inhibition can subtly impact WRAM performance in later WRAM
trials if sufficient learning deficits exist as in Ts65Dn mice.

DREADD hM4D WRAM Reversal Learning
After 3 days of spatial learning, mice were subjected to a new platform location to
test perseverance and error rate, each collectively assessing reversal learning and cognitive
flexibility. After platform switching, all groups demonstrated perseverance to the original
platform in the initial trial block. I performed a two-way ANOVA to test for differences
within AAV groups (karyotype x trial learning) in order to assess reversal learning aspects
when the LC-NE is inhibited (Figure 3-10, A). Trial learning had the greatest overall effect
(F1,44 = 22.9, p < 0.0001) and accounted for 32% of all variation. However, Tukey’s post
hoc analyses revealed that only the NS GFP group had a significant decrease in
perseverance (p = 0.02) suggesting the LC inhibition interfered with learning the new task.
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Figure 3-10. Inhibitory DREADD hM4D WRAM reversal learning. (A)
Perseverance to original platform location. Only NS mice significantly decreased
perseverance errors. (B) Ts65Dn mice make significantly more errors than NS mice
and LC inhibition (hM4D) exacerbates this effect in Ts65Dn mice. Error bars
represent mean ± SEM.
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Since the WRAM task has been practiced over three days, normal mice with strong
cognitive flexibility should rapidly learn the new target cue after platform switching. All
mice demonstrated high error rates when finding the new hidden platform in the first trial
block due to the platform reversal. Within four trials, however, mice with normal cognitive
flexibility quickly learn the new platform locations and then make minimal errors. I
performed a two-way ANOVA to test for differences within AAV groups (karyotype x trail
learning) in order to assess if LC-NE inhibition affected error rate (Figure 3-10, B). I found
that with practice, mice make significantly fewer errors in the final trial block (F1,44 = 32.9,
p < 0.0001). However, karyotype significantly affected the overall performance outcome
(F3,44 = 12.3, p < 0.0001) upon LC inhibition and accounts for 30% of total variance.
Tukey’s post hoc analyses revealed that only the NS GFP and NS hM4D groups made
significantly fewer errors from start to finish (NS GFP, p = 0.0009 and NS hM4D, p =
0.02). After reversal learning, the NS GFP group made significantly fewer errors than the
TS GFP group (p = 0.04) and the Ts65Dn hM4D group (p < 0.0001). LC inhibition in
Ts65Dn resulted in significantly more errors than the Ts65Dn GFP group (p = 0.02).
Overall, hM4D-mediated inhibition of the LC caused mice to make more average errors in
the second trial block with the greatest effect seen in Ts65Dn mice.

3.3.4 β1-Adrenoreceptor Immunostaining
We have previously shown that Ts65Dn mice have significant elevations in β1-AR
expression at 11-13 months (Fortress, Hamlett et al. 2015). Since treatment with the NE
precursor, L-DOPS, normalizes this phenotype we originally presumed β1-AR expression
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is partly driven by a feedback regulation response to declining NE levels caused by
degeneration of the of the pontine LC-NE nucleus in Ts65Dn mice at that age. In this study,
LC morphology seems intact in Ts65Dn mice at 4 months of age so I presumed no β1-AR
expression differences would be detected in LC terminal projection fields. Further, I
hypothesized that hM4D inhibition of the LC would cause β1-AR expression levels to
increase. After immunostaining of β1-AR, I observed significant changes in overall
expression (Figure 3-11). I quantified β1-AR intensity and performed a two-way ANOVA
to test for differences within AAV groups (karyotype x treatment) in order to assess if LCNE inhibition would cause compensatory effects on β1-AR expression levels at 4 months
of age. For all measures, I observed that β1-AR intensity was predominantly affected by
karyotype (F1,35 = 29.9, p < 0.0001) but also by treatment (F3,35 = 3.365, p = 0.029). Factor
interaction was significant (F3,35 = 4.82, p = 0.0065) since LC inhibition only significantly
affected Ts65Dn mice.

In the hippocampus (Figure 3-11, A), Tukey’s post hoc analyses revealed that
DREADD inhibition of the LC had no effect on β1-AR intensity in the NS GFP and NS
hM4D groups. As expected both NS groups had significantly lower β1-AR staining
intensity than the Ts65Dn GFP group (p = 0.0003 and p = 0.0001 respectively).
Surprisingly, DREADD inhibition of the LC normalized expression in the Ts65Dn hM4D
group to equivalent levels observed in either NS group, which is significantly lower than
the Ts65Dn GFP group (p = 0.006). β1-AR immunostaining (Figure 3-11, C-F), revealed
dense punctate fibers with clear elevations in the Ts65Dn GFP group. In the perirhinal
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Figure 3-11. Inhibitory DREADD hM4D β1-AR immunostaining. (A)
Hippocampus. Ts65Dn mice have significantly elevated expression when compared to
NS mice. LC inhibition (hM4D) in Ts65Dn mice normalized expression. (B) Parietal
Cortex. Ts65Dn mice have significantly elevated expression when compared to NS
mice. LC inhibition (hM4D) in Ts65Dn mice normalized expression. (C-F)
Hippocampus immunostaining featuring LCNE fiber staining. (G-J) parietal cortex
immunostaining featuring LCNE fiber staining. Error bars represent mean ±SEM.
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cortex (Figure 3-11, B), Tukey’s post hoc analyses revealed that DREADD inhibition of
the LC again had no effect in the NS GFP and NS hM4D groups. Both NS groups had
significantly lower β1-AR intensity than the Ts65Dn GFP group (p = 0.006 and p =
0.004repectively). DREADD inhibition of the LC normalized β1-AR expression in the
Ts65Dn hM4D group to equivalent levels observed in either NS group, which is
significantly lower than the Ts65Dn GFP group (p = 0.05). β1-AR immunostaining (Figure
3-11, G-J), again revealed dense punctate fibers with elevations only in the Ts65Dn GFP
group. Altogether, the findings suggest that DREADD inhibition of LC-NE normalized
aberrant β1-AR expression at afferent innervation fields in Ts65Dn mice. It is possible that
chronic suppression of LC-NE release in the target regions can lead to degeneration of NE
neurites, and thus also a reduction in β1-AR.

3.3.5 Microglial CD45 Immunostaining
The Granholm Lab has previously shown that Ts65Dn mice have significant
elevations in microglial activation at 8 months of age relative to NS mice (Lockrow, Boger
et al. 2010). In Ts65Dn mice, this was observed as higher CD45 expression concurrent
with a greater frequency of heavily ramified or amoeboid cellular phenotypes in the
hippocampus and various cortex fields (Lockrow, Boger et al. 2011). Since treatment with
the selective DSP-4 NE neurotoxin selectively ablates NE innervation in afferent
innervation fields and exacerbates microglial activation, I presumed that DREADD
mediated inhibition of the LC might also elevate the neuroinflammatory phenotype in our
hM4D groups. Therefore, I immunostained CD45 and assessed microglial activation as
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seen in Figure 3-12. Inhibition of LC-NE neurons via hM4D DREADDs gave rise to a
significant increase in CD45 immunostaining, and increased morphological signs of
microglial activation, both in the hippocampus and the frontal cortex. To confirm the
observed effects, I quantified CD45 intensity and performed a two-way ANOVA to test for
differences within AAV groups (karyotype x treatment) in order to assess if LC-NE
inhibition had effects on CD45 expression patterns at 4 months of age. For all measures, I
observed that CD45 intensity was predominantly affected by karyotype (F11,126 = 3.92, p <
0.0001) and also by treatment (F1,126 = 4.32, p = 0.039). Factor interaction was significant
(F3,35 = 4.82, p = 0.0065) since LC inhibition affected expression levels in NS and TS mice.

In the frontal cortex (Figure 3-12, A), Tukey’s post hoc analyses revealed that
Ts65Dn GFP mice had significantly greater CD45 intensity than NS GFP mice (p = 0.014).
DREADD inhibition of the LC significantly elevated CD45 intensity in the NS hM4D
group relative to the NS GFP group (p = 0.003) and in the Ts65Dn hM4D group relative
to the TS GFP group (p = 0.04). DREADD inhibition of the LC creates a hyper-activated
microglial phenotype in Ts65Dn that was almost three-fold higher than that observed in
the NS GFP mice. CD45 immunostaining (Figure 3-12, C-F), revealed more frequency of
activated microglia (white arrows) in the Ts65Dn, and in the hM4D group where LC
inhibition occurred. In the parietal cortex (Figure 3-12, B), Tukey’s post hoc analyses
revealed that Ts65Dn GFP mice exhibited significantly greater CD45 intensity that NS
GFP mice (p = 0.007). DREADD inhibition of the LC significantly elevated CD45 signal
intensity in the Ts65Dn hM4D group relative to the Ts65Dn GFP group (p = 0.04). CD45
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Figure 3-12. Inhibitory DREADD hM4D microglial CD45 staining. (A) Frontal
Cortex. Ts65Dn mice have significantly elevated expression when compared to NS
mice. LC inhibition (hM4D) causes significant elevations in expression in both NS and
Ts65Dn mice. (B) Parietal Cortex. Ts65Dn mice have significantly elevated expression
when compared to NS mice. LC inhibition (hM4D) causes significant elevations in
expression in both NS and Ts65Dn mice. (C-F) Frontal Cortex immunostaining
featuring activated microglia (white arrows). (G-J) Parietal Cortex immunostaining
featuring activated microglia (white arrows). Error bars represent mean ± SEM.
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immunostaining (Figure 3-12, G-J), revealed frequency denser pattern of activated
microglia (white arrows) in the Ts65Dn, and in the hM4D group of both karyotypes. As
seen in two brain regions, hM4D inhibition of the LC caused a shift towards a more
activated microglial phenotype in Ts65Dn that was at least 2.5 times higher than observed
in NS GFP mice. Altogether, the findings suggest that hM4D inhibition of LC-NE
exacerbates neuroinflammation as observed by increased CD45 expression and higher
frequency of activated cellular phenotypes in both NS and Ts65Dn mice.

Collectively, these results show significant DREADD-mediated effects on LC
function, both in young and in middle-aged Ts65Dn mice. hM3D mediated stimulation of
LC-NE activity in residual LC neurons of middle-aged (14 months old) Ts65Dn mice
exerted significant beneficial effects on hyperactivity, center activity, and performance in
the NORT. hM4D mediated inhibition of LC-NE activity in young (4 month old) Ts65Dn
mice exerted a significant reduction in performance of the behavioral tasks, coupled with
alterations in beta adrenoreceptors and activation of microglial cells in the frontal cortex
and hippocampus. Finally, the AAV-GFP experiment revealed that AAV injections per se
did not alter behavioral performance in the NORT, either in NS or Ts65Dn mice.

3.4 Discussion
The findings presented here are the first to demonstrate that hM3D/CNO-mediated
LC activation can restore memory function in adult Ts65Dn mice. We observed that
artificially stimulating LC-NE function acutely via selective hM3D/CNO-mediated LC
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activation and systemically via the NE pro-drug, L-DOPS, enhanced cognition in Ts65Dn
mice in hippocampal-dependent behavioral tasks, including the NORT and the
spontaneous alternation task. Further, when comparing the behavioral performance in the
two experiments, it was evident from group to group comparison (Figures 3-7 and 3-8),
that the AAV injections themselves did not produce any behavioral alterations in either
Ts65Dn or NS mice. Previous work by us and others has shown that Ts65Dn mice undergo
a progressive loss of LC-NE neurons, beginning at six months of age (Salehi A 2009,
Lockrow, Boger et al. 2011), and the current work extended and confirmed these findings.
Stimulation of the DREADD receptors via i.p. injection of CNO also reduced hyperactivity
in Ts65Dn mice, and increased center time in the spontaneous locomotion box, suggesting
that hyperactivity and anxiety may have been corrected with DREADD stimulation of the
LC-NE transmitter system. Further, double labeling using HA and TH antibodies
confirmed efficient and selective transduction of DREADD receptors into LC-NE neurons,
with an average of 98% co-expression of TH and the HA tag. Similarly, Vazey and AstonJones also found a close to 100% transduction efficiency by the same construct in LC
neurons, corroborating transduction efficiency observed in this study (Vazey EM 2014).

Several pharmacological and genetic manipulations in rodents have linked NE
production in the LC to hippocampal function. DβH-knockout mice that are deficient in
DβH exhibit memory retention deficits which can be reversed by treatment with the β1
agonist Xamoterol (Murchison, Zhang et al. 2004). In humans with DS, the LC undergoes
an accelerated and significant degeneration by as much as 60% compared to age-matched
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non-DS brains (German, Manaye et al. 1992). The LC-hippocampal NE circuit is important
for blood-brain barrier integrity, regulating neuroinflammatory processes, and has direct
effects on learning and memory (for review, see O’Donnell et al., 2012). It has been shown
that development of AD pathology is aggravated by LC-NE neurodegeneration
(Chalermpalanupap T 2013), and we have reported similar findings regarding DS-AD
neuropathology in the Ts65Dn mouse (Lockrow, Boger et al. 2011). In a recent study,
crossed DβH knockout mice with APP/PS1 mice overexpressing mutant APP and PS1.
They found that LC-NE loss in the AD mouse leads to greater deficits in hippocampaldependent memory tasks and that L-DOPS administration alleviated these effects,
providing additional evidence for the important role of LC-NE neurons for neuropathology
and memory deficits occurring both in idiopathic AD and in DS-AD (Hammerschmidt T
2013). The current data extend the knowledge in this area by demonstrating that stimulation
of remaining LC-NE neurons exerts powerful effects on behavior related to hippocampal
function.

The findings presented here are the first to demonstrate that hM3D/CNO-mediated
LC activation can regulate cognition in the Ts65Dn mouse model of DS. Previously, our
laboratory has shown that the loss of LC-NE can exacerbate cognitive impairment and
neuropathology in Ts65Dn mice (Lockrow, Boger et al. 2011), suggesting a role for NE
dysfunction in the accelerated neuropathology observed in Ts65Dn mice. As seen with LDOPS administration, artificially restoring LC-NE function via selective hM3D/CNOmediated LC activation enhanced hippocampal-dependent memory in Ts65Dn mice, and
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corroborates the findings of others demonstrating a role for NE in facilitating cognition
(Salehi, Faizi et al. 2009, Dang, Medina et al. 2014, Salehi, Ashford et al. 2016). Our group
has recently shown that stimulation of hM3D DREADD receptors in the LC-NE neurons
by systemic injection of the inert DREADD ligand CNO doubles the firing frequency of
LC-NE neurons and facilitates cortical EEG changes (Vazey and Aston-Jones 2014),
suggesting that activation of hM3D receptors following CNO administration can drive LC
neuronal firing rates. Our results presented herein expand upon these studies by
demonstrating that LC-NE activity driven by CNO-mediated hM3D stimulation affects
both consolidation and retrieval of hippocampal-dependent memory in the Ts65Dn DS
mouse model. The findings also demonstrate that AAV-DREADD intracranial injections
resulted in a near complete transduction of TH-positive LC neurons, suggesting that the
PRSx8-hM3D-HA vector represents an effective method for assessing behavioral
consequences of selectively stimulating or inhibiting LC neurons using the newly
developed DREADD systems.

These DREADD/CNO experiments further demonstrate that acute activation of a
residual, albeit degenerating, LC-NE pathway, is sufficient to normalize deficits in
hippocampal-dependent memory in Ts65Dn mice. This is supported by evidence that
pharmacologically restoring NE levels in Ts65Dn mice and in DβH-deficient mice enhance
hippocampal-dependent memory (Salehi, Faizi et al. 2009, Murchison, Schutsky et al.
2011, Dang V 2014). In addition to enhanced performance in the NORT, hM3D stimulation
of the LC-NE in Ts65Dn mice gave rise to increased center time and reduced hyperactivity
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in the spontaneous locomotion chamber. Reduced center time may be a reflection of
anxiety as well as hyperactivity, which may lead to reduced attention and/or performance
in memory tasks (Warner G 2014). Specifically, impaired executive function is closely
connected to LC-NE degeneration (Vazey EM 2012), and individuals with DS exhibit
deficits in this cognitive domain (Krinsky-McHale, Devenny et al. 2008, Lanfranchi,
Jerman et al. 2010).

As a first to the field, I employed novel inhibitory hM4D DREADDs, to explore
the role of LC-NE inhibition on the performance of behavioral tasks and development of
AD pathology in a mouse model for DS, Ts65Dn mice. I found significant hyperactivity in
Ts65Dn groups, regardless of hM4D stimulation, and significantly reduced novel object
discrimination profiles in the NORT. For Ts65Dn and NS mice that received AAV-hM4D
and CNO treatment, I observed reduced discrimination in the NORT, both in the short- and
long-term interval. Even though LC morphology seems intact between the cohorts (Figure
3-4), whether this intact structure functions normally is doubtful based on memory
performance results. This is supported by evidence that pharmacological restoration of NE
levels of LC function in older Ts65Dn mice and in DβH-deficient mice enhances working
memory and novelty discrimination performance (Salehi, Faizi et al. 2009, Dang V 2014).
On the other hand, hM4D stimulation in 4 months old Ts65Dn and NS mice did not give
rise to reduced performance in the WRAM except in the last day, demonstrating that spatial
reference memory was not overtly affected by inhibiting LC-NE firing rates in young (4
months old) mice. As mice work longitudinally through the WRAM task, they typically
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demonstrate steady improvements in performance, seen as 10-30% improvements in error
rate over each preceding trial. LC inhibition did reveal spatial memory task effect in final
trials of the WRAM, but this was observed only in the Ts65Dn mice, which suffer
deficiencies throughout task duration. Thus hM4D-mediated effects may not necessarily
exacerbate spatial memory deficits but may influence the ability to perfect the task with
practice.

DREADD hM4D inhibition of the LC-NE revealed unanticipated effects in β1adrenoreceptor expression in terminal afferent fields. We have previously shown that
Ts65Dn mice have significant elevations in β1-AR expression at 11-13 months (Fortress,
Hamlett et al. 2015) and that treatment with the NE precursor, L-DOPS, normalized β1AR expression. In this study, we originally hypothesized that hM4D inhibition of the LC
would cause β1-AR expression to increase with the assumption that β1-AR expression is
mainly driven by a feedback regulation response to declining NE levels caused by LC
degeneration. Surprisingly, LC inhibition normalized β1-AR expression specifically in
Ts65Dn mice. This finding indicates that NE alone may not be the primary driver of
abnormal elevations of β1-AR phenotype in Ts65Dn mice and that other possibilities must
be considered. DREADD hM4D receptors signaling results in G protein-coupled inwardlyrectifying potassium channel (GIRK) channel-mediated neuronal inhibition, so perhaps
aberrations of LC influence on this channel in Ts65Dn mice causes elevations in β1-AR,
which could underly a molecular mechanism driving the observed compensatory response.
Since β1 receptor knockout mice exhibit impaired memory retrieval, an optimal expression
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level of these receptors seems to be necessary for many aspects of memory performance
and has major implications for hippocampal-dependent behavioral tasks (Murchison,
Schutsky et al. 2011), perhaps by facilitating excitatory transmission, as suggested by
others (Zhang L 2013). Understanding the cellular mechanisms downstream of β1 receptor
activation is necessary for facilitating hippocampal memory in aging Ts65Dn mice may
enhance the discovery of novel drug targets for both the AD and DS-AD populations.
Further studies are needed to better understand the mechanisms that drive significant
elevations in β1-AR expression in Ts65Dn mice.

It was previously shown that Ts65Dn mice have significant elevations in microglial
activation at 8 months of age relative to NS mice. In Ts65Dn mice, this was observed as
higher CD45 expression concurrent with a greater frequency of heavily ramified or
amoeboid cellular phenotypes in the hippocampus and various cortex fields (Lockrow J
2011). Treatment with DSP-4, a select neurotoxin of LC neurons would be expected to
significantly decrease NE tone in afferent innervation fields and has been observed to
exacerbate microglial activation. I hypothesized that DREADD mediated inhibition of the
LC might also elevate the neuroinflammatory phenotype in all hM4D groups that receive
CNO. As seen in Figure 3-12, hM4D-mediated LC inhibition significantly elevates the
neuroinflammatory phenotype in our hM4D groups as observed by CD45 intensity and
increases in cellular phenotypes that are prototypical of activated microglia. Here I report
that enhanced microglial activation is already present at 4 months of age in Ts65Dn mice.
At such a young age, I contemplate the importance of the LC in preventing microglial
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activation and chronic neuroinflammation. In this study, all animals received 9 days of
daily LC inhibition, which was sufficient to manifest a neuroinflammatory phenotype.
With clinical DS-AD, such microglial activation occurs years before the certain appearance
of Aβ plaques in DS by the age of 20. These findings add further support the theory that
LC dysfunction underpins early neuroinflammation in the DS population.

Neurotrophins exert significant influence on neuron survival, synaptic plasticity,
learning and memory (Chao 2003). The neurotrophin, BDNF, is highly expressed
throughout the central nervous system, especially in the hippocampus and cerebral cortex
(Phillips, Hains et al. 1990, Wetmore, Ernfors et al. 1990). BDNF is critical to the survival
and function of hippocampal, cortical, cholinergic, noradrenergic and dopaminergic
neurons (Alderson, Alterman et al. 1990, Hyman, Hofer et al. 1991, Ghosh, Carnahan et
al. 1994, Holm, Rodriguez et al. 2003) and for synaptic plasticity and memory processing
in the adult brain (Alonso, Vianna et al. 2002, Bekinschtein, Cammarota et al. 2008).
Recent studies revealed a link between NE and enhanced BDNF synthesis. Stimulation of
hippocampal astrocytes with NE resulted in increased release of BDNF (Zafra, Lindholm
et al. 1992). Stimulation of embryonic hippocampal neurons with NE activates the
Phosphoinositide-3-kinase and MAPK signaling cascades and induces BDNF (Chen,
Nguyen et al. 2007). Furthermore, BDNF mRNA transcription was significantly elevated
by ~200% specifically in response to NE stimulation (Vaghi, Polacchini et al. 2014). BDNF
has also been explored regarding dementia risk because expression levels are correlated
with lifestyle factors such as reduced caloric intake (Lee, Seroogy et al. 2002) and increased
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physical activity (Neeper, Gomez-Pinilla et al. 1995, Vaynman, Ying et al. 2003). Reduced
levels of BDNF in the brain is thought to be associated with in Alzheimer’s disease
(Sutherland, Wong et al. 1993, Pappas and Parnavelas 1997, Nagahara, Merrill et al. 2009,
Iulita, Do Carmo et al. 2014). Since BDNF is a key regulator of neuronal plasticity and
survivability, it is considered a major pharmaceutical target to prevent neurodegeneration.
Degeneration of the LC-NE would have widespread repercussions on early cognitive
impairment, chronic inflammation and neurotrophic support, it has emerged as a central
therapeutic target to prevent DS-AD. The work accomplished thus far will provide a sound
basis for BDNF studies in the near future.

Collectively, our results came from artificially stimulating LC-NE function acutely
via hM3D/CNO-mediated LC activation or via inhibiting LC-NE function via hM4D/CNO
mediated LC silencing. Utilizing DREADD technology enables the discrimination of
neuronal contributions to complex behavior without actions on neighboring cells or
peripheral systems. Our study provides direct evidence for the feasibility of DREADD
receptor technology to explore the role of discrete neuronal populations in
neurodegenerative disorders at physiological active CNO concentrations that are not likely
to retroconvert to appreciable levels of Clozapine, a known psychoactive drug. Our
findings expand upon previous findings by us and others (Murchison, Zhang et al. 2004,
Salehi A 2009, Murchison, Schutsky et al. 2011) suggesting that the LC-NE pathway is a
plausible target for new therapeutics in treating DS-AD and idiopathic AD. The increase
in the number of aging adults with DS will provide a significant opportunity and challenge
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to improve their quality of life in the very near future. AD-related neuropathology is an
unfortunate fact for aging adults with DS and the findings here further implicate the
important role the LC-NE will have for each individual. Therefore, employing NEenhancing drugs for individuals with DS-AD may lead to significant improvement not only
in memory but also in anxiety and attention-related behaviors. This is especially important
since classical AD medications may be less effective in DS-AD compared to idiopathic
AD (Iulita, Do Carmo et al. 2014), and there are currently no effective medications
available to mediate cognition in DS patients (Warren B. Zigman 2004, Nelson, Johnson
et al. 2005). It is imperative to test and verify the efficacy of pharmacological drugs that
can modulate noradrenergic functions in this population, to decrease neuroinflammation
and decrease the prevalence of DS-AD in society.
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Chapter 4. A Specialized Pro-Resolving Mediator Approach in Ts65Dn

4. Introduction
Chronic neuroinflammation may represent an overall disturbance of innate
immunity in the brain, which is manifested by alterations in resident microglia cells, the
degree of which is highly affected by aging, genetics, diet and daily activity (McGeer and
McGeer 2004). In Chapter 1, I introduced how Ω3 fatty acids can be transformed into
potent SPMs that are highly efficacious in modulating inflammatory responses. Several
studies have revealed an important role for SPMs in the nervous system, but the
experiments conducted in this Chapter specifically focus on RvE1. RvE1 initiates a wellcharacterized resolution response via a conserved class GPCRs (see Figure 4-1). RvE1 is
known to bind to ChemR23 and BLT1 receptors, which mediated release of intracellular
Ca2+, prevent of cAMP accumulation, and alter signaling pathways that are known players
in AD and DS-AD (Ohira T 2010, Oh, Pillai et al. 2011, Perluigi M 2014, Burkewitz, Weir
et al. 2016, Paschoal, Amano et al. 2017). mTOR and ERK proteins are effectors of these
signaling pathways and both have been shown to be abnormal in individuals diagnosed
with DS-AD (Mattson 2007, Williams B 2007 , Iyer, van Scheppingen et al. 2014, Perluigi
M 2014) and in mouse models of DS-AD (Ahmed, Dhanasekaran et al. 2013, Tramutola,
Lanzillotta et al. 2016). RvE1 was also observed to have a profound binding capacity to
PPAR-γ (Arita, Yoshida et al. 2005, Schwab, Chiang et al. 2007, Oh, Pillai et al. 2011,
Herova, Schmid et al. 2015), which makes its therapeutic value comparable to
rosiglitazone, a proven PPAR-γ agonist that also has therapeutic potential for AD
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(Muralikumar, Vetrivel et al. 2017). As mentioned in the Introduction, the ChemR23 and
BLT1 receptors along with PPAR-γ are highly expressed in both neurons and microglia in
the brain and thus are assumed to be major contributors to proresolution outcomes that
would be relevant to neuronal systems.

One of the most pressing questions in the field is how do to decrease inflammation
in the brain to stop AD progression without chronic adverse side effects? In recent studies,
Schultzberg, Granholm and co-investigators identified and quantified SPMs and their
receptors in the brain of AD patients and found several dysfunctions including reduced
SPMS, significant elevations of receptors and alterations of enzymes linked to SPM
synthesis (Wang, Zhu et al. 2015). In the OmegAD study, Ω3 administration did not cause
significant elevations in a specific SPM measures for patients with AD despite being given
over 6 months (Wang, Hjorth et al. 2015). Altogether, this research suggested that an
intervention that could bypass the normal Ω3-to-SPM enzymatic process by direct delivery
of SPMs at an effective dose could possibly be a viable way to resolve neuroinflammation
and potentially prevent AD pathology.

4.1 Chapter 4 Specific Aims
I constructed and implemented an ideal first-of-kind methodological approach to
administer purified resolution agonists chronically in Tc65Dn mouse model, which mimics
major hallmarks of early neurodegeneration and persistent neuroinflammation seen in the
DS population. My approach has strengths because it effectively bypasses the complexity
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of all enzyme mechanisms that are needed to create SPMs naturally, with the expectation
this kind of treatment would directly activate the resolution pathway. The central
hypothesis in this Chapter was that resolution agonists could activate brain resolution,
reduce neuroinflammation and prevent memory loss in a mouse model of DS. I tested this
hypothesis with the potent EPA-derived SPM, RvE1, which was given as a chronic
therapeutic for one month followed by measures of peripheral cytokines, microglial
activation, and several behavioral indices.

4.2 Chapter Specific Methods

4.2.1 Animal Cohorts
Ts65Dn mice and normosomic (NS) littermate controls (all male) were obtained
from Jackson Laboratories (Bar Harbor, ME). All mice were aged 8 months before
treatment. Cohort size is provided in Figure 4-1.

Figure 4-1. Chapter 4 Cohort size

4.2.2 Pharmacological Treatments
RvE1 crosses the blood-brain barrier, like its parent EPA compound, suggesting an
effective treatment outcome could be achieved in the brain (Freund-Levi Y 2014). At 8
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months of age, mice received a subcutaneous mini-osmotic pump (Alzet, Cupertino, CA)
delivering one of two sterile solutions: Vehicle (5% EtOH, 95% saline) or Resolvin E1,
[10 ng/g body weight/day] dissolved in the vehicle. The pump was calibrated to deliver
approximately 2.3 microliters per day for a maximum of 35 days to deliver a daily dose of
300 ng to a 30 gram mouse per day. After implantation, the minor incision was closed using
sterile monofilament nylon suture, and topical antibiotic ointment was applied. Animals
were kept warm until normal consciousness and mobility were regained, and sutures were
removed after complete healing of the incision, which was usually after 7 days.

Figure 4-2. Experimental Design. All mice were aged 8 months and then received the
mini-osmotic pump filled with select treatment. This resulted in four experimental
groups NS (Veh or RvE1) and Ts65Dn (Veh or RvE1) that were continuously dosed
for 35 days. Behavior task were initiated only 25 days after dosing began and were
completed before dosing was finished.

4.2.3 Behavioral Tests
After 25 days of continuous chronic treatment, four behavioral experiments
occurred sequentially: spontaneous locomotion, NORT, the 3-day WRAM, WRAM
reversal and rotarod. These behavior tasks are commonly used throughout this dissertation
and are fully described in the General Methods (see Chapter 2).
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4.2.4 Tissue Preparation
Within one week of behavioral testing, all mice were euthanized using an overdose
of isoflurane, and the brains were rapidly dissected. Tissues were prepared for
immunohistochemistry and western blot as described in General Methods (Chapter 2).

4.2.5 Immunostaining
Details about primary antibodies used in Chapter 4 are included below.

4.2.6 Statistical Considerations
I tested all data sets for outliers using Grubbs’ with alpha set at 0.05 and found no
outliers. I performed Shapiro-Wilk normality test and found that all data sets passed
normality and were well suited for univariate/parametric tests including analysis of
variance (ANOVA) and linear regression. For behavior data, I performed ordinary twoway ANOVA to test for differences between the four groups (karyotype x treatment), and
Tukey’s post hoc analysis was used to examine statistical patterns that were not specified
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a priori. For the 3-day WRAM task, I performed a linear regression to test for significant
differences in slope and elevation (y-intercept) over the repeated measures. For western
blot and immunostaining data, I performed ordinary two-way ANOVA to test for
differences between the four groups (karyotype x treatment), with Tukey’s post hoc
analysis to examine statistical patterns that were not specified a priori. All data were
graphically represented as mean ± SEM.

4.3 Results
4.3.1 RvE1-mediated Behavior
RvE1-mediated Spontaneous Locomotion Behavior
Because hyperactivity has been observed in the Ts65Dn mouse model and may
influence other behavioral components (Lockrow J 2011), I first examined the effects of
RvE1 treatment on baseline motor activity in Ts65Dn mice (Figure 4-3). I then tested
overall motor ability in a rotarod task (Figure 4-3, A) and found no significant difference
in either NS or Ts65Dn mice regardless of treatment. In the open field task, I observed no
significant effects of treatment on center time for any group Figure 4-3, B), suggesting that
anxiety was not a confounding factor and that RvE1 treatments did not enhance anxiety.
For total distance traveled in the open field task (Figure 4-3, C), Veh–treated Ts65Dn mice
exhibited significant elevations in spontaneous behavior relative to the Veh-treated NS
mice (p < 0.0001). RvE1 treatment significantly decreased overall locomotion in the
Ts65Dn (p = 0.009) suggesting that of the hyperactivity observed in Ts65Dn mice can be
at least partially corrected by this SPM therapy.
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Figure 4-3. Locomotor Behavior. (A) Rotorod movements were equivalent between
all cohorts. (B) RvE1 treatment had no effect on center time for NS or Ts65Dn mice.
(C) Ts65Dn mice show significant elevations in hyperactivity, which was normalized
by RvE1 treatment. Error bars represent average ± SEM.
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RvE1-mediated NORT Performance
I next evaluated if chronic RvE1 therapy could impact NORT performance in NS
or Ts65Dn mice (Figure 4-4). Each analysis was performed independently at 90 minutes
(short-term memory) and at 24 hr (long-term memory) when novel objects were
introduced. I observed no significant differences in total exploration time at either interval
(Figure 4-4, A) for any group, suggesting that the treatment did not affect their natural
exploratory drive. For all comparisons, I performed two-way ANOVAs to test for
differences between groups (karyotype x treatment). At the 90 minute interval (Figure 44, B-left), the main statistical effect was attributable to karyotype 18% of all variation (F1,28
= 16.27, p = 0.0004), to treatment with 26% of all variation (F1,28 = 23.44, p < 0.0001) with
an interaction effect equaling 24% of all variation (F1,28 = 21.24, p < 0.0001) since RvE1
treatment only affected Ts65Dn performance. Tukey’s post hoc analysis revealed that the
mean discrimination index was significantly less in vehicle-treated Ts65Dn mice compared
to NS mice (p < 0.0001). Importantly, the RvE1 treatment per se did not appear to exert
any behavioral effects on NS mice. Finally, RvE1 treatment significantly increased
performance for the Ts65Dn mice (p < 0.001) to novel object discrimination levels
observed in age-matched NS mice

At the 24 hour interval (Figure 4-4, B-right), the main effect was attributable to
karyotype equaling 27% of all variation (F1,27 = 26.93, p < 0.0001), to treatment with 28%
of all variation (F1,27 = 28.20, p < 0.0001) with an interaction effect equaling 14% of all
variation (F1,27 = 13.84, p = 0.0009) since RvE1 treatment only exerted effects on Ts65Dn
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Figure 4-4. NORT Behavior. (A) Mice explored objects robustly in all trials. RvE1
treatment had no significant effect on amount of time Ns and Ts65Dn mice spent
exploring the objects at both the 90 minute and 24 hour interval. (B) RvE1 treatment
had no effect on NS mice in the NORT task. Ts65Dn mice display sever deficits
which are normalized by RvE1 treatment at both intervals. Error bars represent
average ± SEM.
Page 133

mice. Tukey’s post hoc analysis revealed that the mean discrimination index was
significantly less in vehicle-treated Ts65Dn mice compared to NS mice (p < 0.0001).
Again, RvE1 treatment significantly increased performance for the Ts65Dn mice (p <
0.001) equivalent to NS ability at this time interval in the NORT. Collectively, these
findings suggest that RvE1-treatment significantly improves performance in this working
memory task, both at shorter and longer inter-trial intervals, specifically in 8 month old
Ts65Dn male mice. Age-matched NS control mice with RvE1 treatment exhibited close to
identical behavioral performance compared to Vehicle-treated NS mice, strongly
suggesting that optimal performance cannot be further improved under this paradigm. The
main conclusion from this task is that the chronic RvE1 treatment profoundly enhanced
familiarity memory in the Ts65Dn mice by an unknown mechanism.

RvE1-mediated WRAM Performance
To assess spatial reference memory, I performed a three day WRAM (see Chapter
2) and recorded errors to find the hidden platform (Figure 4-5). Since normal mice steadily
improve performance in this task over three days, I expected significant effects in task
perfection. I performed a repeated measures two-way ANOVA (Treatment x Trail Day) on
total errors as the dependent variable. I found that the main effect was shared between task
perfection which equaled 30% of all variation (F2,58 = 68.71, p < 0.0001), and treatment
which contributed 31% of all variation (F3,29= 11.7, p < 0.0001). Altogether, the perfection
of the task over days was impacted by RvE1 treatment in the Ts65Dn group only. Tukey’s
post hoc analysis revealed that Ts65Dn mice made significantly more errors than NS
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groups on all three days (Day1, p = 0.006; Day 2, p = 0.004; Day 3, p = 0.001). RvE1treated Ts65Dn mice showed a significant decrease in errors on the last two days (Day 2,
p = 0.008; Day 3, p = 0.001). Collectively, these findings suggest that RvE1-treatment
significantly improves performance in this spatial reference memory task, specifically in 8
month old Ts65Dn male mice. Age-matched NS control mice with RvE1 treatment
exhibited close to identical behavioral performance compared to vehicle-treated NS mice,
suggesting that optimal performance in this task cannot be further improved under this
experimental paradigm.

Figure 4-5. WRAM Behavior. NS mice perfected performance over the 3-day task.
RvE1 treatment had no significant effect on amount of errors NS made each day.
Ts65Dn mice display significantly more errors and less task perfection. Chronic RvE1
treatment normalized Ts65Dn performance that that observed in NS mice. Error bars
represent average ± SEM.
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RvE1-mediated WRAM Reversal Learning
After 3 days of spatial learning, mice were subjected to a new platform location to
test perseverance to the original platform location (more perseverance equals less cognitive
flexibility) and errors (a test of flexible ability to switch to a new platform. I expected NS
mice to display low perseverance and few errors upon finishing this new task due to rapid
perfection of the task after practice. After platform switching, all groups demonstrated
perseverance to the original platform in the initial trial block. I performed a two-way
ANOVA to test for differences between the groups (Treatment x Practice) in order to assess
reversal learning aspects when the LC-NE is inhibited (Figure 4-6, A). As expected,
practice had the greatest overall effect in this test (F1,20 = 55.1, p < 0.0001). Tukey’s post
hoc analyses revealed that both NS groups had a significant decrease in perseverance (p <
0.0001) and the RvE1 treated Ts65Dn mice displayed a significant decrease in
perseverance (p < 0.0001) relevant to Veh-treated Ts65Dn mice. The Veh-treated Ts65Dn
group persevered to the original platform location significantly more than the Veh-treated
NS group (p = 0.002) and the RvE1-treated Ts65Dn group (p = 0.013). Altogether, Ts65Dn
mice have deficits in reversal learning as assessed by this task.

Since the WRAM task has been practiced over three days, normal mice with strong
cognitive flexibility should rapidly learn the new target cue after platform switching. All
mice demonstrated high error rates in finding the new hidden platform in the first trial block
due to the platform reversal. I performed a two-way ANOVA to test for differences
between the groups (Treatment x Practice) in order to assess if RvE1-treatment affected
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Figure 4-6. WRAM Cognitive Flexibility. (A) After platform switching, all mice
displayed perseverance choice to the old platform location. NS mice quickly learned
the new platform location while Veh-treated Ts65Dn mice displayed deficits. RvE1
nullified this deficit in Ts65Dn mice. (B) All mice made many errors at the start of this
cognitive flexibility task. At finish, NS made few errors regardless of treatment while
Veh-treated Ts65Dn mice made significantly more errors. Chronic RvE1 treatment
normalized Ts65Dn performance to that observed in NS mice. Error bars represent
average ± SEM.
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error rate (Figure 4-6, B). As seen before, practice contributed the largest effect in mice
making significantly fewer errors at the end of this task (F1,20 = 79.53, p < 0.0001). Since
RvE1 treatment had a strong effect on the Ts65Dn group only, an interaction effect of 11%
of total variation was observed (F3,20 = 7.74, p = 0.0013). Tukey’s post hoc analyses
revealed that both NS groups made significantly fewer errors (p = 0.0002) and the RvE1
treated Ts65Dn group also had a significant decrease in perseverance (p < 0.0001). By trail
finish, the vehicle-treated T365Dn group made significantly more errors than the vehicletreated NS group (p < 0.0001) and the RvE1-treated Ts65Dn group (p < 0.0001).
Collectively, these findings suggest that RvE1-treatment significantly improves cognitive
flexibility, specifically in 8 month old Ts65Dn male mice. Age-matched NS control mice
with RvE1 treatment exhibited close to identical behavioral performance compared to
vehicle-treated NS mice, suggesting that optimal performance in this task cannot be further
improved under this paradigm. A combined comparison of the NOR and WRAM memory
tasks reveals that the RvE1-treated Ts65Dn mice are much more like the NS groups
(Figure 4-7). In both performance and in overall standard error, the vehicle-treated Ts65Dn
group demonstrated greater variance.

4.3.2 RvE1-mediated Responses in the Resolution Proteome
RvE1 treatment mediates profound improvements in memory and hyperactivity in
the Ts65Dn mice. I was interested if these effects might be mediated by overall changes or
response in SPM enzymes, GPCRs that bind RvE1, PPAR-y, and the ERK signaling
pathway. I performed western blot analysis of all groups with n=8 for each study. For each
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Figure 4-7. Compensation in RvE1-Binding GPCRs. (A) ChemR23 was equivalent
in the Veh-treated NS and Ts65Dn brain. Reduced levels suggested a compensatory
response to RvE1-treatment in both cohorts (B) BLT was equivalent in the Veh-treated
NS and Ts65Dn brain. Reduced levels suggested a compensatory response to RvE1treatment in both cohorts. Error bars represent average ± SEM.
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protein marker, I performed a two-way ANOVA to test for differences between the groups
(karyotype x treatment). I first assessed overall effect in the brain, and then parsed the
analyses into three different brain regions (frontal cortex, hippocampus, and parietal
cortex) in order to ascertain how the treatment affected different regions that have distinct
importance to memory performance For ChemR23 (Figure 4-7, A), I found that the major
effect was with Treatment alone which accounted for 33% of total variation (F1,91 = 45.5,
p < 0.0001). Tukey’s post hoc analyses revealed that RvE1-treatment significantly
decreased ChemR23 abundance in both NS mice (p = 0.0001) and Ts65Dn mice (p <
0.0001). RvE1 treatment decreased ChemR23 in all brain regions with p-values reported
(Figure 4-7, A-lower panels). For BLT1 (Figure 4-7, B), I found that the major effect was
with Treatment alone equaling 33% of total variation (F1,90 = 32.18, p < 0.0001). Tukey’s
post hoc analyses revealed that RvE1-treatment significantly decreased BLT1 abundance
in both NS mice (p = 0.0002) and Ts65Dn mice (p = 0.0028). RvE1 treatment decreased
ChemR23 in all brain regions with significant p-values reported for frontal cortex and
hippocampus only (Figure 4-7, B-lower panels).

For PPAR-y (Figure 4-8, A), I found that the major effect was with Treatment
alone equaling 24% of total variation (F1,89 = 28.16, p < 0.0001). Tukey’s post hoc analyses
revealed that RvE1-treatment significantly decreased ChemR23 abundance in both NS
mice (p = 0.0007) and Ts65Dn mice (p = 0.0042). RvE1 treatment decreased PPAR-y in
all brain regions but were significant only in the hippocampus as seen by the p-values
reported (Figure 4-8, A-lower panels). Since RvE1 is known to increase phosphorylation

Page 140

of ERK in vitro, I were interested in testing whether our in vivo therapy might recapitulate
these findings. I quantified total ERK and phospho (p44/42) ERK and normalized each
signal the average of the Veh-treated NS group and then took the ratio in order to compare
relative ERK activation. For this ratio (Figure 4-8, B), I found that the Ts65Dn mice have
higher levels ERK activation. The major effect was with karyotype equaling 13% of total
variation (F1,88 = 14.76, p = 0.0002) and with treatment effect equaling 10% of total
variation (F1,88 = 11.34, p = 0.0011). Tukey’s post hoc analyses revealed that RvE1treatment significantly increased ERK activation in both NS and Ts65Dn mice but the
overall effect was only significant in the latter (p = 0.0039). RvE1 treatment had little effect
in the parietal cortex while increasing the ratio in frontal cortex and hippocampus. ERK
activation was significantly increased for RvE1-treated NS and Ts65Dn groups only in the
frontal cortex when compared to the Vehicle-treated groups as seen by the p-values
reported (Figure 4-8, B-lower panels).

Ts65Dn mice have been previously observed to have significant loss of CalbindinD28 positive neurons in the hippocampus (Lockrow, Boger et al. 2011). I was interested in
testing whether this 30 day treatment might halt or reverse this hallmark of Ts65Dn
neurodegeneration. For Calbindin-D28 (Figure 4-8, C), I found that the major effect was
only with Karyotype alone equaling 23% of total variation (F1,91 = 25.99, p < 0.0001).
Tukey’s post hoc analyses revealed that Ts65dn mice have significantly less CalbindinD28 levels only in hippocampus (p = 0.061) (Figure 4-8, C-lower panels). Over this
treatment window, RvE1-treatment had no observable effect on the decreased Calbindin-
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Figure 4-8. Compensation in RvE1-Binding GPCRs. (A) ChemR23 was equivalent
in the Veh-treated NS and Ts65Dn brain. Reduced levels suggested a compensatory
response to RvE1-treatment in both cohorts (B) BLT was equivalent in the Veh-treated
NS and Ts65Dn brain. Reduced levels suggested a compensatory response to RvE1treatment in both cohorts. Error bars represent average ± SEM.
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Figure 4-9. RvE1 nonresponsive markers. Chronic RvE1 treat had no significant
effects on (A) Enzymes that convert Ω3 to SPMs (B) A resolution GPCR that does not
bind RvE1, or in (C) Two different early intermediate synaptic plasticity markers. Error
bars represent average ± SEM.
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D28 relative abundance in Ts65Dn mice. I next quantified protein levels of two SPM
enzymes, phospho-5-LOX and 15-LOX (Figure 4-9, A), and found that NS and Ts65Dn
mice were equivalent for both enzymes and that RvE1 treatment had no overall effects. For
ALX-FPL2, a GPCR that does not bind RvE1, (Figure 4-10, B), I found that NS and
Ts65Dn mice were equivalent and that RvE1 treatment had no overall effects. For the
synaptic plasticity markers, Arc and Synapsin (Figure 4-9, C), I found that NS and Ts65Dn
mice were equivalent for both markers and that RvE1 treatment had no overall effects.
Collectively, these findings suggest that RvE1-treatment significantly reduced relevant Gcoupled receptors while having no effect on non-relevant receptors. RvE1-treatment
significantly reduced PPAR-y and increased the ratio of p-ERK to total ERK. Interestingly,
different brain regions were affected distinctly for the protein markers that were analyzed.
This chronic RvE1-treatment was unable to halt or rescue Calbindin-D28 deficits in the
hippocampi of the 8 month old Ts65Dn male mice.

4.3.3 Immunohistochemistry
Sustained inflammation in the brain together with microglia activation can lead to
neuronal damage. A recent study revealed that RvE1 treatment could reduce microglial
activation in vitro (Rey, Nadjar et al. 2016). I was interested whether this chronic RvE1
therapy might recapitulate this finding especially in the Ts65Dn mice which have been
shown to have increased microglial activation in various brain regions (Hunter, Bachman
et al. 2004). I assessed gross morphology at 100x magnification and found that the overall
distribution of Iba1+ microglial is equivalent between NS and Ts65Dn mice (Figure 4-10,
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Figure 4-10. Iba1 responsive to RvE1 therapy. Veh-treated Ts65Dn mice show
elevated Iba1 staining with more rounded punctate microglial relative to NS cohorts.
Chronic RvE1 treatment reversed this aberrant microglial phenotype.
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A and C) at 8 months of age. A closer inspection at 600X magnification did reveal sporadic
swollen, ameboid microglial phenotype with higher Iba1 expression in the hippocampus of
Ts65Dn mice (Figure 4-10, C white arrows) compared to NS mice. Interestingly, RvE1treatment over 30 days reduced the overall occurrence of this microglial phenotype in the
Ts65Dn mice suggesting that microglial activation may be reduced (Figure 4-10, D).

4.3.4 RvE1-mediated Changes in Many Peripheral Cytokines
Sustained chronic inflammation is a hallmark feature of Ts65Dn mice in both the
brain and in the serum (Lockrow, Boger et al. 2011, Lorenzo, Chen et al. 2011, Roberson,
Kuddo et al. 2012, Hamlett, Boger et al. 2016). Studies have revealed that RvE1 imparts a
significant decrease in inflammatory cytokines in various model systems (Ishida, Yoshida
et al. 2010, Flesher, Herbert et al. 2014). Given this support along with the significant
effects seen with PPAR-y, I sought to test whether this 30-day systemic RvE1 treatment
might affect overall inflammation in the Ts65Dn mice. I performed a multiplex cytokine
analysis in all groups. For each cytokine assessed, I performed a two-way ANOVA to test
for differences between the groups (karyotype x treatment). Overall, I observed significant
increases in Veh-treated Ts65Dn mice compared to Veh-treated NS mice for many
cytokines. In all reported cases, RvE1-treatment significantly reduce cytokine abundance
in the Ts65Dn mice with no observable effect seen in NS mice. Overall effects of cytokines
are reported as a table in Figure 4-11. Tukey’s post hoc analyses revealed that Ts65dn
mice have significantly higher cytokine levels for all cytokines listed and these elevations
were normalized to NS levels with RvE1 treatment, with p-values reported in Figure 4-12.
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Figure 4-11. Peripheral Cytokines Overall Effects. Two-way ANOVA analyses for
nine cytokines that displayed significant effects to chronic RvE1- treatment.
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Interestingly, this cytokine panel represents innate immunity (IL-1ɑ, IL-1β, IL-6, IL-12,
IL-9, TNF-ɑ), adaptive immunity (IL-4, IL 5) and IL10, an anti-inflammatory cytokine.

Figure 4-12. Peripheral cytokine quantification. Two-way ANOVA analyses for
nine cytokines that displayed significant effects to chronic RvE1- treatment. (A-I) All
cytokines listed were significantly reduce upon RvE1-treatment in Ts65Dn mice.
Tukey’s post hoc p-values are reported. Errors bars represent an average ± SEM.
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4.4 Discussion
An exacerbated inflammatory response is a feature of DS-AD and also seen in the
Ts65Dn mouse model (Wilcock and Griffin 2013, Wilcock, Hurban et al. 2015, Head, Lott
et al. 2016, Iulita, Ower et al. 2016). Chronic neuroinflammation may trigger loss of
function in cells of the central nervous system and increase the likelihood of
neurodegeneration and the classical hallmarks of DS-AD (Solana, Pawelec et al. 2006,
Perry 2010, McGeer and McGeer 2013). Targeted blockade of inflammatory responses
aggravate the progression of AD and thus raise the question about how to best manipulate
the immune response to succeed in the management of neurodegenerative disorders (WyssCoray and Mucke 2002, Lucin and Wyss-Coray 2009). The recent realization that
resolution of inflammation is a highly coordinated and active process controlled by
endogenous pro-resolving mediators, and that inflammatory cells undergo classical and
alternative activation, highlight new potential molecular targets to modulate
neuroinflammation in the brain and elsewhere (Serhan 2007, Serhan, Chiang et al. 2008,
Gordon and Martinez 2010). Furthermore, the resolution processes are altered in AD
(Wang X 2015) in that many SPMs are reduced in CSF, and several resolution receptors
seem to show compensatory elevations.

The Omega-3 FAs, EPA and DHA, seem to have distinct roles in the brain
particularly as membrane components where DHA is critical. COX-2, 5-LOX, and other
conversion enzymes act as gateway control points to various SPMs and likely coordinate
the conversion process with high temporal and spatial precision. In this study, I sought to
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bypass this gate by utilizing readily available SPMs to drive the resolution process without
the confoundings of enzymatic conversion efficiency. The findings presented here were
the first to demonstrate that chronic administration of the SPM, RvE1, significantly
reduced hallmark peripheral inflammation, and microglial activation in the Ts65Dn mouse
model to levels that were equivalent to NS mice. Regarding elevated cytokine expression
in the blood of Ts65Dn mice, RvE1 significantly reduced these cytokines that are typically
associated with innate immunity and adaptive immunity and also decreased one antiinflammatory cytokine. The exact nature of this effect is presumed to relate to ERK1/2
signaling or by PPAR-y mechanisms.

RvE1 significantly increased the ratio of p-ERK to total ERK, which recapitulates
findings in a cardiac model where RvE1 increased Akt, ERK1/2, and endothelial nitric
oxide synthase phosphorylation (Keyes KT 2010). Similarly, the SPM, LXA4, promotes
cell survival in murine and human macrophages via activation of the ERK1/2 pathway
(Prieto, Cuenca et al. 2010). Interestingly, I observed the ERK activation increase to be
strongest in the frontal cortex followed by hippocampus with little change in the parietal
cortex. The ERK1/2 proteins are members of the mitogen-activated protein kinase
superfamily that can mediate cell proliferation (Meloche and Pouyssegur 2007), survival
or apoptosis (Cagnol and Chambard 2010). In neurons, ERK1/2 phosphorylation mediates
the effects of BDNF on synaptic plasticity, nuclear signaling, and memory formation
(Finkbeiner, Tavazoie et al. 1997, Blanquet 2000, Pizzorusso, Ratto et al. 2000), and spine
growth in CA1 pyramidal neurons of the hippocampus (Alonso, Medina et al. 2004). The
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effect is relevant to DS-AD where Aβ is highly produced because sub-chronic injections
of oligomeric forms of Aβ1-4 into the dorsal hippocampus produces cognitive impairments
via long-lasting reductions in ERK1/2 phosphorylation. RvE1 acts as an agonist of
ChemR23 and a partial agonist to BLT1, both proven GPCRs that affect ERK1/2 signaling.
This interesting balance of GPCR signaling may affect synaptic plasticity. The profound
improvements in Ts65Dn performance in memory tasks, particularly in cognitive
flexibility, and the decreases in hyperactivity suggested this, but other factors may also be
at play. Particularly, PPAR-y also binds RvE1 and upon doing so likely activates and
translocates to the nucleus to decrease cytokine production. I observed a significant
decrease in all RvE1 binding receptors and proteins (ChemR23, BLT1, and PPAR-y) upon
treatment, but with no effect on ALX-FPL2, which does not bind RvE1. Whether PPAR-y
nuclear translocation was affected by RvE1 treatment remains to be explored.

In order to prevent, or significantly slow down, neuron loss and AD progression for
individuals with DS, it seems a therapy has to inhibit a plethora of biological dysfunctions
including; accumulations of Aβ peptide products, especially Aβ42, excessive P-Tau,
oxidative stress, neurotrophic losses, and neuroinflammation concurrently. The primary
target of NSAIDs and other therapeutic inhibitors like aspirin, ibuprofen or rofecoxib is
COX-2, an important enzyme that has broad and multifaceted impacts on inflammatory
processes. COX-2 is responsible for the generation of inflammatory prostaglandins and
other prostanoids from arachidonic acid or from endocannabinoids (Ricciotti and
FitzGerald 2011, Alhouayek and Muccioli 2014). COX-2 metabolites can be further
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modified to secondary metabolites that act as ligands to distinct receptors that drive potent
anti-inflammatory properties. The COX-2 enzyme is coupled to noradrenergic influences
from the LC. Specifically, COX-2 mRNA expression is highly influenced regulated by NE,
which provides yet another facet of the LC noradrenergic systems role in regulating
inflammation. The NE effect was mediated by β-ARs, since only β-AR agonists (and not
α-AR agonists) produced similar results (Alhouayek and Muccioli 2014). Elevated COX2 expression has been described in AD (Hewett, Uliasz et al. 2000, Bazan, Colangelo et al.
2002) and COX-2 protein levels in the hippocampus of AD patients may correlate with the
severity of dementia (Ho, Purohit et al. 2001). The intersection of NE and COX-2 reveals
yet another noradrenergic process that may either promote or inhibit neuroinflammation,
depending on the balance of signaling mechanisms, bioavailable metabolites and
downstream secondary metabolite production by other enzymes.

I have observed critical behavioral and molecular evidence pointing to the
endogenous pro-resolution RvE1 pathway as a potential candidate to reduce
neuroinflammation in DS-AD and other age-related inflammatory disorders. The present
study supports further inquiry into SPM supplementation in the DS population especially
since ChemR23 was recently found also to bind Aβ42. Interestingly, Aβ42 binding led to
internalization of the Aβ42-ChemR23 complex, suggesting a potential role for Aβ42
clearance or potentially as a signaling endosome (Peng, Yu et al. 2015). I conclude that
enhancing RvE1 in the brain may reduce the severity of AD-like neuropathology, decrease
amyloid plaques, Tau phosphorylation and inflammation, as well as possibly improve
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cognitive performance. However, the reductions in ChemR23, BLT1, and PPAR- y protein
levels in response to chronic RvE1 therapy are hard to ignore. Whether this reduction could
pose harm to an animal over longer periods needs to be investigated further.
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Chapter 5. Novel AD Biomarkers in Individuals with Down syndrome

5. Introduction
Neuropathological biomarkers of AD, including Aβ40 and Aβ42, have been detected
in brain tissue and cerebrospinal fluid (CSF) decades before the onset of dementia in the
general population (Blennow and Zetterberg 2015), and in DS (Englund, Anneren et al.
2007). Performing lumbar punctures (LPs) in those with DS is challenging; thus there is a
need for the development of reliable blood-based biomarkers for AD in this population.
Most cell types in the body, including neurons, release small endosomally-derived vesicles,
known as exosomes (Coleman and Hill 2015, Fiandaca, Kapogiannis et al. 2015).
Exosomes contain proteins, mRNA and miRNA that reflect their cellular origin and play a
prominent role in cellular signaling, removal of unwanted proteins, and transfer of cellular
pathogens to other cells (Coleman and Hill 2015). Because of their small size, secreted
exosomes diffuse into biological fluids (blood, CSF, and urine) and circulate in interstitial
space, both in the brain and the periphery (Salido-Guadarrama, Romero-Cordoba et al.
2014). Neuronal exosomes have unique neuron-specific surface markers, which enable
targeted examination from circulating biological fluids (Fiandaca, Kapogiannis et al. 2015,
Goetzl, Boxer et al. 2015, Goetzl, Boxer et al. 2015).

Neuronal exosomes are involved in processing of APP, one of the genes involved in
AD neuropathology (Haass, Lemere et al. 1995, Rajendran, Honsho et al. 2006, Sharples,
Vella et al. 2008, Perez-Gonzalez, Gauthier et al. 2012), and they play a crucial role in Aβ
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clearance (Yuyama, Sun et al. 2015). Exosomes receive APP from early endosomes after
cleavage into Aβ peptides, which are then secreted from the cells in exosomes (Yuyama,
Sun et al. 2015). Neuronal exosomes contain toxic Aβ peptide and P-Tau entities, and
transmit these to neighboring cells, other brain regions and the circulatory system,
suggesting that neuronal exosomes can vectorize pathology. Neuronal exosomes that are
extracted from either plasma or CSF can therefore specifically assess relevant
neuropathological processes within CNS neurons (Vingtdeux, Sergeant et al. 2012,
Jaunmuktane, Mead et al. 2015). Other findings indicate that AD biomarkers found in
neuronal exosomes accurately predict the onset of dementia as early as ten years before
symptom onset in patients with sporadic AD or FTD (Fiandaca, Kapogiannis et al. 2015,
Kapogiannis, Boxer et al. 2015). Exosomal biomarkers have not been analyzed in
individuals with DS. In this part of the study, I originally hypothesized that neuronal
exosomes obtained from blood in DS would have elevated levels of amyloid-beta (Aβ)
peptides and P-Tau that could document a preclinical AD phase in the DS population.

Despite intensive investigation in recent years, there is still an incomplete
understanding of the etiology and pathophysiology of AD and DS-AD. Therefore, the best
strategies for prevention and treatment are still elusive. Brain-derived neurotrophic factor
(BDNF) has been explored in dementia risk, and because it is correlated with lifestyle
factors such as reduced caloric intake (Lee, Seroogy et al. 2002) and increased physical
activity (Neeper, Gomez-Pinilla et al. 1995, Vaynman, Ying et al. 2003) and is thought to
be associated with healthy lifestyle and successful aging. BDNF is highly expressed
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throughout the central nervous system especially in the hippocampus and cerebral cortex
(Phillips, Hains et al. 1990, Wetmore, Ernfors et al. 1990), and is important in the survival
and function of hippocampal and cortical, as well as cholinergic , noradrenergic and
dopaminergic, neurons (Alderson, Alterman et al. 1990, Ghosh, Carnahan et al. 1994,
Holm, Rodriguez et al. 2003). In addition, BDNF is critical for synaptic plasticity and
memory processing in the adult brain (Alonso, Vianna et al. 2002, Bekinschtein,
Cammarota et al. 2008). In the second portion of Chapter 5, I hypothesized that serum
BDNF levels would be altered in those with DS relative to controls without DS and that
exosomal levels of AD biomarkers would be correlated with serum BDNF levels.

5.1 Chapter 5 Specific Aims
The results presented here are from an international collaboration, including
investigators from Hospital of Sant Pau in Barcelona (Spain), UCI (Irvine, CA), Barrow
Neurological Institute and Banner Sun Health Research Institute (Sun City, AZ), the
Linnaeus University in Sweden, and Medical University of South Carolina (MUSC,
Charleston, SC). The overall aims were to examine alterations in levels of neuronal
exosome AD biomarkers in children, young adults, and older adults with DS in comparison
to age-matched non-DS controls, and also whether AD biomarkers were altered in
individuals with DS that display dementia. The objectives of this study were: 1) to examine
if the AD biomarkers, Aβ42, P-T181-Tau, and P-S396-Tau, were altered in neuronal
exosomes in children, young adults, and older adults with DS in comparison to agematched non-DS controls, 2) to determine whether these AD biomarkers were altered in
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individuals with DS that display dementia 3) to establish a serum BDNF profile in children,
young adults, and older adults with DS, 4) to determine whether these AD biomarkers were
altered in individuals with DS that display dementia and finally 5) to determine if any
correlations exist between all biomarkers.

5.2 Chapter Specific Methods

5.2.1 Participant Demographics
All participants gave written consent approved by an IRB or equivalent regulatory
agency at all of the collaborative institutions. Demographics for exosome and serum BDNF
analyses are shown in Figure 5-1.
Figure 5-1. Chapter 5 demographics.

Page 157

5.2.2 Diagnosis of DS Cognitive Status
The two groups of young controls and young individuals with DS (age 8-35) showed
no evidence of cognitive decline by caretaker reports (No Cognitive Impairment; NCI,
Table 1). The adult controls (>35 years) were participants in a healthy aging study at the
Linnaeus University (Drs. Mohammed and Granholm, Co-PIs) or part of a healthy blood
donor study at the UCI Institute for Clinical and Translational Science (Dr. Ira Lott). Agematched control samples for the young group (<35 years) were obtained from the National
Institutes of Health (NIH). All control donors were free from chronic medical conditions
including dementia based on the established neuropsychological assessments (Aprahamian
I 2011, Lees, Selvarajah et al. 2014).

The participants in the adult DS group (>35 years) were subjected to cognitive testing
batteries adjusted to DS criteria. A consensus diagnosis of non-cognitively impaired (NCI),
early symptomatic dementia or fully-symptomatic dementia of Alzheimer’s-type (DS-AD)
was established based on a neurological and neuropsychological assessment that included
an adapted neuropsychological battery with multiple cognitive domains. Dementia was
defined by DSM-IV criteria. The “early symptomatic group” refers to individuals with DS
that display only mild signs of dementia since MCI has not been formally defined for the
DS population. Approximately half of the participants who were adults with DS were
obtained from the Barcelona cohort, and about half were obtained from the UCI cohort,
with a minority of the samples obtained from the Arizona cohort. Although there is some
overlap between the cognitive tasks performed at these two sites (see below), the cognitive

Page 158

batteries used were slightly different. Since the readout of the results of the current study
was not dependent on cognitive measurements, and not used for correlations or other
statistical analyses, details of the different batteries are not thoroughly discussed.

In the Barcelona cohort, participants were given a neurological evaluation and
assessed by a neuropsychologist and performed the following cognitive tests: 1) Kaufman
Brief Intelligence Test (K-BIT) to assess general intelligence, 2) Down syndrome–Brief
cognitive exam (MEC-SD) which is a brief cognitive assessment to estimate progression
of cognitive impairment in people with DS, 3) Neuropsychiatric Inventory (NPI 12 item
version) to assess dementia-related behavior symptoms, and 4) CAMDEX-DS structured
informant interview to assess changes in daily living activities, cognition, and behavior
related to the onset of dementia. During a follow-up neuropsychological assessment visit,
the following cognitive tasks were administered: 1) CAMCOG-DS, which is a structured
cognitive assessment which includes neuropsychological domains: orientation, language,
memory, attention, praxis, abstract thinking and perception, 2) Picture Cancellation task to
assess attentional processes, 3) Digit Span (forward and backward), to assess attention and
working memory, 4) Modified Cued Recall Test, to assess episodic memory (short and
long term memory), adapted for use in people with mild and moderate intellectual
disability, 5) Cats and Dogs test, to assess executive functioning (inhibition/mental
flexibility), 6) Ideomotor praxis from the Barcelona Neuropsychological Test Battery, and
7) Dementia Questionnaire for People with Learning Disabilities (DMR), a screening tool
which measures cognitive and functional deterioration as a result of dementia.
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In the cohort from the University of California at Irvine, participants with DS
participating at the UCI site completed a neuropsychological test battery annually. The
battery included both direct and indirect (informant) based measure that assessed several
cognitive, behavioral and adaptive behavior domains and has been shown to be sensitive
to dementia-related change in adults with DS. The informant based DMR was in common
across all sites. At each visit, a study neurologist performed a dementia evaluation
according to DSM-IV criteria using information gathered directly from the participants as
well as their informants. The study neurologist performing the examination was blinded to
the results of the neuropsychological testing. Dementia status of nondemented, possible or
probable AD dementia was established by the evaluating professionals based on a
consensus of their expert opinions.

5.2.3 Isolation of Neuronal Exosomes
Isolation and analysis of neuronal exosome AD biomarkers were performed
according to Dr. Ed Goetzl’s protocol at the NIH. I had the opportunity to spend time at
Dr. Goetzl’s laboratory at NIH, where I learned to perform the exosome studies and could
transfer these techniques to Dr. Granholm’s laboratory (Fiandaca, Kapogiannis et al. 2015).
(Fiandaca et al., 2015). Briefly, 0.25 mL of plasma was incubated with 0.15 mL
thromboplastin-D (Fisher Scientific, Inc., Hanover Park, IL) at room temperature for 1
hour, followed by addition of 0.15 mL Dulbecco’s balanced salt solution (magnesium and
calcium free, Sigma) containing triple concentration of protease and phosphatase inhibitor
cocktails (protease inhibitor cocktail, Roche Applied Sciences. Inc., Indianapolis, IN;
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phosphatase inhibitor cocktail, Pierce Halt, Thermo Scientific, Inc.). After centrifugation
(1,500 g, 20 min), the supernates were mixed with 0.126 mL of ExoQuick exosome
precipitation solution (System Bioscience, Mountainview, CA) and incubated at 4o C for
one hour to precipitate exosomes. The exosome suspensions were again centrifuged at
1,500 g for 30 minutes (4o C) and resuspended in 0.25 mL ddH2O with triple concentration
inhibitor cocktail, as described for immune cell exosomes (Kapiogannis et al., 2014). Each
sample received 0.05 mL of 3% bovine serum albumin (BSA, 1:3.33 dilution of Blocker
BSA 10% solution in DBS (Thermo Scientific Inc.). To isolate neuronal exosomes, the
samples were then incubated for 1 hour with 1 microgram mouse anti-human CD171 (clone
5G3, L1CAM, eBioscience, San Diego, CA). Then 0.01 mL of Streptavidin-Plus Ultralink
agarose resin (Thermo Scientific, Inc.) biotinylated with the EZ-Link sulfo-NHS-biotin
system (Thermo Scientific Inc.) plus 0.04 mL of 3% BSA was added to the exosome
suspension and incubated at room temperature for 1 hour. The immuno-absorbed samples
were then centrifuged at 200 g at 4o C for 10 min followed by removal of supernates and
each resin pellet was suspended in 0.1 mL of 0.05M glycine-HCl (pH 3.0) by vortexing
(10 sec), incubated at room temperature for 5 min and then centrifuged at 4,000 g at 4o C
for 10 min. The resultant supernates were transferred to a clean tube and then received 0.01
mL of 1M Tris-HCl (pH 8.0), 0.025 mL of 3% BSA and 0.365 mL M-PER mammalian
protein extraction reagent (Thermo-Fisher, Inc.) with triple concentration inhibitor
cocktails followed by vortex-mixing. Samples were stored at -80o C prior to enzyme-linked
immunosorbent assays (ELISAs) for AD biomarkers. The yield of neuronal exosome from
blood samples has been demonstrated previously (Kapiogannis et al., 2014).

Page 161

Neuronal exosomes have unique neuron-specific surface markers, which enable
targeted examination from circulating biological fluids (Fiandaca, Kapogiannis et al. 2015,
Goetzl, Boxer et al. 2015, Goetzl, Boxer et al. 2015). Specifically, L1-CAM (also called
CD171), is highly expressed on the neuron surface in all brain regions allowing for
enrichment neuron-derived exosomes. L1-CAM is also expressed in renal collecting ducts,
vascular endothelial cells, and dendritic reticulum cells (Allory, Audard et al. 2008, Vella,
Hill et al. 2016) but overall protein abundance is comparatively low when compared to the
brain. In comparison, scaling L1-CAM expression by organ volume and expression levels
reveals that the brain has at least 20 fold higher total expression compared to other tissues
analyzed (Soria, Pampliega et al. 2017). It is important to note that many carcinomas have
an abnormally high expression of L1-CAM. Thus neuronal targeting may be limited in
patients with cancer (Inaguma, Wang et al. 2016). Taken together, L1-CAM is a relatively
stringent, surface protein that allows predominant immuno-enrichment of neuronal
exosomes for biomarker studies.

After L1-CAM immuno-extraction of neuronal exosomes, size parameters were
quantified by nanoparticle tracking analysis (NTA) (Malvern, Salsbury, UK), and revealed
an average vesicle size distribution. NTA is a method for visualizing and analyzing
particles in liquids that determines particle size to the rate of Brownian motion. The rate of
movement is related only to the viscosity and temperature of the liquid and is not influenced
by particle density or refractive index. The technique is used in conjunction with a
microscope and a specialized illumination unit that together allow small particles,
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approximately 10-1000 nanometers, in liquid suspension to be visualized. Computer
software captures the rate of particle movement and then calculates a sphere hydrodynamic
radius based on the Stokes–Einstein equation. The technique calculates particle size on a
particle-by particle basis, overcoming inherent weaknesses in ensemble techniques such as
dynamic light scattering (Filipe, Hawe et al. 2010). NTA was conducted for a selection of
neuron exosome isolations to ensure repeatability of technique.

5.2.4 ELISA Analyses of Neuronal Exosome Biomarkers
Neuronal exosome proteins were quantified using standard ELISA kits for Aβ42,
human P-S396-Tau (Life Technologies/Invitrogen, Camarillo, CA), human P-T181-Tau
(Innogenetics Division of Fujirebio US, Inc., Alpharetta, GA), and the tetra-spanning
exosomal marker, human CD81 (American Research Products-Cusabio, Waltham, MA).
The CD81 antigen standard curve was validated using human purified recombinant CD81
antigen (Origene Technologies, Inc., Rockville, MD). The mean value of all CD81 levels
for each 96-well plate was set at 1.00, and a normalization value for each sample was
calculated from the ratio of its CD81 level to that of the mean for the plate. ELISA values
for Aβ42, P-T181-Tau, and P-S396-Tau were then adjusted proportionally to CD81. Mean
levels of one sample set yields levels of that analyte for the same unit mass of exosomes,
assuming that the CD81 amount per unit mass of exosomes is the same for all subjects. For
this study, the Granholm lab received 38 samples in the form of serum aliquots and 46 in
the form of plasma aliquots, evenly divided between the different groups examined herein.
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5.2.5 ELISA Analyses of Serum BDNF Biomarkers
Serum total BDNF protein was quantified using standard the Quantikine ELISA kit
for total BDNF (R&D Systems, Minneapolis, MN). Microtiter plate wells were coated with
100 µl of the primary antibody, at a concentration of 1-10 µg/ml in coating buffer. The
plate and incubate overnight at 4°C and then washed 3 times with wash buffer. Blocking
solution was added to each well and incubated for 60 minutes at 37°C following by washing
4 times with wash buffer. Blood samples were diluted, and 100 µl of diluted samples and
standards were added to individual wells in triplicate. Samples were incubated for 90
minutes at 37°C and then washed 3 times with wash buffer. Diluted enzyme-conjugated
detection antibody was added to each well and incubate for 1 hour at 37°C followed by
washing 3 times with wash buffer. The reactive substrate solution was added to each well
and incubated at room temperature in the dark for 30 minutes, followed by addition of stop
solution. Absorbance was read on a 96-well plate reader after thorough mixing. Details
about ELISA quantification kits used in this study are included below.

5.2.6 Statistical Analyses
For exosome population tests, I first examined population differences in AD
markers between the control non-DS group and cases with DS. Grubb’s method was used
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to check for outliers in each neuronal exosome biomarker which resulted in 2 out of 84
values excluded from the Aβ42 and P-S396-Tau data sets. D’Agostino-Pearson normality
tests were performed on control non-DS and DS groups for each neuronal exosome
biomarker to test suitability for subsequent parametric analyses. Linear regression analyses
were performed for each neuronal exosome biomarker over age to assess potential age
effects. Pearson correlation analyses were performed to determine whether age affected
group differences in terms of the neuronal exosome AD biomarkers.

The incidence of AD is known to be higher in individuals with DS after the age of
35 (Hartley, Blumenthal et al. 2014). For exosome grouped tests, the total population was
subdivided at the age of 35 in order to determine differences between age (younger: < 35
years, older: >35 years), DS (control-DS) and for interaction effects. A two-way ANOVA
examined the interaction between dependent variables, age x DS, for each biomarker,
followed by Tukey’s post hoc test for multiple comparisons. Student’s t-tests were used to
test for significant differences between genders within each group for each neuronal
exosome biomarker. The older adult DS group (>35 years) consisted of all individuals with
DS, independent of dementia status. This group was subdivided into two groups 1) NCI ,
and 2) those with early or with fully symptomatic dementia. Student’s t-tests were used to
test for significant differences between these groups for each neuronal exosome biomarker.
All statistical analyses were performed with GraphPad Prism 6 (GraphPad Software, Inc.,
La Jolla, CA) with alpha set at 0.05.
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For Serum BDNF studies, I observed a bimodal relationship in BDNF levels over
cross-sections of age. I subdivided the data into two groups from ages 4-19 and ages >20.
I performed linear regression analyses over these age groups to assess the intersection and
slope differences. In adults over 40 years of age, I performed one-way ANOVA to test for
significant differences in BDNF levels between Controls, those with DS without cognitive
decline and DS with apparent cognitive decline.

5.3 Results

5.3.1 Neuronal Exosome Secretion is Elevated in DS
Several studies have shown that classical markers of exosomes, such as CD63 and
CD81, are tetraspanning membrane proteins that are enriched in exosomes (Booth, Fang et
al. 2006, Raposo and Stoorvogel 2013) and thus provide an effective marker of total
exosome isolation that can also use in normalization of subsequent analyses of other
biomarkers. As mentioned earlier, the expulsion of toxic proteins may be one function of
exosomes. In the context of DS, where toxic Aβ peptides and aberrant P-Tau proteins are
significantly elevated in neurons, one would postulate that exosomes may be recruited to
enhance expulsion. In our recent study, which was a collaboration between several DS
clinics both in the US and abroad, we hypothesized that neuron-derived exosomes might
be more abundantly represented in those with DS relative to an age-match control
population without DS. To test this hypothesis, we isolated neuron-derived exosomes as
previously described (Hamlett, Goetzl et al. 2016) and quantified CD81 by enzyme-linked
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immunosorbent assay (ELISA) (Cusabio, Waltham, MA) against a standard curve of
recombinant CD81 (Origene Technologies, Rockville, MD) (Figure 5-2). The cohorts
included a population of participants with DS (8-62 years old) compared to levels found in
neuron-derived exosomes obtained from plasma of control participants (8-77 years old),
and both populations were age and gender matched.

We quantified the size of neuron-derived exosomes by nanoparticle tracking
analysis (Malvern, Salsbury, UK), and revealed an average vesicle size distribution at
117nm (Figure 5-2, A) for multiple exosome preparations. We quantified the levels of
CD81 expression in both populations (Figure 5-2, B) and found that individuals with DS
have a 39% higher average level (1433 ± 87 pg/ml) of this exosomal normalization marker
relative to controls (1027 ± 87pg/ml), and a student’s t-test revealed the difference was
significant (p = 0.002). We further divided the control and DS groups into two age
categories, below 35 and above 35 years old (Figure 5-2, C). A two-way ANOVA
(Karyotype x Age) revealed that only having DS was the primary driver of CD81 levels
with no significant effects found for age. Tukey’s posthoc adjusted comparisons revealed
significantly increased CD81 levels for individuals with DS, for both in the young (p =
0.05) and older DS groups (p = 0.04) compared to age-matched controls. These findings
demonstrated that neuron-derived exosomes are more abundant in blood samples acquired
from those with DS. This result is interesting, as similar observations have been made in
vitro with DS cell cultures (Skogberg, Lundberg et al. 2014) and in vivo with the Ts2Cje
mouse models of DS (Perez-Gonzalez and Levy 2016).
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Figure 5-2. CD81 exosome marker levels are elevated in people with DS. (A) Our
neuronal exosome isolation technology captures L1CAM+ exosomes that have an
average size diameter of 117nm. Grey shading represents ± SEM from several exosome
isolations. (B) CD81 quantification reveals that the DS cohort has over 39% more
circulating neuronal exosomes than age-matched controls. (C) Two-way ANOVA of
younger (<35) and older (>35) revealed that only having DS had significant effect on
neuronal exosome secretion levels, and no age effects were observed. Error bars
represent an average ± SEM.
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5.3.2 Effects of DS and Age on AD Biomarkers
Three neuronal exosome biomarkers, Aβ42, P-T181-Tau, and P-S396-Tau, were
significantly elevated in the DS population relative to the control population (Figure 5-3,
A-C); Student’s t-test, p < 0.0001 for each biomarker; n = 37 for control non-DS, and n=
47 for DS participants).

Figure 5-3. Overall neuronal exosome AD biomarkers in control and DS
populations. (A) Aβ42: participants with DS exhibited significantly elevated levels (p
< 0.0001) compared to age-matched control participants. (B) P-T181-Tau: participants
with DS exhibited significantly elevated levels (p < 0.0001) compared to age-matched
controls. (C) P-S396-Tau: participants with DS exhibited significantly elevated levels
(p < 0.0001) compared to age-matched controls. Error bars represent ± SEM. N = 37
for non-DS control participants, and N=47 for participants with DS.
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I further divided the control and DS groups into two age categories, below 35 and
above 35 years old (high AD incidence), and performed a two-way ANOVA to test for
interaction. For all three neuronal exosome biomarkers, there was a highly significant
effect of having DS, no age effect and no significant interaction found. For Aβ42 levels
(Figure 5-4, A; F1,78 = 44.46, p < 0.0001), Tukey’s post hoc analyses revealed significant
elevations in young DS (p = 0.024) and older DS groups (p < 0.0001) compared to agematched controls. Analysis revealed that 29.5% of total variation was attributed to DS
alone due to over 2.5-fold expression differences. For P-T181-Tau levels (Figure 5-4, B;
F1,80 = 64.53, p < 0.0001), Tukey’s post hoc analyses revealed significant elevations in
young and older DS groups (both p < 0.0001) compared to age-matched controls Analysis
revealed that 36.4% of total variation was attributed to DS alone due to greater than 2-fold
expression differences. For P-S396-Tau levels (Figure 5-4, C; F1,78 = 50.76, p < 0.0001),
Tukey’s post hoc analyses revealed significant elevations in both young (p = 0.002) and
older DS groups (p < 0.0001), compared to age-matched controls. Analysis revealed that
33.7% of total variation was attributed to DS alone due to over 2-fold expression
differences. These findings demonstrated that these neuronal exosome markers were all
significantly elevated in those with DS compared to age-matched controls regardless of
age category.

A linear regression analysis of each neuronal exosome biomarker across age was
performed to determine whether there were significant age-related trends in the DS group
or the age-matched control group (Figure 5-5).
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Figure 5-4. Group differences in AD biomarkers in neuronal exosomes isolated
from blood of individuals with and without DS of different ages. Age was divided
into those below 35 years of age vs. those above 35 years of age. Note that both young
and older individuals with DS exhibited significantly increased levels of all three AD
biomarkers, compared to age-matched controls. (A) Aβ42: younger participants with
DS exhibited significantly elevated levels (p = 0.024) compared to age-matched
controls. Older participants with DS exhibited significantly elevated levels compared
to age-matched controls (p < 0.0001). (B) P-T181-Tau: younger participants with DS
exhibited significantly elevated levels (p = 0.001) compared to age-matched controls.
Older participants with DS exhibited significantly elevated levels compared to agematched controls (p < 0.0001). (C) P-S396-Tau: younger participants with DS
exhibited significantly elevated levels (p = 0.002) compared to age-matched controls.
Older participants with DS exhibited significantly elevated levels compared to agematched controls (p < 0.0001). Error bars represent ± SEM.
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Figure 5-5. Effects of age on AD biomarkers in neuronal exosomes isolated from
blood samples of individuals with and without DS. No age effects were observed for
either Aβ42, P-T181-Tau or P-S396-Tau. (A) Aβ42: There was no significant effect of
age on Aβ42 levels in the DS group. The y-intercepts for DS group and non-DS control
group were significantly different (p < 0.0001). Age-matched control participants did
not exhibit any main effects of age. (B-C) P-T181-Tau and P-S396-Tau: No age effects
were observed for either P-T181-Tau or P-S396-Tau. However, the y-intercepts for both
P-T181-Tau and P-S396-Tau were significantly different (p < 0.0001) between the DS
group and age-matched control group. Dotted lines represent the 95% confidence band
of the best fit line.
Aβ24 levels were 210% greater (Figure 5-5, A; F1,79 = 67.71, p < 0.0001) in the DS (mean:
6.74 ± 1.71) compared to the control (mean: 2.17 ± 0.61) group. However, there was no
association between age and Aβ42 levels for the non-DS control group (p = 0.729) or the
DS group (p = 0.454), indicating no significant age effects on Aβ42 levels, even when all
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DS groups were included in the analysis. I observed a significant doubling of P-T181-Tau
levels (Figure 5-5, B; F1,81 = 98.16, p < 0.0001) for DS (mean: 146.3 ± 27.73) relative to
the non-DS control group (mean: 71.92 ± 13.40). The slope of P-T181-Tau levels was also
not significantly different from zero for either group: non-DS control (p = 0.861) and DS
(p = 0.076). Similarly, the levels of P-S396-Tau were 76% greater (Figure 5-5, C; F1,79 =
69.61, p < 0.0001) for the DS group (mean: 22.87 ± 4.09) relative to the non-DS control
group (mean: 12.95 ± 1.68). Similarly, the slope of P-S396-Tau was not significantly
different from zero for either group: non-DS control (p = 0.069) and DS (p = 0.962). All
three neuronal exosome biomarker had at least a 2-fold elevation in levels for participants
with DS regardless of age or dementia diagnosis.

Pearson correlation analyses revealed that Aβ42 levels were significantly correlated
with P-S396-Tau (r = 0.438, p = 0.008) and a trend for P-T181-Tau and P-S396-Tau (r =
0.316, p = 0.059) in the non-DS control group. Based on this analysis, Aβ42 significantly
correlated with P-T181-Tau (r = 0.261, p = 0.022) and P-T181-Tau significantly correlated
with P-S396-Tau (r = 0.32, p = 0.029) in the DS group Figure 5-6.

Figure 5-6. Pearson correlations of AD biomarkers in neuronal exosomes and Age.
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5.3.3 Gender Effects on AD Biomarkers
Student’s t tests revealed no significant difference (p > 0.10) between male and
female participants for the Aβ42 or the P-S396-Tau levels, but showed a significant gender
effect for the P-T181-Tau levels only in the older controls (p = 0.05) and the older DS
group (p = 0.02) (Figure 5-7). Since there was no gender effect on P-T181-Tau levels for
any young groups, I excluded gender from further analyses and focused on dementiarelated effects within the DS participants.

Figure 5-7. Student’s t tests of AD biomarkers in neuronal exosomes by Gender.
5.3.4 Effects of Dementia Status in Aged DS Subjects
I further divided the adult DS group into two categories: 1) those with NCI and 2)
those with early or fully symptomatic dementia indicative of DS-AD Figure 5-8. Aβ42
levels were significantly decreased (p = 0.048) in adults with DS and dementia symptoms,
relative to those with no apparent dementia (Figure 5-8, A). P-T181-Tau levels were not
significantly different between the two groups (Figure 5-8, B). By contrast, P-S396-Tau
levels were significantly elevated (Student’s t-test, p = 0.008) in participants with early or
fully symptomatic dementia compared to those with DS and no dementia (Figure 5-8, C).
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Altogether, these data suggest that neuronal exosome levels of Aβ42 and P-Tau follow
different trajectories in adults with DS who exhibit symptoms of dementia.

Figure 5-8. Neuronal exosome levels by clinical diagnosis (A) Aβ42: Student’s t test
revealed a significant decrease in Aβ42 levels for adults with early symptomatic or fully
symptomatic dementia compared to no apparent dementia subgroup (p = 0.048). (B) PT181-Tau: There was no significant overall effect between the two groups. (C) P-S396Tau: Student’s t test revealed a significant increase for DS adults diagnosed with early
or fully symptomatic dementia relative to DS adults with no apparent dementia. Error
bars represent ± SEM.
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5.3.5 Serum BDNF Levels in DS Subjects
I further assessed serum BDNF levels from the three adult DS groups: 1) those not
cognitively impaired, NCI 2) those with early symptomatic dementia, MCI and 3) those
with fully symptomatic dementia, DS-AD and from a control population without DS or
cognitive impairments (Figure 5-9, B). I performed a one-way ANOVA to test whether
there are significant changes between the groups and found that both DS-NCI and DS-AD
have significant elevations of serum BDNF relative to a control population based on
Tukey’s post hoc multiplicity adjusted values (p = 0.003 and p = 0.001) respectively. All
DS groups had 30% or greater average serum BDNF levels relative to the control
population. Counterintuitively, cognitive impairment seems to further elevate BDNF
measures (DS-NCI: 30% increase, DS-MCI: 35% increase, DS-AD 65% increase)
although this effect may be related to age given the relationship of BDNF and AD.

5.3.6 Correlation of BDNF Levels to Neuron-derived Exosome Biomarkers in DS
Within the two biomarkers studies, there were a total of 31 patient samples with DS
that were commonly analyzed. I perform a linear regression analysis of each neuronal
exosome biomarker plotted against corresponding BDNF level (in x-axis) to determine
whether there were significant trends in the DS group. The was no correlation between
neuronal exosome levels of Aβ42 or P-Tau and circulating BDNF levels
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Figure 5-9. Serum BDNF levels in the DS population. (A) Circulating BDNF levels
show a positive increase of age until around 20 years, then decreased steadily well into
60 years of age. The slopes and y-intercepts for both periods were significantly different
(p < 0.0001) between the younger and older DS group. Dotted lines represent the 95%
confidence band of the best fit line. (B) Although those with DS show a trend to have
more circulating BDNF in serum, one way ANOVA revealed that there are no
significant differences between the groups. Error bars represent an average ± SEM.

5.4 Discussion
In this Chapter, I reported Aβ42 and P-Tau levels from neuronal exosomes isolated
from blood samples in individuals with DS, as a function of age and dementia status. The
manuscript was published in 2016 (Hamlett et al., 2016), and I was the first author. The
findings show a marked increase in AD biomarker levels in individuals with DS as early
as 8 years of age. Extrapolation of the linear regressions suggests that these abnormal
neuronal exosome biomarker levels may be elevated already at birth in DS, but further
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studies are needed to confirm this hypothesis. DS adults diagnosed with dementia exhibited
lower Aβ42, and higher P-S396-Tau levels compared to non-cognitively impaired adults
with DS. This reveals that different AD biomarkers follow different trajectories in
exosomes as a consequence of the AD process. I found that circulating BDNF levels
increase steadily in the DS population until the age of 20 and then begin to decrease. There
was no significant difference in circulating BDNF levels between controls or individuals
with DS regardless of cognitive status, but I did see strong correlations with neuronal
exosome P-Tau levels, where increases in BDNF resulted in a decrease in total P-Tau.

It is not surprising that Aβ42 levels were elevated early in DS because the APP gene
is located on chromosome 21 (Hartley, Handen et al. 2014, Wiseman, Al-Janabi et al.
2015), and previous studies have shown elevations of toxic amyloid peptides in the plasma
of young adults with DS (Hoyo, Xicota et al. 2015). A recent positron emission tomography
(PET) imaging study, using the beta-amyloid, plaque-specific Pittsburgh compound-B
(PIB), showed an accumulation of Aβ in DS, but only in those >35 years of age (Annus,
Wilson et al. 2015). In contrast, others have shown that levels of Aβ42 in plasma were
lower in individuals with DS diagnosed with dementia compared to subjects with DS but
no dementia (Schupf, Zigman et al. 2010). Diffuse amyloid plaques have been described
as early as age 15 in postmortem brain samples from people with DS (Mann, Yates et al.
1984, Lemere, Grenfell et al. 1999). Increased levels of Aβ42 have also been reported in
the CSF of adults with DS (Wisniewski, Wisniewski et al. 1985, Hartley, Blumenthal et al.
2014, Mondragon-Rodriguez, Perry et al. 2014) and in children with DS (Englund,
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Anneren et al. 2007). Interestingly, findings from the Dominantly Inherited Alzheimer
Network (DIAN), an international registry of individuals at risk for developing autosomal
dominant AD, suggest that early biomarkers predict onset and trajectory of dementia in
vulnerable populations (Moulder, Snider et al. 2013). The DIAN studies showed early high
levels of AD biomarkers in the CSF, followed by reduced Aβ levels in CSF, demonstrating
that early blood or CSF biomarkers can be used to mark the onset of AD, where PET
imaging might only capture changes in the brain after pathological processes have already
been activated. The sensitivity discrepancy between PET imaging versus plasma and CSF
studies may reflect PIB binding affinity preferences to protein-lipid components (Matveev,
Spielmann et al. 2014) or PIB tracer signal strength.

Since the Tau gene is not known to be affected by the trisomy, it is more surprising
that the P-Tau levels, including both phosphorylation loci studied here, are elevated early
in DS. Phosphorylation of Tau protein at the carboxyl terminus has been shown to be one
of the earliest pathological events in both AD and in DS-AD (Mondragon-Rodriguez, Perry
et al. 2014), and may occur prior to accumulation of brain fibrillary P-Tau. Here, I found
that neuronal exosome levels of both P-T181-Tau and P-S396-Tau were significantly
increased in younger individuals with DS compared to age-matched controls and that this
hyperphosphorylation profile persisted into late adulthood when DS co-occurred with AD
dementia. The highest levels of exosomal P-S396-Tau were found in cases diagnosed with
dementia, suggesting that P-Tau continues to accumulate in exosomes as AD pathology
progresses. The data here support previous P-Tau observations regarding AD-related
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progression in adults with DS but also suggest that significant elevations occur, at least in
neuronal exosomes, as early as 8 years of age in children with DS. In view of our novel PTau findings, future studies targeting earlier age ranges in DS should be undertaken to gain
insight into the early neuropathological processes associated with DS. The data reported
here may also bolster new in vivo imaging studies, using novel P-Tau radioligands (Dani,
Edison et al. 2016). The biological mechanisms driving the elevated P-Tau levels early in
those with DS remain unknown.

Alternative mechanisms for Tau dysregulation can be found in several genes involved
in the trisomy. For example, SOD1 is located on the triplicated segment of Chr. 21, and is
involved in oxidative stress which exacerbates AD pathology in the DS brain (Schupf, Lee
et al. 2015). In addition, hyperphosphorylation of Tau can be influenced by dysregulation
of alternative splicing of Tau reported in DS as well as in AD (Ginsberg, Che et al. 2006)
and may underlie the abnormal hyperphosphorylation of Tau (Iqbal, Gong et al. 2013).
Furthermore, two genes located on Chromosome 21, the Dual-specificity tyrosine
phosphorylation-regulated kinase 1A (DYRK1A) gene, and regulator of calcineurin 1
(RCAN1), are highly expressed in the DS brain (Ferrer, Barrachina et al. 2005, Harris,
Ermak et al. 2007, Kimura, Kamino et al. 2007), and have been implicated in the
dysregulation of Tau phosphorylation associated with early onset AD in DS. Interestingly,
Dyrk1A-mediated phosphorylation of RCAN1 induces a targeted phosphorylation cascade
that leads to Tau phosphorylation (Jung, Park et al. 2011). Taken together, dysregulation
of these genes suggests a novel set of molecular mechanisms underlying the increase in
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Aβ42, P-S396-Tau, and P-T181-Tau that I observed in neuronal exosomes isolated from
children with DS which will be further explored in continued studies.

Here I discovered that serum BDNF levels in the DS population follow a unique
trajectory over age when compared to the biomarkers found in neuronal exosomes. Higher
serum BDNF levels may protect against the future occurrence of dementia and AD so as
BDNF levels drop (after the age of 20) those with DS may lose these protective properties.
Previous findings suggest a role for BDNF in the biology and possibly in the prevention of
dementia and AD (Weinstein, Beiser et al. 2014). I observed a strong correlation between
serum BDNF and only P-Tau cargos in neuronal exosomes and a manner that higher BDNF
levels significantly decreased P-Tau. While the exact interface behind this mechanism is
unknown, BDNF is known to induce a rapid dephosphorylation of tau protein through a
PI-3Kinase signaling mechanism (Elliott, Atlas et al. 2005) which speaks to the
connections of BDNF and tauopathy. These findings may suggest that BDNF may protect
against the inappropriate spread of P-Tau species in neuronal exosomes, which could be a
therapeutic target. Given that increases in toxic Aβ42 peptides impairs vesicular sorting
and increase exosome biogenesis (Almeida, Takahashi et al. 2006), BDNF levels may
afford more protection to with DS. I did notice a slight trend for BDNF increases in those
with DS, with slightly higher BDNF in DS patients that have suffered cognitive decline.
This leaves speculation as to whether there is a protective response in progress.
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I reason that neuronal exosome isolated from blood may provide a unique insight into
BDNF biology as assessed from only brain origins. Further work is needed to test whether
circulating serum BDNF is equivalent to neuronal exosome BDNF for those with or
without DS. It is also possible that the isoform of BDNF that I measured using a selective
commercial ELISA kit represents mostly pro-BDNF and not the mature form (mBDNF).
Studies in individuals with AD have shown a significant increase in pro-BDNF and a
reduction in mBDNF (Neto, Borges et al. 2011). Decreased levels of the mature form of
BDNF in aging has been associated with decreased hippocampal synaptic plasticity,
neurogenesis, and cognitive ability (Erickson, Miller et al. 2012) and may be reflective of
the age-related cognitive impairment observed in both NS and TS mice. Further studies are
also needed to reveal which specific forms of BDNF are present in neuron-derived
exosomes versus in serum itself. These studies can lead to significant increase in
knowledge regarding different biological mechanisms involved in DS-AD vs. AD in the
general population.

In sum, the capacity to quantify Aβ42 and P-Tau in neuronal exosomes from easily
acquirable blood samples has permitted us to show significant abnormalities in these
proteins at an early age in individuals with DS. As expected, due to the increase in APP
gene dosage, Aβ42 levels were increased throughout the lifespan in participants with DS,
but paradoxically were significantly reduced in those with a clinical diagnosis of dementia.
Amyloid levels are also reduced in CSF in patients with DS-AD, as well as AD in the
general population (Blennow 2004, Dekker, Fortea et al. 2017). It is plausible that Aβ42 is
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sequestered in the brain with the onset of dementia, as also suggested by previous blood
levels of this AD biomarker in the DS population. On the other hand, P-S396-Tau and PT181-Tau levels were increased early in life, and P-S396-Tau showed a significant further
increase in dementia suggesting that Tau phosphorylation plays a role in dementia onset
and progression in DS.

The repeatability of my data suggests that this neuronal exosome approach offers
several benefits for interrogation of early events in AD pathogenesis in DS. Exosomal
screening allows insight into the profile of proteins secreted from neurons. This is
particularly useful when working in the DS community where confounds of intellectual
disability and functionality make a diagnosis of dementia more difficult. Another
significant benefit is that outcome measures can be reliably obtained either from serum or
plasma samples from a consortium of biobanks since data are normalized against the same
neuronal exosomal marker. Finally, a neuronal exosome approach may prove useful in
evaluating potential drug targets for early intervention of AD, while enabling reliable
measures of therapeutic efficacy. Future studies will include comparison studies between
whole plasma and neuronal exosome amyloid levels, as well as an expanded search for
other biomarkers in neuronal exosomes that may predict dementia and/or other conditions
in adults with DS.
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Chapter 6: Discussion

6.1 Brief Overview
The primary goal of my studies was to examine biological mechanisms for
neuropathology in Down syndrome. LC-NE activity, BDNF, and inflammation are three
facets of DS-AD that are modulated by highly coordinated processes and upon individual
failure creates disruption in the whole. This interplay underlies why DS-AD reflects an
emergent spectrum of neuronal disorders that occur together. In Chapter 3, the first aim
of my dissertation studies was to understand the mechanisms by which the LC-NE may
alter memory performance and neuroinflammation in Ts65Dn mice. I employed two study
paradigms: 1) LC inhibition at four months when LC morphology appears intact and 2) LC
stimulation at 14 months when the LC has suffered neurodegeneration. The first series of
experiments were designed to assess whether stimulation of the LC-NE after degeneration
is evident, would rescue memory deficits neuroinflammation. The second series of
experiments were designed to assess whether inhibition of the LC-NE before degeneration
is evident, would enhance memory deficits and exacerbate neuroinflammation. Having
determined that inflammation may be rapidly modulated by LC-NE activity, Chapter 4
assessed the efficacy of activating the resolution system via a proresolution mediator SPM
therapeutic approach. The first series of experiments were designed to test the efficacy of
administering a purified resolution mediator, RvE1, to rescue memory deficits, chronic
neuroinflammation and a peripheral component of inflammation in Ts65Dn mice. In
Chapter 5, I utilized a novel method for purifying neuronal exosomes from blood and
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examined three circulating neuronal exosome biomarkers, Aβ42, P-T181-Tau and P-S396Tau along with serum BDNF levels over broad cross sections of age with the hypothesis
that exosome markers and circulating BDNF levels would define a preclinical period for
DS-AD. One potential therapeutic option to prevent neuroinflammation, as observed in
Ts65Dn mice, may be to artificially enhance proresolution mediators. In summary, my
dissertation work demonstrated that the LC-NE modulates memory performance and
neuroinflammation with great precision in mice. Behavioral modulation was directly
affected within 10 minutes while molecular markers of neuroinflammation were affected
in only 9 days of LC inhibition. Finally, initiation of proresolution therapy or other
inflammation-targeted interventions for DS-AD may need to occur long before cognitive
scores begin to decline in the DS population as novel blood biomarkers reveal 2-3 times
higher AD biomarkers already in childhood in the DS population.

6.2 In-depth Discussion of the Findings from the DREADD studies (Chapter 3)
Ts65Dn mice exhibit declarative memory deficits, especially in spatial and working
memory (Holtzman, Santucci et al. 1996, Hunter 2004), and this memory loss coincides
with degeneration of cholinergic neurons (Granholm 2000, Hunter, Bachman et al. 2004),
hippocampal and LC-NE neurons (Lockrow, Fortress et al. 2012, Fortress, Hamlett et al.
2015) in the brain. Our recent evidence linked neuroinflammation as a general contributor
to the multifaceted neurodegeneration in Ts65Dn mice (Hunter 2004, Lockrow J 2011). I
will first discuss the LC influence on neuroinflammation from the perspective of
adrenoreceptor functions with a novel insight gleaned from the DREADD studies. Then I
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will discuss specific NE effects on memory indices observed at pre-degenerative and postdegenerative intervals of LC decline.

6.2.1 DREADD and Adrenergic Crosstalk: A GPCR Mystery at the Synapse
In Chapter 3, I used DREADD receptors to specifically control LC-NE neurons in
mice during cognitive tasks. Although these designer receptors have been designed to
respond only to CNO, they still maintained signaling through Gq or Gi and β-arrestin
signaling pathways, which was presumed to be identical to normal M3 and M4 receptors.
Similarly, the adrenoreceptors also signal through Gs or Gi and β-arrestin signaling adapter
molecules. In our experimental paradigm, the neurons of the LC express both DREADDs
and adrenoreceptors, but the physiological consequences of Hsa21 trisomy on the
architecture of GPCRs are not fully explored. In Figure 3-10, I observed significant
elevations of β1-AR expression in Ts65Dn relative to NS mice already at four months of
age. The near 30% increase was found in both hippocampus and frontal cortex, both areas
that are extensively innervated by the LC. I assumed that adrenoreceptor elevation might
be in part due to a compensatory response to physiological changes in LC-NE function
which may reduce NE release in terminal fields, already at four months of age. Likewise,
I hypothesized that hM4D-mediated inhibition of the LC-NE firing rate would potentially
exacerbate the β1-AR phenotype in both karyotypes. Surprisingly, hM4D inhibition of the
LC normalized Ts65Dn brain β1-AR levels to that observed in NS mice without any
observable effects on β1-AR levels in NS mice. Degeneration of LC-NE neurons occurs
both in DS-AD and in AD and is an early event in the degenerative process (Braak and Del
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Tredici, 2012). LC-NE degeneration exacerbates other AD pathology (Kalinin, Gavrilyuk
et al. 2007, Heneka, Nadrigny et al. 2010) but changes in adrenoreceptors in the AD brain
could also lead to a protracted response to NE. Both α1-AR and α2-AR have been shown
to be decreased in AD, while I demonstrate changes in β1-AR in Ts65Dn mice.

DREADD hM4D inhibition of the LC resulted in an unanticipated normalization
of β1-AR density which could be explained by several potential mechanisms.
Norepinephrine activates nine different adrenergic receptors with different functional
outcomes, depending on the expression pattern of these receptors and G protein affinities.
Most adrenergic receptors are expressed in LC neurons and are anterogradely transported
to the terminals, with ɑ1 (Gq-coupled), ɑ-2 (Gi-coupled), and β1-3 (Gs-coupled) all present
at the presynaptic and postsynaptic terminals. Since these receptors are present on both
sides of the synapse, it is difficult to know by which receptor subtypes and at which
locations intervention mediate effects. When presynaptic, adrenoreceptors, like the
α2 receptors, can function as autoreceptors to inhibit further release of NE by negative
feedback. If LC-NE activity is suppressed in Ts65Dn mice, one may expect compensatory
elevations in all adrenoreceptors. In support of this expectation, a recent study observed
significant elevations in the β2 adrenoreceptor in presynaptic terminals of Ts65Dn mice
(Dang, Medina et al. 2014). If compensatory elevations of the ɑ2 (Gi-coupled)
adrenoreceptors occur within presynaptic terminals of the LC, the interference could
manifest dysfunction in NE release, resulting in NE deficiency from a morphologically
normal LC. Post-synaptic ɑ2 adrenoreceptors may yield a blunted response to NE by

Page 189

decreasing of intracellular cAMP production. Another explanation could be involved with
G-protein cross talk between hM4D and β1-AR in the presynaptic terminals of the LC, a
biological phenomena also known as functional agonism. In line with this, adrenoreceptors
likely form homodimers and heterodimers, that result in more complex receptor functions.

Studies have revealed a similar biological mechanism where selective agonists of
M2 mAChR potentiate β2-AR-signaling (Fernandes, Fryer et al. 1992, Pera and Penn
2014). Although these studies were conducted in smooth muscle, I believe that the
activation of the Gi-coupled hM4D used in this study was equivalent to M4 or M2 Gicoupled receptors, possibly leading to similar Gi cross-talk to β1-AR. This may produce
the acute effects in memory that I observed while having long term consequence of NE
release from the LC presynaptic terminal. Functional agonism has been documented in
several other GPCR systems where Ca2+ signaling by one type of GPCR can be enhanced
or inhibited by stimulation of a different type of GPCR (Werry, Wilkinson et al. 2003),
which bolsters the idea of crosstalk as a potential mechanism in this unusual β1-AR
observation. Finally, it is also possible that chronic inhibition of the LC-NE neuron firing
rate in Ts65Dn mice (with an already compromised NE transmitter system) gives rise to
degeneration of postsynaptic terminals, which could account for the loss of β1 receptors in
Ts65Dn mice after chronic hM4D stimulation. This notion will be followed up with
specific staining of NE terminals in target regions (to be performed after my thesis
defense).
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Given this interesting GPCR effect in β1-ARs, I postulate that NE signaling could
be dysfunctional even if the LC is morphologically normal and releasing NE to terminal
fields. All β-adrenoreceptors are Gs-coupled and upon activation render adenylate cyclase
activated, which hydrolyzes adenosine triphosphate (ATP) into cyclic adenosine
monophosphate (cAMP). If adrenoreceptors are desensitized or not properly incorporated
into a correct signaling architecture at the pre- or postsynaptic terminals, one would
hypothesize a blunted neuronal cAMP response to NE release. In line with this hypothesis,
basal production of cAMP was significantly reduced in the hippocampus and cerebral
cortex of Ts65Dn compared to NS mice, but whether this results in an adrenoreceptor
deficiency in signaling is unknown. Although not speciﬁc, cAMP has been used as a
measure of NE signaling in mouse models of neurodegeneration (Dierssen, Vallina et al.
1997, Heneka, Nadrigny et al. 2010, Baamonde, Martinez-Cue et al. 2011).

It would be interesting to explore this GPCR effect with selective agonist and
antagonists of adrenoreceptors in electrophysiological experiments to further test receptor
elevations or cAMP deficiencies seen in Ts65Dn mice. Although this is an interesting
continuation of my studies, it was not possible to conduct these studies within the frame of
my dissertation. Regarding cAMP reason, human studies of cardiac tissue revealed that
metoprolol agonism of β1-AR restores ion channel functions by an unknown mechanism.
In another study, formoterol, a long-acting β2 adrenergic agonist, improved cognitive
function promotes dendritic complexity in Ts65Dn mice, but the mechanism remains
unknown (Dang V 2014). In contrast, Prazosin is an α1-AR antagonist that reduces Aβ
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generation in neuronal cultures and improves behavioral and inflammatory outcome
measures in a mouse model for AD (Katsouri, Vizcaychipi et al. 2013). Whether these
kinds of pharmacological treatment would be beneficial in normalizing basal cAMP
deficits in Ts65Dn mice remains a mystery. Clinically, patients with hypertension who took
beta blockers had decreased dementia incidence and cognitive decline rate (Khachaturian,
Zandi et al. 2006, Rosenberg, Mielke et al. 2008), but the mechanism behind this
correlation remains unknown. GPCRs can also be impaired by designer peptides that could
be potentially employed in similar studies (Gilchrist, Mazzoni et al. 1998). Lastly,
immunoprecipitation methods of adrenoreceptors that target bound-factors should also be
explored since deficiencies or interference in docking and adapter proteins could
undermine GPCR architecture. How the balance of adrenoreceptors orchestrate adequate
responses to NE in Ts65Dn mice is still an open question, and our observations suggest
further studies aimed at answering this question would be valuable.

6.2.2 LC-NE modulation of inflammation had temporal precision
In regards to neuroinflammation, the interface of noradrenergic tone has significant
effects on microglia. In particular, agonism of β-adrenoceptors, either by norepinephrine
or alternatively by dobutamine, depresses brain inflammation and is neuroprotective across
various paradigms that activate microglia (Mori, Ozaki et al. 2002, Dello Russo, Boullerne
et al. 2004, Kong, Ruan et al. 2010, Markus, Hansson et al. 2010). Forskolin, a
phosphodiesterase inhibitor, also elevates cAMP and thus mimics some of the antiinflammatory effects of β-adrenergic agonists on microglia (Prinz, Hausler et al. 2001).
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Recent studies in the Granholm lab revealed that microglial morphological changes were
present at low levels as early as four months of age in Ts65Dn mice and that microglial
activation increased throughout aging (Lockrow, Boger et al. 2011). In Chapter 3, I
recapitulated this previous finding by showing that CD45 staining was significantly
elevated in Ts65Dn mice relative to normosomic controls. Specifically, DREADD hM4D
inhibition of the LC during the behavioral task period (9 days in total) significantly elevated
CD45 expression by as much as 40% in both NS and Ts65Dn mice (Figure 3-11). Whether
there is an increase in microglial cell number or merely an increase in Cd45 expression
levels in existing microglial cells is yet to be explored. However, I cannot conclude that
this measure is exclusively from existing microglial cells as new evidence in the field
suggests that CD45-positive microglia in the brain can be derived from peripheral
monocyte extravasation from the blood through the BBB during pro-inflammatory status
such as stroke or injury (Mandrekar-Colucci and Landreth 2010). Altogether, these data
reflected a robust inflammatory response that was increased following selective NE
inhibition, but future studies are utilizing multiplexed immunofluorescence, or perhaps
inducible genetic tagging methods would be needed to tease apart distinct cellular
contributions of this phenotype in the brain.

Whether changes in the NE are a late manifestation of Ts65Dn pathology or an
early contributor to inflammatory and neurodegenerative changes remains a central
question in vivo. I have observed that the apparent gross structure and cell density of the
LC seem to be equivalent between NS and Ts65Dn mice at 4 months of age (Hamlett,
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Boger et al. 2015) (Figure 3-2). Yet, given the remarkable time precision of LC influence
on CD45 expression, I hypothesize that an unknown LC dysfunction could underlie the
elevated CD45 expression I observed in Ts65Dn mice. This hypothesis was tested
previously by assessing the effects of DSP-4 neurotoxic depletion of LC neurons on
inflammatory morphology, in which the Granholm lab discovered that inflammation in
Ts65Dn mouse was exacerbated by LC lesions using the specific DSP-4 NE neurotoxin
(Lockrow, Boger et al. 2011). Our findings are consistent with work in other mouse models
of AD (Heneka, Ramanathan et al. 2006, Pugh, Vidgeon-Hart et al. 2007) also was
demonstrated in a standard C57BL/6J mice at 2 months of age (Yao, Wu et al. 2015).
Furthermore, stimulating microglia with L-DOPS supplementation led to reduced
microglial activation under naïve conditions in Ts65Dn while NE supplementation
increased microglial phagocytosis of Aβ (Heneka, Nadrigny et al. 2010, Kalinin, Polak et
al. 2012, Fortress, Hamlett et al. 2015). Altogether, neuroinflammation is modulated with
high precision very early in life and has implications in the appropriate recycling of Aβ. It
seems that any disruption of adrenergic control can lead to abnormal inflammation in very
short time periods. Thus chronic disruption would set the stage for the inflammatory
phenotype seen in the brain of Ts65Dn mice.

Current literature on inflammation and neurodegeneration suggests that although
immune dysfunction was initially thought to be a secondary effect of amyloid accumulation
in AD, it is now considered an early event that exacerbates and potentially precedes AD
pathological cascades (Lucin and Wyss-Coray 2009, Heneka, Carson et al. 2015).
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Specifically, the presence of Aβ in the brain has been shown to prime microglia and elicit
the production of immune mediators. In the context of chronic activation, glia and
astrocytes undergo morphological changes that can result in dysregulation of immune
feedback loops and reduced levels of critical trophic factors (Heppner, Ransohoff et al.
2015). These dynamic alterations may aggravate Tau propagation and ultimately lead to
neuronal death. Characteristics of DS biology is not only the increased expression of
amyloid precursor protein, but also the upregulation of neuroinflammatory astrocyteinduced proteins (e.g. S100), excess production of inflammatory cytokines (e.g. IL-1α
and ), increased interferon (INF) and JAK/STAT signaling, and chronic microglial
activation (Donato, Cannon et al. 2013). Moreover, overexpression of Hsa21 products
leads to increased activation of the p38-MAPK inflammatory pathways, which promote
hyperphosphorylation of Tau and neurofibrillary tangle formation (Sheng, Jones et al.
2001). The net result of these understudied cascades is a chronic, pro-inflammatory
environment poised to promote AD pathology. Given that nearly all adults with DS display
neuropathological evidence of AD by the age of 40, they represent the largest and most
understudied early onset Alzheimer’s disease group (Wilcock 2012). As such, I believe
that adults with DS represent a critical cornerstone to our understanding of
neuroimmunological changes underlying late onset and early onset AD biology while also
offering a window into modifiable inflammatory risk factors.

Individuals with DS have pervading inflammatory issues already early in life that
may underlie the high prevalence of AD. Blood levels of inflammatory markers are
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increased early in those with DS (Rodrigues, Debom et al. 2014), and the inflammatory
markers correlate with AD biomarkers in adults (Naude, Dekker et al. 2015). When
measuring serum levels of inflammatory biomarkers in a mouse model of DS, the Ts65Dn
mice, I found significant elevations in several pro-inflammatory cytokines (IL-1β, TNFα,
IL-6) as well as increased levels of both Granulocyte-colony stimulating factor (G-CSF),
which is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem
cells and release them into the bloodstream, and Granulocyte-macrophage colonystimulating factor (GM-CSF), which is a glycoprotein secreted by macrophages that
function as a signaling cytokine, see Figure 4-12. These data demonstrate that this DS
mouse model exhibits inflammatory traits similar to those observed in humans with DS
and can be used to model the role of peripheral inflammatory processes for development
of DS-AD.

6.2.3 LC-NE Activity is Necessary for Specific Memory Indices
NS mice were not impaired in the NORT task at any age assessed, and the controlGFP cohorts were not affected by treatment with CNO. This suggests that our surgical
procedure, viral manipulations, and aging itself had no overall effect on this measure.
Similarly, a DSP-4 lesion does not seem to affect intact and/or young animals to the same
extent as aged or diseased (Lockrow, Boger et al. 2011). Ts65Dn mice consistently showed
a severe NORT deficit that was approximately 75-85% reduction in discrimination index
across all ages assessed. I found that LC-NE modulation of this activity to be essential for
hM4D-mediated inhibition of the LC significantly impaired NORT performance in NS
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mice to a level that is similar to naïve (not treated with CNO) Ts65Dn performance levels
at 4 months of age. The effects were both rapid (only 10 mins) and persistent in both shortterm (90 min) and long-term (24hr) intervals when CNOA was given daily. Together with
proven targeting success, I feel that these data fully support the role of the LC-NE in rodent
object memory. Remarkably, the Ts65Dn performance levels at 4 months of age were not
significantly different from NORT impairments observed at 14 months of age. I previously
assumed that degeneration of LC-NE neurons, which is overtly apparent at 12 months of
age, was responsible for a noradrenergic deficiency that was responsible for deficient
NORT performance. The deficient NORT performance observed in 4 month old Ts65Dn
mice suggests that physiological dysfunction of the LC-NE neurotransmitter system may
exist at very early ages in Ts65Dn mice long before the apparent loss of neurons. Of
interest, Ts65Dn mice do occasionally show a slight yet significant perseverance to the
familiar object rather than the normal drive to investigate the novel object with higher
frequency. This tendency for perseveration fits well with previous studies in Ts65Dn mice
(Hyde, Frisone et al. 2001, Driscoll, Carroll et al. 2004) and may affect performance in this
task, following a delayed inter-trial interval.

DREADD hM4D-mediated inhibition of the LC-NE had minimal impact on spatial
reference memory in 4month old Ts65Dn mice. As seen in the meta-analysis in Figure 110, Ts65Dn mice make over 100% more errors in the final trails of the WRAM task
compared to NS mice while NS mice retain similar performance across all ages studied.
This suggests that aging itself (at least up to 10 months of age) is less correlated to a
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WRAM performance than aneuploidy. In our study, Ts65Dn mice consistently showed a
severe spatial memory deficit with approximately 100% more errors mid-way through the
task and over 200% more errors than age-matched NS mice by the final trails. Interestingly,
I found that hM4D inhibition of the LC had little impact in this task overall but did observe
a significant deficiency effect during the very last trials (Figure 3-8). Expanding the “winstay” WRAM task to 4-5 days may be valuable for future Ts65Dn studies. After a brief
rest, the mice were subjected to a WRAM-based cognitive flexibility task by switching the
platform to a new location. Although Ts65Dn mice make more errors, they do demonstrate
perseverance to the platform arm by the trial end (Figure 3-9, A) suggesting that an
understanding of the task objective was achieved. Interestingly, Ts65Dn mice failed to lose
this perseverance phenotype even after being introduced to a new platform location eight
times, and this effect is exacerbated by hM4D inhibition of the LC. Furthermore, The NS
mice gained a perseverance phenotype with hM4D inhibition of the LC. When analyzed
by total errors in this new condition, I observed that NS mice quickly learned the new
platform location but seemed to make more errors with LC inhibition. This LC inhibition
effect was significant with Ts65Dn mice (p = 0.02) further suggesting that the LC
modulates cognitive flexibility which is already deficient in Ts65Dn mice. NS mice
typically improve performance in the WRAM task by as much as 20% as they performed
one trial block to the next and this improvement is steady across days, and all trial blocks.
The Ts65Dn mice made similar gains over the trials initially but lost this ability in final
trial blocks suggesting a deficiency in their ability to perfect the task.
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In this task, I assumed that the drive to escape the water is equivalent between NS
and Ts65Dn mice, but the LC is known to modulate motivation (Aston-Jones, Rajkowski
et al. 2000), which may bias escape drive. The concept of motivation is captured in the
Yerkes-Dodson relationship between LC activity, arousal, and performance on the task
(Aston-Jones and Cohen 2005). The importance of arousal relates to attention and
motivation. Dampened arousal can lead to inattentive behavior and drowsiness while
heightened arousal (by enriched environmental events that strongly motivate memory) can
facilitate behavior performance. The LC-NE activity is known to mediate the balance
between arousal and inattentiveness by the frequencies and timings of tonic and phasic
burst activation. Normally, LC neurons exhibit a tonic activity mode, which is associated
with task disengagement. Environmental enrichments that drive increased need for taskrelated decision processes (such as swimming in the WRAM) cause a shift to punctuated
phasic LC activation which is proposed to optimize task performance. LC-NE dysfunctions
in Ts65Dn mice could manifest decreased tonic LC activity and/or deficits on burst mode
phasic LC-NE activations. Our data supports this theory since hM3D stimulation of the
LC-NE significantly increased performance in the NORT task (Figure 3-5).

The mechanisms behind NE influence on hyperactivity in Ts65Dn and other
rodents models is intriguing. In the Colobomo mouse model, hyperactivity is thought to
result from of a 50% reduction in the synaptosomal associated protein-25 kD protein
(SNAP-25), a presynaptic protein that regulates vesicle release by exocytosis. In this
model, depletion of NE by DSP-4 significantly reduced the locomotor activity which
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broadly suggests that NE regulation is linked to hyperactivity. Interestingly, in this mouse
model, interventions with an antagonist of ɑ2 adrenoreceptors (yohimbine, clonidine, or
guanfacine) ameliorated hyperactivity (Hess, Jinnah et al. 1992) which suggested a role for
adrenoreceptors. In Humans, polymorphisms in three adrenergic receptor gene regions
(ADRA2A, ADRA2C, and ADRA1C ) have been associated with hyperactivity associated
with Attention Deficit Disorder (ADHD), which further suggests the involvement of the
noradrenergic functions in hyperactivity. Interestingly, polymorphisms in the
norepinephrine transporter (NET) are also associated with ADHD. A study examining the
relationship between NET and ADHD found that drugs that act as blockers of NET are also
efficacious in treating ADHD (Biederman and Spencer 2000). LC-enhancing medications,
such as Atomoxetine or L-DOPS (Asherson, Stes et al. 2015) have been utilized for
individuals with ADHD and could be considered in future clinical treatment paradigms for
DS-AD patients since attentional deficits and executive dysfunction are both common in
DS (Lanfranchi, Jerman et al. 2010). In Chapter 3, I found that hM3D stimulation of the
LC-NE decreased hyperactivity and perseverance. In stark contrast, hM4D inhibition of
the LC-NE had no effects on hyperactivity in either NS or Ts65Dn mice. This fidning
suggest other transmitter systems may be involved. For instance, dopamine is also known
to affect locomotor activity in rodents (Viggiano, Ruocco et al. 2004) and the balance of
dopaminergic and noradrenergic in the prefrontal cortex are likely influencing the
contrasting outcomes. Altogether, these observations clinically relate to short-term
attentional deficits in people with DS (Mauerberg-deCastro, Cozzani et al. 2009,
Lanfranchi, Jerman et al. 2010) which imply potential LC dysfunctions in the DS
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population that may be remedied by pharmacological treatments. Declining LC function is
also hypothesized to underlie sleep disturbance (Vazey and Aston-Jones 2014).
Interestingly, when sleep rhythm disturbance in several animal models, including Ts65Dn
mice, is correlated with declarative memory deficits (Ruby, Fernandez et al. 2013,
Takeuchi, Duszkiewicz et al. 2016). Over 50% of children with DS experience sleep
problems (Fernandez, Nyhuis et al. 2017) and this may be related to LC function.

6.3 In-depth Discussion of the Findings from the Resolution studies in Chapter 4
I explored a proresolution mediator approach with the primary focus of limiting the
inflammatory phenotype in the Ts65Dn mouse. Since RvE1 has shown great efficacy in
other inflammatory modulation approaches, I hypothesized that a chronic 1 month would
provide protection to 8-month-old Ts65Dn. Remarkably, our RvE1 treatment normalized
all memory indices and cognitive flexibility deficits measured in Ts65Dn mice without
effects on NS mice. This profound result prompted a deeper investigation into the receptors
and signaling outcomes of the treatment. I first discuss the proresolution outcomes of RvE1
therapy from the perspective of neuroinflammation and peripheral cytokine measures.
Then I discuss specific RvE1-mediated molecular changes and how these may underlie the
profound improvements in all memory indices performed by Ts65Dn mice.

6.3.1 RvE1 mediates activation of ERK1/2 signaling
RvE1 is known to bind ChemR23 and BLT1, both Gαi-coupled protein receptors
but how chronic binding affects these receptors is unknown. Under our treatment paradigm,
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I observed significant decreases in both receptors of about 30-40% regardless of brain
region assessed (Figure 4-8). These results indicate that at least two different RvE1
receptors mediate resolution signaling. The changes observed in both receptors could be a
compensatory modulation to the therapy, but the mechanism of this response is unknown.
Importantly I did not observe this compensatory effect in the closely related ALX-FPL2
receptor, which does not bind ChemR23, which suggests a response outcome specific to
the RvE1 ligand. I anticipated that activation of these receptors would increase the ratio of
phosphorylated ERK to total ERK, suggesting increased activation, and observed 10-20
increases in this p-ERK ratio primarily in the frontal cortex and the hippocampus, with
little change in the parietal cortex for both NS and Ts65Dn mice. ERK activation seems to
have pleiotropic effects that are relevant to neurodegeneration. For instance, sustained
activation of ERK has been observed from neurotoxic lesion with 6-OHDA (Kulich and
Chu 2001) suggesting that ERK activation plays a direct mechanistic role in toxicity.
Abnormal ERK activation has also been observed in the prefrontal cortex of a mouse model
of Autism (Faridar, Jones-Davis et al. 2014). I observed that Ts65Dn mice trend to
preexisting elevations of this p-ERK ratio especially in the frontal cortex when compared
to NS mice (Figure 4-8). This correlation speaks to the fact that individuals with DS have
high rates of autistic behavior (Naerland, Bakke et al. 2017).

In contrast, increased ERK activation also mediates neuroprotective effects. For
example, neuroprotection by BDNF against cell death is mediated by ERK and other
pathways that involved downstream changes in DNA promoter binding and mRNA
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translation (Nguyen, Yao et al. 2005). How ERK signaling can have a multifaceted effect
is partly due to compartmentalization within each cell of the brain. Distinct protein
scaffolding molecules are required for ERK activation at the plasma membrane,
endosomes, and the Golgi apparatus (Omerovic and Prior 2009). ERK-activation is able to
target both cytoplasmic and nuclear molecules depending on the site of phosphorylation.
ERK activation at the Golgi apparatus is sequestered in the cytoplasm and targets
cytoplasmic molecules. To that point, recent evidence revealed that ERK activation also
had cross-reactivity with other protein kinases, particularly p38 protein. Most of the
proinflammatory cytokines are regulated by NF-κB, which is itself regulated by p38
MAPK (Carter, Knudtson et al. 1999). In vitro assays demonstrated that ERK was able to
phosphorylate PPARγ (Adams, Reginato et al. 1997) which has implications for its role in
inflammatory regulation. Currently, the downstream targeting bias of ERK activation by
proresolution receptors is a central question that remains unanswered. Also, the specific
activation status and localization of PPARγ remains to be elucidated.

Clearly, ERK is a complex signaling effector that has both negative and positive
outcomes. In Chapter 5, I did not determine if ERK-related scaffolding molecules and
cytoplasmic or nuclear fractions had biased signaling outcomes under the proresolution
intervention. Future experiments could be employed to more closely follow the
phosphorylation cascade in a time course upon RvE1 treatment. This kind of study may
best be applied in a cell culture in vitro model ideally from human IPS cells that have been
differentiated to form microglia or neurons but could also be performed in a typical
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fibroblast or neuroblastoma lineage. Such experiments could define a time course in which
to further explore the same signaling dynamics in the Ts65Dn mouse were sample are more
limited to exploratory work.

6.3.2 Chronic RvE1 therapy normalized the Ts65Dn inflammatory phenotype
My work also supported the hypothesis that neuroinflammation affects CalbindinD28k (Cal 28k) morphology in the hippocampus. Extending the work of Hunter et al
(2004), I showed that early alterations were present in Cal 28k-positive CA1 pyramidal
neurons at an age prior to BFCN atrophy (Figure 3-2). This finding is consistent with
human aging, as Cal 28k expression is reduced during normal aging, and precedes
cholinergic dysfunction during AD (Mufson, Ginsberg et al. 2003). Morphology changes
in Cal 28k are not only early, but are progressive as well, and there is a near complete loss
of Cal 28k expression in the CA1 hippocampus of 18-month-old Ts65Dn mice (Figure 32). In these studies, I additionally determined that Cal 28k reductions are partially
connected to inflammation, as neuroinflammatory increases brought on by NE depletion
contributed to Cal 28k loss (Figure 3-10). Interestingly, similar losses to Cal 28k have
been noted in the human CA1 during AD (Sutherland, Wong et al. 1993). Combined with
my findings, this may suggest that modulation of inflammation can be more powerful than
mere suppression.
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In the context of longevity, this type of inflammatory effect may offer a new
therapeutic window to stop AD progression in the DS community. The profound effects I
observed in Ts65Dn memory performance after RvE1 administration could have been at
least partially driven by modulation of the hematopoietic system and/or reprogramming of
white blood cells. Mechanisms behind how the immune system signals to the brain in
response to systemic inflammation are not fully understood. Inflammation can initiate
signaling from the hematopoietic system to various organs including the brain. The
traditional view of this communication has been that individual factors, such as
inflammatory cytokines, are released by immune cells that in turn bind to specific targets
cells (neurons, glia, or oligodendrocytes) in the brain where they exert their effects. But
our recent studies in Chapter 5 prove that extracellular vesicles are readily found in the
blood. As an alternative approach to resolution signaling it may be gainful to isolate
exosomes from mice (or rats to increase the blood draw volume) at both pre- and postRvE1 intervention and perform proteomic studies on the cargo contained within. One might
hypothesize that the beneficial effects were also vectorized in these vesicle systems.

6.4 In-depth Discussion of Findings from the Biomarker Studies in Chapter 5
I implemented a novel technology that enables explorations of the cargo found in
neuronal exosomes. The biomarkers in this specialized cargo revealed a unique phenotype
in those with DS that has profound implications on why, how and when AD begins in this
population. Our BDNF studies over broad cross sections of age revealed interesting trends
with the highest clarity seen in the field so far. Altogether, these studies inform the clinical
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mindset on when therapeutic interventions may be needed for those with DS.

6.4.2 Neuronal Exosomes offer a Snapshot of Brain Health
The cargo inside neuronal exosomes provides a specific proteomic niche in which
to explore novel biological aspects of brain health. No other method allows such a snapshot
of neuronal activity with minimal invasiveness, a feature that makes our methodology
highly relevant to the clinic. Alarmingly high levels of all three AD biomarkers were found
to occur across all ages, even as early as 8 years of age. An interesting question lies in how
children with DS are able to escape the pathological events that may be correlated with the
high exosomal transfer of expelled proteins? The protective mechanism could be related to
LC modulation of inflammation, active resolution processes, and even neurotrophic
support, with the latter being discussed in the next section. As seen in studies of CSF,
neuronal exosomes also recapitulate decreases in Aβ42 in those with DS that have suffered
abnormal cognitive impairments. The correlations of these biomarkers to the current
knowledge of AD are profound. Clinical trials focused on AD would likely benefit by using
this type of biomarker as a novel, and sensitive way to assess the efficacy of an intervention.
I presume that any intervention that can help neurons better deal with the burden of amyloid
plaques and hyperphosphorylated Tau would likely reduce the need to expel these proteins
via exosome mechanisms.
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6.4.2 Serum BDNF and the Neuronal Exosome P-Tau connection
Decreased levels of the mature form of BDNF in aging have been associated with
decreased hippocampal synaptic plasticity, neurogenesis, and cognitive ability (Erickson,
Miller et al. 2012) and may also be reflective of the age-related cognitive impairment
observed in both NS and TS mice (Bimonte-Nelson, Hunter et al. 2003). BDNF clearly
follows a downward trajectory in the DS population that initiates at about the age
of twenty. Given that mature BDNF signaling, via tyrosine receptor kinase B (TrkB)
receptors, is capable of decreasing Tau phosphorylation, it is not surprising that I
found significant correlations between BDNF and two types of dementia -related PTau species. A disconnect lies in how circulating BDNF, which comes fro m many
sources, may influence the cargo of neuronal exosomes. One explanation could be
that the majority of circulating BDNF actually comes from brain sources which had
direct interface with the exosome cargo. Alternatively, circulating BDNF from all
sources may cross the blood brain barrier and find an interface in the brain by other
means. Further studies are needed to reveal which specific forms of BDNF are present in
neuron-derived exosomes versus in serum itself. These studies can lead to a significant
increase in knowledge regarding different biological mechanisms involved in DS-AD vs.
AD in the general population relative to BDNF processes.
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6.5 Trisomy 21 in Society
Identifying the factors that contribute to or reduce healthy aging can lead to
improved precision medicine that could prevent the onset of aging-related diseases like
AD. Although genetics may account for some portion of longevity, general stability of gene
expression is also a primary driver for healthy aging. The studies conducted in this
dissertation were conducted for the benefit of those with Trisomy 21 and on mouse models
that recapitulate the syndrome of this aneuploidy. To fully understand how this work
affects society, one must consider the reality of Trisomy 21 as a spectrum. Down syndrome
may best describe those who have an absolute or high penetrance of Trisomy 21 in their
body structure. On the other end of the spectrum, all individuals have some level of
Trisomy 21 in their cells, which may be highly variable depending on the tissue or cellular
level examined. A big question that remains to be answered is “What is the nature of
aneuploidy in society.” The pursuit of this question could reveal a biological fact of nature
that could have unforeseen influence at all levels, from individuals to nations.

6.6 Future Directions
In sum, the experiments that I conducted for this dissertation have led to many
significant observations in LC-NE modulation, novel therapeutic leads from Ω3 lipid
biology, and in biomarkers for AD. One important lesson I have learned during my tenure
in the Granholm lab is on the importance of working together and with others to find
solutions to emerging scientific questions. Collaboration with clinical professionals, and
other institutions were fundamental to the success of the exosome biomarkers studies.
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Furthermore, I found the biological insight gained from many collaborative experts during
the manuscript writing process to be extremely helpful for proper interpretation of the
findings. I had the opportunity to get training directly from Dr. Goetzl, who is the leading
expert in neuronal exosome isolation and characterization. This experience will
undoubtedly enhance my future investigations and empower my career as I progress toward
being a postdoctoral researcher. It is with hope that my work will yield positive outcomes
for individuals that have Trisomy 21 and also bring positive educational gains for “you”
the current reader. There was no better joy than that felt when a bulk of my research effort
featured in this dissertation was débuted at an international conference focused on Trisomy
21. How better to end a graduate experience that was a long time coming.
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